{"PMC7458659": [["In the absence of an effective treatment or vaccination (as of June 2020), the public health response has so far relied on nonpharmaceutical measures to limit the spread of the epidemic, such as physical distancing, case isolation, and manual contact tracing [1].", [["an effective treatment", "TREATMENT", 18, 40], ["vaccination", "TREATMENT", 44, 55], ["nonpharmaceutical measures", "TREATMENT", 123, 149]]], ["Many countries have therefore resorted to partial or full \u201clockdown\u201d measures to control the epidemic, severely limiting social and economic interactions among their citizens.", [["full \u201clockdown\u201d measures", "TREATMENT", 53, 77]]], ["Although lockdowns may help countries to keep the number of infections under control [2], they come at a great social and economic cost [3-6].IntroductionCOVID-19 is difficult to trace by traditional methods as COVID-19 cases are infectious 1-2 days before experiencing symptoms and contacts on average become infectious 3-4 days after exposure.", [["infections", "DISEASE", 60, 70], ["IntroductionCOVID", "TEST", 142, 159], ["COVID", "TEST", 211, 216], ["symptoms", "PROBLEM", 270, 278], ["infectious", "PROBLEM", 310, 320], ["infectious", "OBSERVATION", 310, 320]]], ["The window to achieve containment by manual contact tracing is thus extremely short.", [["manual contact tracing", "TEST", 37, 59]]], ["Ferretti and colleagues [7] have proposed digital (app-based) contact tracing as an alternative measure to contain the epidemic without the large economic costs of lockdowns.", [["contact tracing", "TEST", 62, 77], ["large", "OBSERVATION_MODIFIER", 140, 145], ["economic", "OBSERVATION_MODIFIER", 146, 154]]], ["The idea is to use low-energy Bluetooth connections between phones to record the interactions users have with others, particularly those interactions that may pose a higher risk of infection (eg, spending more than 15 minutes within 2 meters of another person).", [["infection", "DISEASE", 181, 190], ["person", "SPECIES", 253, 259], ["low-energy Bluetooth connections", "TREATMENT", 19, 51], ["infection", "PROBLEM", 181, 190], ["infection", "OBSERVATION", 181, 190]]], ["If a user is diagnosed with COVID-19, they can use the app to declare the diagnosis, which then notifies all other users who have come in close contact with the infected person, asking them to isolate at home for 14 days or until they have been tested by the public health authority.", [["person", "SPECIES", 170, 176]]], ["The main advantage over traditional (manual) forms of contact tracing is that the app allows instantaneous notification of contacts, which is a key determinant of the effectiveness of case isolation and contact tracing strategies for COVID-19 [7].", [["COVID-19", "CHEMICAL", 234, 242], ["contact tracing", "TEST", 54, 69], ["case isolation", "TREATMENT", 184, 198], ["COVID", "TEST", 234, 239], ["main", "OBSERVATION_MODIFIER", 4, 8], ["advantage", "OBSERVATION_MODIFIER", 9, 18]]], ["Other advantages are that the automatic recording of contacts scales up easily, and avoids the loss of information due to patients\u2019 recall bias and/or imperfect knowledge of the people they have been in contact with.IntroductionMore and more countries are currently developing various types of contact-tracing apps and several countries have already launched one (eg, Singapore [8], Germany [9], and France [10]).", [["patients", "ORGANISM", 122, 130], ["people", "ORGANISM", 178, 184], ["patients", "SPECIES", 122, 130], ["people", "SPECIES", 178, 184]]], ["The success of app-based contact tracing, however, critically depends on people\u2019s willingness to use the app.", [["people", "ORGANISM", 73, 79], ["people", "SPECIES", 73, 79], ["based contact tracing", "TEST", 19, 40]]], ["Hinch and colleagues\u2019 [11] epidemic simulation in the United Kingdom shows that the app reduces infections at all levels of uptake but that it is only sufficient to stop the epidemic if approximately 60% of the population use it.", [["infections", "DISEASE", 96, 106], ["the app reduces infections", "PROBLEM", 80, 106], ["infections", "OBSERVATION", 96, 106]]], ["It is therefore important to gauge the strength of public support for this approach and to understand the factors that may hinder or facilitate uptake.", [["public support", "TREATMENT", 51, 65], ["this approach", "TREATMENT", 70, 83]]], ["It is also possible that such a technological solution may not work as well for the less digitally literate share of the population, further increasing the unequal impact of the COVID-19 pandemic within and across countries [13].", [["a technological solution", "TREATMENT", 30, 54], ["the COVID", "TEST", 174, 183], ["pandemic", "PROBLEM", 187, 195], ["also possible", "UNCERTAINTY", 6, 19], ["unequal", "OBSERVATION_MODIFIER", 156, 163]]], ["It is unclear, however, whether the public would be willing to support this more intrusive solution.IntroductionIn light of the many open questions surrounding the viability of app-based contact tracing, we designed a survey to measure public support for this approach in five countries that are currently hit by the COVID-19 pandemic: France, Germany, Italy, the United Kingdom, and the United States.", [["public support", "TREATMENT", 236, 250], ["this approach", "TREATMENT", 255, 268]]], ["The specific objectives of our study are to (a) assess the overall acceptability among the public of app-based contact tracing under different installation policies (eg, voluntary installation or automatic installation by the government); (b) uncover country-level and individual-level variation in support for the app; and (c) understand the main mechanisms that may facilitate or impede app usage across various subgroups of countries and individuals.Survey Design ::: MethodsWe conducted large online surveys in five countries (France, Germany, Italy, the United Kingdom, and the United States) to measure the acceptability of app-based contact tracing for COVID-19 before apps were introduced in any of the five countries.", [["our study", "TEST", 27, 36], ["automatic installation", "TREATMENT", 196, 218], ["COVID", "TEST", 660, 665], ["large", "OBSERVATION_MODIFIER", 491, 496]]], ["We abstracted from any details about centralized versus decentralized data storage procedures.", [["decentralized data storage procedures", "TREATMENT", 56, 93]]], ["We then collected demographic information and concluded the survey with questions about respondents\u2019 attitudes toward the government under different installation regimes.Survey Design ::: MethodsWe kept the survey design as similar as possible across all five countries, with a few exceptions to accommodate country differences with regard to lockdown measures in place at the time of taking the survey.", [["different installation regimes", "TREATMENT", 139, 169], ["Methods", "TREATMENT", 188, 195], ["lockdown measures", "TREATMENT", 343, 360]]], ["The US survey (deployed last) contained a few additional questions, including robustness checks.", [["The US survey", "TEST", 0, 13], ["robustness checks", "TEST", 78, 95]]], ["See Section A in Multimedia Appendix 1 for more details.Survey Design ::: MethodsEthics approval was obtained from the University of Oxford (reference number ECONCIA20-21-06).Survey Design ::: MethodsNo personal information was collected as part of the study.Target Population, Sample Size, and Attrition ::: MethodsThe surveys were administered between March 20 and April 10, 2020.", [["Methods", "TREATMENT", 193, 200], ["the study", "TEST", 249, 258], ["Methods", "TREATMENT", 309, 316], ["Size", "OBSERVATION_MODIFIER", 285, 289]]], ["A total of 10,375 individuals started the survey and 10,308 consented to participate (participation rate=99%).", [["individuals", "ORGANISM", 18, 29], ["participation rate", "TEST", 86, 104]]], ["Out of the people who consented to participate, 6166 passed the comprehension check and started the main questionnaire.", [["people", "ORGANISM", 11, 17], ["people", "SPECIES", 11, 17], ["the comprehension check", "TEST", 60, 83]]], ["After removing incomplete responses and duplicates, we had a sample of 6061 complete and unique responses (completion rate=59%).", [["a sample", "TEST", 59, 67], ["completion rate", "TEST", 107, 122]]], ["To control for the potential effect of our recruitment method, we repeated the German survey with a probability-based sample in an offline recruited online panel.", [["our recruitment method", "TREATMENT", 39, 61]]], ["See Section B in Multimedia Appendix 1 for further details on recruitment, filtering and attrition, and the final sample.Statistical Analysis ::: MethodsOur main outcome variables measure respondents\u2019 intention to have the app installed on their phone under the two installation regimes (opt-in vs opt-out).", [["the final sample", "TEST", 104, 120]]], ["In our regression analysis, we dichotomized these outcome measures (1=definitely or probably install/keep the app; 0=otherwise).Statistical Analysis ::: MethodsWe used multivariate regression analysis (linear probability models; probit and ordered logit in additional analyses presented in Multimedia Appendix 1) to examine the relationship between intention to install and a number of covariates: age, gender, country, presence of comorbidities (diabetes, high blood pressure, heart or breathing problems), usage of mobile phone outside the house, frequency of social interactions, ability to work from home during the lockdown, ability to obtain sick pay while working from home, trust in national government, and incidence of COVID-19 deaths in a respondent\u2019s region of residence (see Section C.3 in Multimedia Appendix 1 for more details).", [["blood", "ANATOMY", 462, 467], ["heart", "ANATOMY", 478, 483], ["diabetes", "DISEASE", 447, 455], ["heart or breathing problems", "DISEASE", 478, 505], ["COVID", "DISEASE", 729, 734], ["deaths", "DISEASE", 738, 744], ["blood", "ORGANISM_SUBSTANCE", 462, 467], ["heart", "ORGAN", 478, 483], ["our regression analysis", "TEST", 3, 26], ["multivariate regression analysis", "TEST", 168, 200], ["probit", "TEST", 229, 235], ["comorbidities", "PROBLEM", 432, 445], ["diabetes", "PROBLEM", 447, 455], ["high blood pressure", "PROBLEM", 457, 476], ["heart or breathing problems", "PROBLEM", 478, 505], ["heart", "ANATOMY", 478, 483]]], ["Table B.2 in Multimedia Appendix 1 presents a summary of these covariates.ResultsWe find broad support for app-based contact tracing.", [["app", "TEST", 107, 110]]], ["Support is high in all countries, across all subgroups of the population, and under both installation regimes (opt-in and opt-out).", [["high", "OBSERVATION_MODIFIER", 11, 15]]], ["Panel B shows that 4059 out of 5995 respondents (67.7%) say they would probably or definitely keep the app installed on their phone under the automatic (opt-out) installation regime.", [["Panel B", "TEST", 0, 7], ["installation regime", "TREATMENT", 162, 181]]], ["In both regimes, the share of respondents who say they would not have the app installed on their phone is very small (red portion of the bars in Figure 1).ResultsSupport is high in all five countries where we implemented the survey: in each country, at least 68% of respondents say that they would install or keep the app.", [["small", "OBSERVATION_MODIFIER", 111, 116], ["high", "OBSERVATION_MODIFIER", 173, 177]]], ["Moreover, Figures 9\u201311 in Multimedia Appendix 1 show that support for the app is generally high across various subgroups of the population (eg, across men and women, across different age groups, etc), suggesting widespread acceptability of the app-based contact tracing solution to the COVID-19 pandemic.ResultsDespite the broad and widespread acceptability of the app, we find that support varies systematically across countries and individuals.", [["men", "ORGANISM", 151, 154], ["women", "ORGANISM", 159, 164], ["men", "SPECIES", 151, 154], ["women", "SPECIES", 159, 164], ["the app", "TEST", 70, 77], ["the COVID", "TEST", 282, 291], ["pandemic", "PROBLEM", 295, 303], ["high", "OBSERVATION", 91, 95], ["widespread", "OBSERVATION_MODIFIER", 212, 222]]], ["Among individual characteristics, we find that those who have less trust in their national government are more hesitant to have the app installed on their phones (Figure 11 in Multimedia Appendix 1).ResultsWe further explore this heterogeneity using multivariate regression analysis, where we examine the relationship between support for the app and a variety of individual- and country-level covariates.", [["multivariate regression analysis", "TEST", 250, 282], ["the app", "TEST", 338, 345]]], ["Figure 2 shows the impact that these covariates have on the probability of definitely or probably installing the app under the opt-in regime, using a linear probability model (see Section C.1 in Multimedia Appendix 1 for a similar analysis of the opt-out regime).ResultsThe analysis confirms that Germany and the United States are significantly less supportive of the app, especially compared to France and Italy.", [["The analysis", "TEST", 270, 282]]], ["Taking the two most extreme cases, respondents in Italy are 15.1 percentage points (95% CI 12.1-18.1) more likely to support the app than respondents in the United States.", [["CI", "TEST", 88, 90]]], ["Surprisingly, Figure 2 shows very little correlation between regional-level COVID-19 mortality rates and support for the app.ResultsAmong individual-level characteristics, we find that people who carry their phone with them more often are more likely to install the app.", [["people", "ORGANISM", 185, 191], ["people", "SPECIES", 185, 191]]], ["Those who always carry their phone with them are 33.6 percentage points (95% CI 26.4-40.8) more likely to support the app than those who carry their phone only rarely.", [["CI", "TEST", 77, 79]]], ["App support is also 3.7 percentage points (95% CI 1.3-6.2) larger among respondents with one or more comorbidities.", [["App support", "TREATMENT", 0, 11], ["CI", "TEST", 47, 49]]], ["People who completely trust the government are 25.9 percentage points (95% CI 21.6-30.3) more likely to install the app than those who do not have any trust in the government.ResultsWe found similar results using an ordered logit model, a linear probability model dichotomizing on just definitely install, and when using a probit model (Multimedia Appendix 1).", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6], ["CI", "TEST", 75, 77], ["an ordered logit model", "TREATMENT", 213, 235], ["a linear probability model dichotomizing", "PROBLEM", 237, 277], ["a probit model (Multimedia Appendix", "TREATMENT", 321, 356]]], ["Interestingly, under the opt-out regime, trust in government displays an even stronger correlation with the intention to keep the app installed on one\u2019s phone.ResultsWe can use the data on respondents\u2019 reasons for or against installing the app to better understand the nature of the observed variation in app support across countries and individuals.", [["app support", "TREATMENT", 305, 316]]], ["A first set of reasons against the app revolved around concerns about government surveillance at the end of the epidemic (mentioned by 2518 out of 5995 respondents, 42%) and cybersecurity (fears that the app could make the phone vulnerable to hackers; 2098/5995, 35%).", [["government surveillance", "TEST", 70, 93]]], ["Respondents also reported that usage of the app may increase feelings of anxiety (1559/5995, 26%), possibly reflecting aversion to feedback about a possible infection.", [["anxiety", "DISEASE", 73, 80], ["infection", "DISEASE", 157, 166], ["anxiety", "PROBLEM", 73, 80], ["infection", "PROBLEM", 157, 166], ["possible", "UNCERTAINTY", 148, 156], ["infection", "OBSERVATION", 157, 166]]], ["Figures 16 and 17 in Multimedia Appendix 1 show the relationship between the probability of selecting a particular reason and country- and individual-level characteristics.ResultsSeveral patterns are of interest.", [["Figures", "TEST", 0, 7]]], ["In contrast, we find that frequent usage of mobile phones is related to a stronger perception of the potential benefits of the app: respondents who more often carry their phone with them are more likely to believe that the app would benefit them, by helping them stay healthy and keeping them informed about the risks of infection.Principal Findings ::: DiscussionIn our study, we find high support for app-based contact tracing\u2014irrespective of age, gender, region, or even country of residence.", [["infection", "DISEASE", 321, 330], ["mobile phones", "TREATMENT", 44, 57], ["infection", "PROBLEM", 321, 330], ["our study", "TEST", 367, 376], ["infection", "OBSERVATION", 321, 330]]], ["Since the effectiveness of app-based contact tracing crucially depends on a sufficient level of uptake, our findings are encouraging for the prospects of this approach.", [["this approach", "TREATMENT", 154, 167]]], ["Although support is high in all countries and subgroups of the population, the data reveal that concerns about cybersecurity and privacy, coupled with trust in government, are important determinants of support.", [["cybersecurity", "DISEASE", 111, 124], ["the data", "TEST", 75, 83], ["high", "OBSERVATION_MODIFIER", 20, 24]]], ["Our analysis shows that this factor has a negative effect on people\u2019s intention to install a contact-tracing app on their phones.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["Our analysis", "TEST", 0, 12], ["negative effect", "OBSERVATION_MODIFIER", 42, 57]]], ["Furthermore, supplementary analysis (Section C.6 in Multimedia Appendix 1) also shows that people with lower trust in government are more in favor of an opt-in installation policy than an opt-out regime where the government asks mobile phone providers to automatically install the app on all phones.", [["people", "ORGANISM", 91, 97], ["people", "SPECIES", 91, 97], ["supplementary analysis", "TEST", 13, 35]]], ["An opt-out regime is likely to translate into higher effective installation rates, for instance, by reducing the negative effects of procrastination or unawareness [15].", [["unawareness", "DISEASE", 152, 163], ["An opt-out regime", "TREATMENT", 0, 17], ["unawareness", "PROBLEM", 152, 163]]], ["Research on the privacy implications of app-based contact tracing, and the potential solutions to these concerns, is currently underway [12,16,17].", [["app-based contact tracing", "TEST", 40, 65]]], ["Interestingly, however, when we asked our respondents how the data collected by the app should be treated, we find that nearly 60% would consent to making the deidentified data available to research.Limitations ::: DiscussionOur study has some limitations that we tried to address in different ways.", [["DiscussionOur study", "TEST", 215, 234]]], ["To ensure that our results do not hinge on our specific sample, we replicated an abridged version of the German survey with a different panel provider that randomly recruits its participants offline.", [["participants", "SPECIES", 178, 190]]], ["Our results remain almost completely unchanged (Section B.3 in Multimedia Appendix 1).Limitations ::: DiscussionSecond, our survey asked hypothetical questions about future behavior.", [["unchanged", "OBSERVATION_MODIFIER", 37, 46]]], ["While studies often find good correlation between what people declare they would do in surveys and actual behavior [18-22], even in relation to app installations [23-26], many things will have changed between the time of the surveys and when countries eventually introduce the app.", [["people", "ORGANISM", 55, 61], ["people", "SPECIES", 55, 61]]], ["For example, at the time of the survey, Italy\u2019s epidemic was close to its peak and the urgency of the situation was very salient.", [["urgency", "OBSERVATION", 87, 94]]], ["Moreover, we made participants aware of the app and explained the app and its potential effects.", [["participants", "SPECIES", 18, 30]]], ["More generally, a reported willingness to install is only a necessary first stage to adoption, and our findings about heterogeneity in support point toward specific subgroups of the population that may need stronger encouragements to adoption.", [["heterogeneity in support point", "PROBLEM", 118, 148]]], ["We show in Section C.9 that respondents in our replication study who did not answer the comprehension questions correctly were less willing to install.", [["our replication study", "TEST", 43, 64]]], ["Further research will be needed to understand how to translate a person\u2019s willingness to install into the person actually installing the app.Limitations ::: DiscussionThird, in our survey, we measured support for the general concept of app-based contact tracing, leaving out specific details regarding the implementation, which were not available to us at the time respondents took the survey.", [["person", "SPECIES", 65, 71], ["person", "SPECIES", 106, 112]]], ["This suggests that our general measure of support for app-based contact tracing may be portable across different implementation settings.Limitations ::: DiscussionFourth, our results analyzing heterogeneity by age rely on coarse age binning.", [["app-based contact tracing", "TEST", 54, 79]]], ["Such banding is subject to flaws if the sample is not distributed well across bands, which is not possible to verify in our study.", [["Such banding", "TREATMENT", 0, 12], ["our study", "TEST", 120, 129], ["banding", "OBSERVATION", 5, 12]]], ["Attitudes towards app-based contact tracing may vary across countries with different levels of development and political regimes.", [["political regimes", "TREATMENT", 111, 128]]], ["In developing countries and among disadvantaged populations, the more limited access to smartphones raises both efficacy and equity issues; the development of low-cost Bluetooth devices with similar functionalities could improve access to digital contact tracing.Conclusions ::: DiscussionIn conclusion, our study shows strong public support for app-based contact tracing to tackle COVID-19.", [["COVID-19", "DNA", 382, 390], ["equity issues", "PROBLEM", 125, 138], ["low-cost Bluetooth devices", "TREATMENT", 159, 185], ["digital contact tracing", "TEST", 239, 262], ["our study", "TEST", 304, 313], ["COVID", "TEST", 382, 387], ["low", "OBSERVATION_MODIFIER", 159, 162]]], ["This is an important finding since public support is a necessary condition for the viability of the approach.", [["public support", "TREATMENT", 35, 49]]], ["Further research is needed to gauge the extent to which public support for app-based contact tracing translates into actual app adoption and, more generally, to evaluate its potential for epidemic control.Authors\u2019 Contributors ::: DiscussionSA and LM were responsible for figures, study design, data collection, data analysis, and writing; HZ for study design, data collection, data analysis, and writing; RB for literature search and data collection; FG and RB for data collection and data analysis; FK for study design, data collection, and data analysis; DN, ST, and JA for study design, data collection, data analysis, and writing.", [["FK", "CHEMICAL", 501, 503], ["JA", "CHEMICAL", 570, 572], ["RB", "PROTEIN", 459, 461], ["epidemic control", "TREATMENT", 188, 204], ["data collection", "TEST", 295, 310], ["data analysis", "TEST", 312, 325], ["study design, data collection", "TEST", 347, 376], ["data analysis", "TEST", 378, 391], ["literature search", "TEST", 413, 430], ["data collection", "TEST", 435, 450], ["FG and RB for data collection", "TEST", 452, 481], ["data analysis", "TEST", 486, 499], ["study design, data collection", "TEST", 508, 537], ["data analysis", "TEST", 543, 556], ["DN", "PROBLEM", 558, 560], ["study design", "TEST", 577, 589], ["data collection", "TEST", 591, 606], ["data analysis", "TEST", 608, 621]]]], "0ace4bd165662dc2eb776a7769e1d737022d6dcf": [["IntroductionSevere acute respiratory syndrome (SARS) is a newly recognized infectious disease with significant health and economic impacts worldwide.", [["acute respiratory syndrome", "DISEASE", 19, 45], ["SARS", "DISEASE", 47, 51], ["acute respiratory syndrome", "PROBLEM", 19, 45], ["SARS", "PROBLEM", 47, 51], ["a newly recognized infectious disease", "PROBLEM", 56, 93], ["acute", "OBSERVATION_MODIFIER", 19, 24], ["respiratory syndrome", "OBSERVATION", 25, 45], ["infectious", "OBSERVATION", 75, 85], ["significant", "OBSERVATION_MODIFIER", 99, 110]]], ["SARS was initially identified in Guangdong province, China in November 2002 and subsequently in Hong Kong, Singapore, Vietnam, Taiwan, countries in Europe and in North America by March and April of 2003 (CDC, MMWR 2003a; Lee et al., 2003; CDC, MMWR 2003b; WHO, 2003; Riley et al., 2003) .", [["SARS", "DISEASE", 0, 4]]], ["The 2003 SARS epidemic was caused by a previously uncharacterized coronavirus, SARS-CoV (Peiris et al., 2003a; Drosten et al., 2003; Ksiazek et al., 2003) .", [["SARS", "DISEASE", 9, 13], ["SARS", "DISEASE", 79, 83], ["coronavirus", "ORGANISM", 66, 77], ["SARS-CoV", "ORGANISM", 79, 87], ["coronavirus", "SPECIES", 66, 77], ["SARS-CoV", "SPECIES", 79, 87], ["a previously uncharacterized coronavirus", "PROBLEM", 37, 77], ["coronavirus", "OBSERVATION", 66, 77]]], ["Typical coronavirus particles were readily visible under electron microscope and the specific coronavirus sequences were detected by reverse transcription polymerase chain reaction (RT-PCR) from most SARS-CoV infected patients (Peiris et al., 2003a; Drosten et al., 2003; Lawrence, 2003) .", [["SARS-CoV infected", "DISEASE", 200, 217], ["coronavirus", "ORGANISM", 8, 19], ["coronavirus", "ORGANISM", 94, 105], ["SARS-CoV", "ORGANISM", 200, 208], ["patients", "ORGANISM", 218, 226], ["coronavirus sequences", "DNA", 94, 115], ["patients", "SPECIES", 218, 226], ["SARS-CoV", "SPECIES", 200, 208], ["Typical coronavirus particles", "PROBLEM", 0, 29], ["electron microscope", "TEST", 57, 76], ["the specific coronavirus sequences", "TEST", 81, 115], ["reverse transcription polymerase chain reaction", "PROBLEM", 133, 180], ["RT-PCR", "TEST", 182, 188], ["coronavirus particles", "OBSERVATION", 8, 29]]], ["SARS-CoV could be isolated and cultivated from sputum specimens and respiratory secretions of SARS patients using Vero cell cultures before the appearance of SARS-specific antibodies in serum, average 21 days following exposure (Peiris et al., 2003b; Booth et al., 2003) .", [["sputum specimens", "ANATOMY", 47, 63], ["respiratory secretions", "ANATOMY", 68, 90], ["Vero cell cultures", "ANATOMY", 114, 132], ["serum", "ANATOMY", 186, 191], ["SARS", "DISEASE", 0, 4], ["SARS", "DISEASE", 94, 98], ["SARS", "DISEASE", 158, 162], ["SARS-CoV", "ORGANISM", 0, 8], ["sputum specimens", "ORGANISM_SUBSTANCE", 47, 63], ["secretions", "ORGANISM_SUBSTANCE", 80, 90], ["patients", "ORGANISM", 99, 107], ["Vero cell cultures", "CELL", 114, 132], ["serum", "ORGANISM_SUBSTANCE", 186, 191], ["Vero cell cultures", "CELL_LINE", 114, 132], ["SARS-specific antibodies", "PROTEIN", 158, 182], ["patients", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "PROBLEM", 0, 8], ["sputum specimens", "TEST", 47, 63], ["respiratory secretions of SARS", "PROBLEM", 68, 98], ["Vero cell cultures", "TEST", 114, 132], ["SARS", "PROBLEM", 158, 162], ["specific antibodies", "TEST", 163, 182], ["serum", "TEST", 186, 191]]], ["The incubation period for SARS ranges from 2 to 10 days, though viremia can be documented approximately 2-5 days following exposure.", [["SARS", "DISEASE", 26, 30], ["viremia", "DISEASE", 64, 71], ["SARS ranges", "PROBLEM", 26, 37], ["viremia", "PROBLEM", 64, 71], ["viremia", "OBSERVATION", 64, 71]]], ["The challenge of early detection of SARS-CoV infection is the low viremia of infected patients.", [["SARS-CoV infection", "DISEASE", 36, 54], ["viremia of infected", "DISEASE", 66, 85], ["SARS-CoV", "ORGANISM", 36, 44], ["patients", "ORGANISM", 86, 94], ["patients", "SPECIES", 86, 94], ["SARS-CoV", "SPECIES", 36, 44], ["SARS", "PROBLEM", 36, 40], ["CoV infection", "PROBLEM", 41, 54], ["the low viremia of infected patients", "PROBLEM", 58, 94], ["CoV", "OBSERVATION_MODIFIER", 41, 44], ["infection", "OBSERVATION", 45, 54], ["low viremia", "OBSERVATION_MODIFIER", 62, 73], ["infected", "OBSERVATION_MODIFIER", 77, 85]]], ["Low viremia yields low to modest specific signal/noise ratio making distinction of the early-infected victims from non-SARS febrile patients difficult.IntroductionInitial efforts to control SARS were directed toward identification of travel-associated cases that originated from China and other SARS epidemic areas, such as Hong Kong (Riley et al., 2003; Lipsitch et al., 2003; Twu et al., 2003) .", [["viremia", "DISEASE", 4, 11], ["febrile", "DISEASE", 124, 131], ["SARS", "DISEASE", 190, 194], ["SARS", "DISEASE", 295, 299], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 132, 140], ["Low viremia", "PROBLEM", 0, 11], ["modest specific signal/noise ratio", "PROBLEM", 26, 60], ["non-SARS febrile patients", "PROBLEM", 115, 140], ["IntroductionInitial efforts", "TREATMENT", 151, 178], ["viremia", "OBSERVATION", 4, 11], ["infected", "OBSERVATION_MODIFIER", 93, 101]]], ["Despite enormous efforts to implement extensive control measures, there were still unrecognized cases of SARS that led to nosocomial clusters and subsequent spread to other health-care facilities and community settings in different regions of the world (Twu et al., 2003; Seto et al., 2003) .", [["SARS", "DISEASE", 105, 109], ["extensive control measures", "TREATMENT", 38, 64], ["SARS", "PROBLEM", 105, 109], ["nosocomial clusters", "PROBLEM", 122, 141]]], ["Several factors might contribute to difficulties to recognize cases of SARS.", [["SARS", "DISEASE", 71, 75], ["Several factors", "PROBLEM", 0, 15], ["SARS", "PROBLEM", 71, 75]]], ["Early symptoms of SARS are nonspecific and more commonly associated with other respiratory illnesses (updated interim US case definition for severe acute respiratory syndrome (SARS), CDC, 12 December 2003) .", [["respiratory", "ANATOMY", 79, 90], ["SARS", "DISEASE", 18, 22], ["respiratory illnesses", "DISEASE", 79, 100], ["acute respiratory syndrome", "DISEASE", 148, 174], ["SARS", "DISEASE", 176, 180], ["Early symptoms", "PROBLEM", 0, 14], ["SARS", "PROBLEM", 18, 22], ["other respiratory illnesses", "PROBLEM", 73, 100], ["severe acute respiratory syndrome", "PROBLEM", 141, 174], ["SARS", "OBSERVATION", 18, 22], ["nonspecific", "OBSERVATION_MODIFIER", 27, 38], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["respiratory syndrome", "OBSERVATION", 154, 174]]], ["Patients with SARS who are immuno-compromised or who have chronic conditions, e.g. diabetes mellitus or chronic renal insufficiency may remain afebrile when acutely ill or have symptoms attributable to underlying disease, delaying SARS diagnosis.", [["renal", "ANATOMY", 112, 117], ["SARS", "DISEASE", 14, 18], ["diabetes mellitus", "DISEASE", 83, 100], ["chronic renal insufficiency", "DISEASE", 104, 131], ["SARS", "DISEASE", 231, 235], ["Patients", "ORGANISM", 0, 8], ["renal", "ORGAN", 112, 117], ["Patients", "SPECIES", 0, 8], ["SARS", "PROBLEM", 14, 18], ["immuno-compromised", "PROBLEM", 27, 45], ["chronic conditions", "PROBLEM", 58, 76], ["diabetes mellitus", "PROBLEM", 83, 100], ["chronic renal insufficiency", "PROBLEM", 104, 131], ["afebrile", "PROBLEM", 143, 151], ["acutely ill", "PROBLEM", 157, 168], ["symptoms", "PROBLEM", 177, 185], ["underlying disease", "PROBLEM", 202, 220], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["renal", "ANATOMY", 112, 117], ["insufficiency", "OBSERVATION", 118, 131], ["disease", "OBSERVATION", 213, 220]]], ["The reappearance of SARS in Toronto, Canada illustrates the possibility that future outbreaks of SARS might occur during the flu season in different parts of the world.", [["SARS", "DISEASE", 20, 24], ["SARS", "DISEASE", 97, 101], ["SARS", "PROBLEM", 20, 24], ["SARS", "PROBLEM", 97, 101], ["SARS", "OBSERVATION", 20, 24]]], ["Thus, it would not be adequate to rely solely on the preliminary clinical symptoms, such as fever and cough to detect and differentiate SARS-CoV infections from other common upper respiratory infections.IntroductionThere are various RT-PCR tests to detect SARS-CoV available using different SARS-CoV genomic sequences (Drosten et al., 2003; Peiris et al., 2003b) .", [["respiratory", "ANATOMY", 180, 191], ["fever", "DISEASE", 92, 97], ["cough", "DISEASE", 102, 107], ["SARS-CoV infections", "DISEASE", 136, 155], ["respiratory infections", "DISEASE", 180, 202], ["SARS-CoV", "ORGANISM", 136, 144], ["upper respiratory", "ORGANISM_SUBDIVISION", 174, 191], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 256, 264], ["SARS-CoV genomic sequences", "DNA", 291, 317], ["SARS-CoV", "SPECIES", 136, 144], ["SARS-CoV", "SPECIES", 256, 264], ["SARS-CoV", "SPECIES", 291, 299], ["the preliminary clinical symptoms", "PROBLEM", 49, 82], ["fever", "PROBLEM", 92, 97], ["cough", "PROBLEM", 102, 107], ["SARS", "PROBLEM", 136, 140], ["CoV infections", "PROBLEM", 141, 155], ["other common upper respiratory infections", "PROBLEM", 161, 202], ["various RT-PCR tests", "TEST", 225, 245], ["SARS", "PROBLEM", 256, 260], ["different SARS", "TEST", 281, 295], ["CoV infections", "OBSERVATION", 141, 155], ["upper", "ANATOMY_MODIFIER", 174, 179], ["respiratory", "ANATOMY", 180, 191], ["infections", "OBSERVATION", 192, 202]]], ["The formats of SARS-CoV RT-PCR assays range from conventional agarose gel based assays to fluorogenic real-time RT-PCR assays.", [["agarose", "SIMPLE_CHEMICAL", 62, 69], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "TEST", 15, 19], ["CoV RT", "TEST", 20, 26], ["PCR assays", "TEST", 27, 37], ["conventional agarose gel", "TREATMENT", 49, 73], ["fluorogenic real", "TEST", 90, 106], ["RT-PCR assays", "TEST", 112, 125]]], ["Real-time RT-PCR may be preferred format due to its simplicity and ability to generate quantitative data.", [["time RT-PCR", "TEST", 5, 16]]], ["However, most of the current real-time SARS-CoV RT-PCR assays have not been validated to document consistent detection sensitivity and specificity to detect low SARS-CoV titers during early stages of illness.", [["illness", "DISEASE", 200, 207], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["SARS-CoV", "SPECIES", 161, 169], ["CoV RT-PCR assays", "TEST", 44, 61], ["low SARS", "PROBLEM", 157, 165], ["CoV titers", "PROBLEM", 166, 176], ["illness", "PROBLEM", 200, 207]]], ["An expected characteristic of SARS-CoV similar to other RNA viruses, such as flaviviruses is the high rate of genetic mutations, which leads to evolution of new viral variants (Leitmeyer et al., 1999; Mangada and Igarashi, 1998; Sanchez and Ruiz, 1996) .", [["SARS", "DISEASE", 30, 34], ["flaviviruses", "DISEASE", 77, 89], ["SARS-CoV", "ORGANISM", 30, 38], ["SARS-CoV", "SPECIES", 30, 38], ["SARS-CoV", "PROBLEM", 30, 38], ["other RNA viruses", "PROBLEM", 50, 67], ["flaviviruses", "PROBLEM", 77, 89], ["genetic mutations", "PROBLEM", 110, 127], ["new viral variants", "PROBLEM", 157, 175], ["SARS", "OBSERVATION", 30, 34], ["viruses", "OBSERVATION", 60, 67], ["genetic mutations", "OBSERVATION", 110, 127], ["new", "OBSERVATION_MODIFIER", 157, 160], ["viral variants", "OBSERVATION", 161, 175]]], ["It is possible that the high mutation rate of SARS-CoV would render any given RT-PCR assay useless if the assay's target sequence is subject to mutational changes.", [["SARS", "DISEASE", 46, 50], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 46, 54], ["target sequence", "DNA", 114, 129], ["SARS-CoV", "SPECIES", 46, 54], ["the high mutation rate of SARS", "PROBLEM", 20, 50], ["RT-PCR assay", "TEST", 78, 90], ["the assay's target sequence", "TEST", 102, 129], ["mutational changes", "PROBLEM", 144, 162]]], ["Thus, a negative test result may not rule out SARS-CoV infection especially for the patients showing early symptoms of SARS.", [["SARS-CoV infection", "DISEASE", 46, 64], ["SARS", "DISEASE", 119, 123], ["SARS-CoV", "ORGANISM", 46, 54], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["SARS-CoV", "SPECIES", 46, 54], ["a negative test result", "TEST", 6, 28], ["SARS", "PROBLEM", 46, 50], ["CoV infection", "PROBLEM", 51, 64], ["early symptoms", "PROBLEM", 101, 115], ["SARS", "PROBLEM", 119, 123], ["infection", "OBSERVATION", 55, 64]]], ["In this study, we report the development of a real-time RT-PCR assay based on the highly conserved 3 -NCR of the genome as a quantitative SARS diagnostic system (Marra et al., 2003; Ruan et al., 2003) .", [["highly conserved 3 -NCR", "DNA", 82, 105], ["this study", "TEST", 3, 13], ["RT-PCR assay", "TEST", 56, 68]]], ["It was retrospectively demonstrated that the assay could be used as an efficient diagnostic to identify SARS-CoV positive samples derived from SARS probable, or suspected patients during Taiwan's 2003 SARS outbreak.Materials and methodsSARS-CoV RNA and cDNA preparation.", [["samples", "ANATOMY", 122, 129], ["SARS", "DISEASE", 143, 147], ["SARS", "DISEASE", 201, 205], ["CoV", "ORGANISM", 109, 112], ["patients", "ORGANISM", 171, 179], ["methodsSARS-CoV", "GENE_OR_GENE_PRODUCT", 229, 244], ["methodsSARS-CoV RNA", "RNA", 229, 248], ["patients", "SPECIES", 171, 179], ["SARS-CoV", "SPECIES", 104, 112], ["the assay", "TEST", 41, 50], ["SARS", "PROBLEM", 104, 108], ["CoV positive samples", "PROBLEM", 109, 129], ["SARS", "PROBLEM", 143, 147], ["Materials", "TEST", 215, 224], ["methodsSARS", "TEST", 229, 240], ["CoV RNA", "TREATMENT", 241, 248], ["cDNA preparation", "TREATMENT", 253, 269]]], ["The SARS-CoV strain used in this study originated from a deceased WHO physician in Vietnam (US CDC isolate known as strain Urbani; Rota et al., 2003) and was obtained from the US Army Medical Research Institute of Infectious Diseases at Fort Detrick, Maryland.", [["Infectious Diseases", "DISEASE", 214, 233], ["SARS-CoV", "ORGANISM", 4, 12], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS-CoV strain", "PROBLEM", 0, 19], ["this study", "TEST", 28, 38], ["Infectious", "OBSERVATION", 214, 224]]], ["Twenty throat swabs of acute respiratory disease (ARD) patients from Fort Jackson, South Carolina were obtained from collections of the Walter Reed Army Institute of Research, Silver Spring, Maryland as negative controls for the SARS-CoV assay (McNeill et al., 2000) .", [["throat swabs", "ANATOMY", 7, 19], ["respiratory", "ANATOMY", 29, 40], ["acute respiratory disease", "DISEASE", 23, 48], ["ARD", "DISEASE", 50, 53], ["SARS", "DISEASE", 229, 233], ["patients", "ORGANISM", 55, 63], ["patients", "SPECIES", 55, 63], ["SARS-CoV", "SPECIES", 229, 237], ["Twenty throat swabs", "PROBLEM", 0, 19], ["acute respiratory disease (ARD)", "PROBLEM", 23, 54], ["acute", "OBSERVATION_MODIFIER", 23, 28], ["respiratory disease", "OBSERVATION", 29, 48]]], ["The viral RNA was extracted and transcribed into SARS-CoV cDNA through reverse transcription (RT) reaction using a commercial RNA extraction kit (Qiagen Inc.) and a RT kit (PE Applied Biosystems Inc., Foster City, California).", [["viral RNA", "RNA", 4, 13], ["SARS-CoV cDNA", "DNA", 49, 62], ["SARS-CoV", "SPECIES", 49, 57], ["The viral RNA", "PROBLEM", 0, 13], ["CoV cDNA", "TREATMENT", 54, 62], ["reverse transcription (RT) reaction", "TREATMENT", 71, 106], ["a commercial RNA extraction kit", "TREATMENT", 113, 144], ["a RT kit (PE Applied Biosystems", "TREATMENT", 163, 194], ["viral RNA", "OBSERVATION", 4, 13], ["PE", "OBSERVATION", 173, 175]]], ["RNA was mixed with RT reaction mixture containing anti-sense SARS-CoV RT primer (5 -CATTATTCACTGTACCCTCGATCG-3 , 20 pmol/reaction) according to the manufacture's instruction.", [["RNA", "RNA", 0, 3], ["RT reaction mixture", "PROBLEM", 19, 38], ["anti-sense SARS", "TEST", 50, 65], ["CoV RT primer", "TREATMENT", 66, 79], ["CATTATTCACTGTACCCTCGATCG", "TEST", 84, 108], ["mixed", "OBSERVATION_MODIFIER", 8, 13], ["anti-sense SARS", "OBSERVATION", 50, 65]]], ["The RT mixture was incubated as followings, 25 \u2022 C, 10 min; 48 \u2022 C, 30 min; 95 \u2022 C, 5 min.", [["The RT mixture", "TREATMENT", 0, 14]]], ["The resultant cDNA was stored at \u221220 \u2022 C until tested.Materials and methodsFluorogenic probe/primers and PCR conditions.", [["cDNA", "DNA", 14, 18], ["The resultant cDNA", "TEST", 0, 18], ["methodsFluorogenic probe/primers", "TEST", 68, 100], ["PCR conditions", "TEST", 105, 119]]], ["The fluorogenic probe (FAM-TTTCATCGAGGCCACGCGGAG-TAMRA) and its flanking primer pair (sense primer, 5 -GGACTTGAAAGAGCCACCACA-3 & and anti-sense primer, 5 -CATTATTCACTGTACCCTCGATCG-3 ) were designed based on the conserved SARS-CoV 3 -NCR of Canadian Tor2 isolate (Marra et al., 2003 ; GenBank accession #278554) and were purchased from PE Applied Biosystems Inc. (Foster City, California).", [["FAM-TTTCATCGAGGCCACGCGGAG-TAMRA", "CHEMICAL", 23, 54], ["FAM", "SIMPLE_CHEMICAL", 23, 26], ["Tor2", "GENE_OR_GENE_PRODUCT", 249, 253], ["fluorogenic probe", "DNA", 4, 21], ["flanking primer pair", "DNA", 64, 84], ["anti-sense primer", "DNA", 133, 150], ["SARS-CoV 3 -NCR", "DNA", 221, 236], ["SARS-CoV", "SPECIES", 221, 229], ["The fluorogenic probe", "TREATMENT", 0, 21], ["FAM-TTTCATCGAGGCCACGCGGAG-TAMRA)", "TREATMENT", 23, 55], ["its flanking primer pair (sense primer", "TREATMENT", 60, 98], ["-GGACTTGAAAGAGCCACCACA", "TEST", 102, 124], ["anti-sense primer", "TREATMENT", 133, 150], ["Canadian Tor2 isolate", "TREATMENT", 240, 261], ["PE", "OBSERVATION", 335, 337]]], ["PCR master mixture contained the following ingredients: 1X ABI PCR buffer II, 2 mM MgCl 2 , 0.4 mM dNTPs', 200 nM HCV-U4 upper primer, 200 nM HCV-L4 lower primer, 20 nM HCV-P4 fluorogenic Taqman probe labeled with 3 -FAM reporter dye and 5 -TAMRA quencher dye, 1.25 unit Taq DNA polymerase (AmpliTaq Gold, ABI, Foster City, California).", [["dNTPs", "CHEMICAL", 99, 104], ["MgCl 2", "CHEMICAL", 83, 89], ["dNTPs", "CHEMICAL", 99, 104], ["3 -FAM", "CHEMICAL", 214, 220], ["5 -TAMRA", "CHEMICAL", 238, 246], ["MgCl 2", "SIMPLE_CHEMICAL", 83, 89], ["dNTPs", "SIMPLE_CHEMICAL", 99, 104], ["3 -FAM", "SIMPLE_CHEMICAL", 214, 220], ["5 -TAMRA quencher dye", "SIMPLE_CHEMICAL", 238, 259], ["DNA", "CELLULAR_COMPONENT", 275, 278], ["II", "TEST", 74, 76], ["MgCl", "TEST", 83, 87], ["dNTPs", "TEST", 99, 104], ["HCV", "TEST", 114, 117], ["U4 upper primer", "TEST", 118, 133], ["HCV", "TEST", 142, 145], ["lower primer", "TEST", 149, 161], ["HCV", "TEST", 169, 172], ["P4 fluorogenic Taqman probe", "TREATMENT", 173, 200], ["FAM reporter dye", "TREATMENT", 217, 233], ["5 -TAMRA quencher dye", "TREATMENT", 238, 259], ["Taq DNA polymerase", "TEST", 271, 289], ["ABI", "TEST", 306, 309], ["upper", "ANATOMY_MODIFIER", 121, 126], ["L4", "ANATOMY", 146, 148], ["lower", "ANATOMY_MODIFIER", 149, 154]]], ["Two microliter of viral cDNA derived from the RT reaction was mixed with 48 l PCR master mixture.", [["viral cDNA", "DNA", 18, 28], ["viral cDNA", "TREATMENT", 18, 28], ["the RT reaction", "PROBLEM", 42, 57], ["48 l PCR master mixture", "TREATMENT", 73, 96], ["viral cDNA", "OBSERVATION", 18, 28]]], ["The PCR-cDNA mixture was subjected to the following amplification conditions: 95 \u2022 C, 10 min heat activation of AmpliTaq Gold enzyme; 40 cycles of 95 \u2022 C, 15 s; 58 \u2022 C, 40 s.", [["PCR-cDNA mixture", "DNA", 4, 20], ["AmpliTaq Gold enzyme", "PROTEIN", 112, 132], ["The PCR", "TEST", 0, 7], ["AmpliTaq Gold enzyme", "TEST", 112, 132], ["C", "TEST", 152, 153], ["C", "TEST", 166, 167]]], ["Two commercially available fluorogenic thermocyclers were used to perform the real-time RT-PCR assay developed in this report, the Rotor-Gene Real-Time PCR thermocycler (Westburg BV Inc., Leusden, The Netherlands), and the MJ Opticon I DNA Engine (MJ Inc., Massachusetts).Materials and methodsConstruction and isolation of the recombinant plasmid containing the SARS-CoV 3 -NCR.", [["plasmid", "ANATOMY", 339, 346], ["DNA", "CELLULAR_COMPONENT", 236, 239], ["recombinant plasmid", "DNA", 327, 346], ["SARS-CoV 3 -NCR", "DNA", 362, 377], ["SARS-CoV", "SPECIES", 362, 370], ["fluorogenic thermocyclers", "TREATMENT", 27, 52], ["PCR assay", "TEST", 91, 100], ["Materials", "TREATMENT", 272, 281], ["methodsConstruction", "TREATMENT", 286, 305], ["isolation", "TREATMENT", 310, 319], ["the recombinant plasmid", "TREATMENT", 323, 346], ["the SARS", "TEST", 358, 366], ["NCR", "PROBLEM", 374, 377]]], ["The sense and anti-sense primers of SARS-CoV were used to generate SARS-CoV cDNA through 35 cycles of PCR amplification.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 36, 44], ["CoV", "ORGANISM", 72, 75], ["anti-sense primers", "DNA", 14, 32], ["SARS-CoV cDNA", "DNA", 67, 80], ["SARS-CoV", "SPECIES", 36, 44], ["SARS-CoV", "SPECIES", 67, 75], ["SARS", "PROBLEM", 36, 40], ["CoV", "PROBLEM", 41, 44], ["CoV cDNA", "TREATMENT", 72, 80], ["PCR amplification", "TREATMENT", 102, 119]]], ["The SARS-CoV 3 -NCR PCR amplicon was then cloned into the SmaI site of pUC19 vector using TA-cloning protocol (Mezei and Storts, 1994) .", [["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 4, 14], ["SmaI", "GENE_OR_GENE_PRODUCT", 58, 62], ["pUC19", "GENE_OR_GENE_PRODUCT", 71, 76], ["SARS-CoV 3 -NCR PCR amplicon", "DNA", 4, 32], ["SmaI site", "DNA", 58, 67], ["pUC19 vector", "DNA", 71, 83], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["NCR PCR amplicon", "TREATMENT", 16, 32], ["TA-cloning protocol", "TREATMENT", 90, 109]]], ["The ligated vector-cDNA mixture was transformed into E. coli JM109 host.", [["E. coli", "ORGANISM", 53, 60], ["JM109 host", "CELL", 61, 71], ["cDNA mixture", "DNA", 19, 31], ["E. coli JM109", "SPECIES", 53, 66], ["E. coli JM109", "SPECIES", 53, 66], ["The ligated vector-cDNA mixture", "TREATMENT", 0, 31], ["coli JM109", "OBSERVATION", 56, 66]]], ["One of the recombinant plasmid clones, pHCV1 was identified as X-gal negative after incubating overnight at 37 \u2022 C on selective LB agar plate containing ampicillin and adequate X-gal, IPTG substrates.", [["clones", "ANATOMY", 31, 37], ["ampicillin", "CHEMICAL", 153, 163], ["IPTG", "CHEMICAL", 184, 188], ["ampicillin", "CHEMICAL", 153, 163], ["IPTG", "CHEMICAL", 184, 188], ["clones", "CELL", 31, 37], ["pHCV1", "GENE_OR_GENE_PRODUCT", 39, 44], ["X-gal", "GENE_OR_GENE_PRODUCT", 63, 68], ["ampicillin", "SIMPLE_CHEMICAL", 153, 163], ["X-gal", "GENE_OR_GENE_PRODUCT", 177, 182], ["IPTG", "SIMPLE_CHEMICAL", 184, 188], ["recombinant plasmid clones", "DNA", 11, 37], ["pHCV1", "DNA", 39, 44], ["X-gal", "DNA", 63, 68], ["the recombinant plasmid clones", "PROBLEM", 7, 37], ["pHCV1", "PROBLEM", 39, 44], ["selective LB agar plate", "TREATMENT", 118, 141], ["ampicillin", "TREATMENT", 153, 163], ["adequate X-gal", "TREATMENT", 168, 182], ["IPTG substrates", "TREATMENT", 184, 199], ["plasmid clones", "OBSERVATION", 23, 37]]], ["The pHCV1 plasmid was extracted and purified by modified alkaline lysis and CsCl-gradient centrifugation from 50 ml of overnight LB broth culture containing 50 mg/ml ampicillin.Quantitative real-time detection of SARS-CoV viral RNA using the 3 -NCR based fluorogenic RT-PCR assayThe assay was optimized by exploring combinations of assay parameters, such as Mg 2+ concentration, flanking primers/probe ratio and concentration, annealing temperature to achieve the highest possible detection efficiency of the SARS-CoV template.", [["CsCl", "CHEMICAL", 76, 80], ["ampicillin", "CHEMICAL", 166, 176], ["Mg", "CHEMICAL", 358, 360], ["CsCl", "CHEMICAL", 76, 80], ["ampicillin", "CHEMICAL", 166, 176], ["Mg 2+", "CHEMICAL", 358, 363], ["pHCV1", "GENE_OR_GENE_PRODUCT", 4, 9], ["CsCl", "SIMPLE_CHEMICAL", 76, 80], ["ampicillin", "SIMPLE_CHEMICAL", 166, 176], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 213, 221], ["Mg 2+", "SIMPLE_CHEMICAL", 358, 363], ["pHCV1 plasmid", "DNA", 4, 17], ["SARS-CoV viral RNA", "RNA", 213, 231], ["flanking primers", "DNA", 379, 395], ["SARS-CoV template", "DNA", 509, 526], ["pHCV1", "SPECIES", 4, 9], ["SARS-CoV", "SPECIES", 213, 221], ["SARS-CoV", "SPECIES", 509, 517], ["The pHCV1 plasmid", "TREATMENT", 0, 17], ["modified alkaline lysis", "TREATMENT", 48, 71], ["CsCl-gradient centrifugation", "TREATMENT", 76, 104], ["overnight LB broth culture", "TREATMENT", 119, 145], ["ampicillin", "TREATMENT", 166, 176], ["SARS", "PROBLEM", 213, 217], ["CoV viral RNA", "TEST", 218, 231], ["fluorogenic RT", "TEST", 255, 269], ["PCR assay", "TEST", 270, 279], ["The assay", "TEST", 279, 288], ["assay parameters", "TEST", 332, 348], ["Mg", "TREATMENT", 358, 360], ["flanking primers/probe ratio", "TREATMENT", 379, 407], ["concentration", "TREATMENT", 412, 425], ["annealing temperature", "PROBLEM", 427, 448], ["the SARS", "PROBLEM", 505, 513], ["CoV template", "TREATMENT", 514, 526], ["alkaline lysis", "OBSERVATION", 57, 71]]], ["The optimal RT and PCR assay conditions obtained were described above, and were used throughout this study.", [["The optimal RT and PCR assay conditions", "TEST", 0, 39], ["this study", "TEST", 96, 106]]], ["Various concentrations of viral RNA were used to demonstrate the quantitative nature of the assay.", [["viral RNA", "RNA", 26, 35], ["viral RNA", "TREATMENT", 26, 35], ["the assay", "TEST", 88, 97], ["concentrations", "OBSERVATION_MODIFIER", 8, 22], ["viral RNA", "OBSERVATION", 26, 35]]], ["Fig. 1a shows typical sigmoid plots representing formation of the SARS-CoV specific PCR products from samples derived from Vero cell culture containing five-fold of SARS-CoV using the fluorogenic SARS-CoV 3 -NCR based RT-PCR system.", [["samples", "ANATOMY", 102, 109], ["cell culture", "ANATOMY", 128, 140], ["SARS", "DISEASE", 66, 70], ["Vero cell", "CELL", 123, 132], ["SARS-CoV", "ORGANISM", 165, 173], ["SARS-CoV specific PCR products", "PROTEIN", 66, 96], ["Vero cell culture", "CELL_LINE", 123, 140], ["SARS-CoV", "SPECIES", 66, 74], ["SARS-CoV", "SPECIES", 165, 173], ["typical sigmoid plots", "PROBLEM", 14, 35], ["the SARS", "PROBLEM", 62, 70], ["CoV specific PCR products", "TREATMENT", 71, 96], ["Vero cell culture", "TEST", 123, 140], ["SARS", "PROBLEM", 165, 169], ["the fluorogenic SARS", "TEST", 180, 200], ["CoV", "TEST", 201, 204], ["sigmoid plots", "OBSERVATION", 22, 35]]], ["SARS-CoV viral stock was serially diluted (dynamic range from 18,000 to 0.24 pfu/reaction) and used to generate viral cDNA to demonstrate that the assay is a copy number dependent reaction.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["viral cDNA", "DNA", 112, 122], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["CoV viral stock", "TREATMENT", 5, 20], ["viral cDNA", "PROBLEM", 112, 122], ["the assay", "TEST", 143, 152], ["a copy number dependent reaction", "PROBLEM", 156, 188]]], ["Wells A1-A8 contained serially diluted viral copy numbers, i.e. pfu/reaction, to yield sequential sigmoid curves arranged from high through low copy number (left to right).", [["A1", "PROTEIN", 6, 8], ["serially diluted viral copy numbers", "TEST", 22, 57], ["sequential sigmoid curves", "TEST", 87, 112], ["sigmoid", "ANATOMY", 98, 105], ["left", "ANATOMY_MODIFIER", 157, 161], ["right", "ANATOMY_MODIFIER", 165, 170]]], ["B6-B8 wells were non-template controls that showed no noise, or background for this assay. (b) Real-time amplification and detection of the cloned SARS-CoV 3 -NCR, pHCV1 using the fluorogenic SARS-CoV 3 -NCR based RT-PCR system.", [["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 147, 157], ["pHCV1", "GENE_OR_GENE_PRODUCT", 164, 169], ["SARS-CoV 3 -NCR", "DNA", 147, 162], ["pHCV1", "DNA", 164, 169], ["SARS-CoV", "SPECIES", 147, 155], ["B6", "TEST", 0, 2], ["noise", "PROBLEM", 54, 59], ["this assay", "TEST", 79, 89], ["the cloned SARS", "TEST", 136, 151], ["CoV", "TEST", 152, 155], ["pHCV1", "TEST", 164, 169], ["the fluorogenic SARS", "TEST", 176, 196], ["CoV", "TEST", 197, 200], ["no", "UNCERTAINTY", 51, 53]]], ["Five-fold serial dilutions of the cloned SARS-CoV plasmid, pHCV1 (from 700,000 to 2 GE/reaction) were used to demonstrate that the assay is a copy number dependent reaction.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 41, 49], ["pHCV1", "ORGANISM", 59, 64], ["SARS-CoV plasmid", "DNA", 41, 57], ["pHCV1", "DNA", 59, 64], ["SARS-CoV", "SPECIES", 41, 49], ["Five-fold serial dilutions", "TREATMENT", 0, 26], ["the cloned SARS", "TEST", 30, 45], ["CoV plasmid", "TEST", 46, 57], ["pHCV1", "TEST", 59, 64], ["the assay", "TEST", 127, 136], ["a copy number dependent reaction", "PROBLEM", 140, 172]]], ["Wells A1-A8 containing serially diluted pHCV1 yielded sequential sigmoid curves arranged from high through low copy number (left to right of the figure).", [["A1", "PROTEIN", 6, 8], ["A8", "PROTEIN", 9, 11], ["pHCV1", "PROTEIN", 40, 45], ["serially diluted pHCV1", "TREATMENT", 23, 45], ["sequential sigmoid curves", "TEST", 54, 79], ["sigmoid", "ANATOMY", 65, 72], ["left", "ANATOMY_MODIFIER", 124, 128], ["right", "ANATOMY_MODIFIER", 132, 137]]], ["B6-B8 wells were non-template controls that showed no noise, or background for this assay. serial dilutions of viral RNA by showing accumulation in fluorescence ( R) as amplification cycle number increases.", [["viral RNA", "RNA", 111, 120], ["B6", "TEST", 0, 2], ["noise", "PROBLEM", 54, 59], ["this assay", "TEST", 79, 89], ["serial dilutions", "TEST", 91, 107], ["viral RNA", "PROBLEM", 111, 120], ["accumulation in fluorescence", "PROBLEM", 132, 160], ["no", "UNCERTAINTY", 51, 53], ["viral RNA", "OBSERVATION", 111, 120]]], ["Threshold cycle (C T ) for each concentration of cDNA is defined as the cycle number where the application software detects the increase of product fluorescence above the calculated background fluorescence (Holland et al., 1991) .", [["cDNA", "DNA", 49, 53], ["C T )", "TREATMENT", 17, 22], ["each concentration of cDNA", "PROBLEM", 27, 53], ["the application software", "TEST", 91, 115], ["increase", "OBSERVATION_MODIFIER", 128, 136]]], ["The C T values for the described viral cDNA concentrations were automatically calculated by application software as the intercepts of the fluorescence signals and the base line of background fluorescence (set as the average of all tested samples from cycle 3 to 15).", [["C T", "GENE_OR_GENE_PRODUCT", 4, 7], ["viral cDNA", "DNA", 33, 43], ["The C T values", "TEST", 0, 14], ["the described viral cDNA concentrations", "PROBLEM", 19, 58], ["the fluorescence signals", "TEST", 134, 158], ["background fluorescence", "TEST", 180, 203]]], ["Parallel sigmoid plots representing serial dilutions of SARS-CoV cDNA template are shown and displayed in sequential order.", [["SARS", "DISEASE", 56, 60], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 56, 64], ["SARS-CoV cDNA template", "DNA", 56, 78], ["SARS-CoV", "SPECIES", 56, 64], ["Parallel sigmoid plots", "PROBLEM", 0, 22], ["serial dilutions", "TREATMENT", 36, 52], ["SARS", "PROBLEM", 56, 60], ["CoV cDNA template", "TREATMENT", 61, 78], ["sigmoid", "ANATOMY", 9, 16]]], ["Higher concentrations of template cDNA resulted in lower C T values, i.e. greater initial viral cDNA template copy numbers required fewer amplification cycles or a smaller C T value to reach the detectable fluorescence level.", [["C T", "GENE_OR_GENE_PRODUCT", 57, 60], ["template cDNA", "DNA", 25, 38], ["viral cDNA", "DNA", 90, 100], ["Higher concentrations of template cDNA", "PROBLEM", 0, 38], ["lower C T values", "PROBLEM", 51, 67], ["greater initial viral cDNA template copy numbers", "PROBLEM", 74, 122], ["fewer amplification cycles", "TREATMENT", 132, 158], ["a smaller C T value", "PROBLEM", 162, 181]]], ["These preliminary results demonstrated that the fluorogenic RT-PCR assay was capable of detecting SARS-CoV viral cDNA in a dose-dependent fashion over at least seven serial five-fold dilutions (4.9 logs dilution).", [["SARS-CoV", "ORGANISM", 98, 106], ["SARS-CoV viral cDNA", "DNA", 98, 117], ["SARS-CoV", "SPECIES", 98, 106], ["the fluorogenic RT-PCR assay", "TEST", 44, 72], ["SARS", "PROBLEM", 98, 102], ["CoV viral cDNA", "TREATMENT", 103, 117]]], ["In addition, the assay was also capable of discriminating specific SARS-CoV viral stock cDNA from background levels (non-template controls showed no fluorescence signal).Comparison of the cloned recombinant plasmid, pHCV1 containing the 3 -noncoding SARS-CoV cDNA and viral cDNA preparation as SARS-CoV copy number standardsThus far, the SARS-CoV cDNA copy standards (presented in plaque-forming units, pfu) used in this study were obtained from laboratory derived SARS-CoV stock.", [["plasmid", "ANATOMY", 207, 214], ["plaque", "ANATOMY", 381, 387], ["SARS", "DISEASE", 465, 469], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 67, 75], ["pHCV1", "GENE_OR_GENE_PRODUCT", 216, 221], ["CoV", "ORGANISM", 255, 258], ["SARS-CoV", "ORGANISM", 465, 473], ["SARS-CoV viral stock cDNA", "DNA", 67, 92], ["cloned recombinant plasmid", "DNA", 188, 214], ["pHCV1", "DNA", 216, 221], ["3 -noncoding SARS-CoV cDNA", "DNA", 237, 263], ["viral cDNA", "DNA", 268, 278], ["SARS-CoV cDNA", "DNA", 338, 351], ["SARS-CoV", "SPECIES", 67, 75], ["SARS-CoV", "SPECIES", 250, 258], ["SARS-CoV", "SPECIES", 294, 302], ["SARS-CoV", "SPECIES", 338, 346], ["SARS-CoV", "SPECIES", 465, 473], ["the assay", "TEST", 13, 22], ["CoV viral stock cDNA", "TEST", 72, 92], ["background levels", "TEST", 98, 115], ["non-template controls", "TEST", 117, 138], ["fluorescence signal", "PROBLEM", 149, 168], ["the cloned recombinant plasmid", "TREATMENT", 184, 214], ["noncoding SARS", "PROBLEM", 240, 254], ["CoV cDNA", "TREATMENT", 255, 263], ["viral cDNA preparation", "TREATMENT", 268, 290], ["SARS", "PROBLEM", 294, 298], ["the SARS", "TEST", 334, 342], ["this study", "TEST", 416, 426]]], ["Live SARS-CoV cannot be safely used in most clinical laboratories and it is also difficult to maintain consistent viral RNA standards for routine usage due to the labile nature of RNA molecules.", [["RNA molecules", "PROTEIN", 180, 193], ["SARS-CoV", "SPECIES", 5, 13], ["Live SARS-CoV", "PROBLEM", 0, 13], ["routine usage", "TREATMENT", 138, 151], ["the labile nature of RNA molecules", "PROBLEM", 159, 193], ["RNA molecules", "OBSERVATION", 180, 193]]], ["Therefore, a recombinant plasmid containing the 3 -noncoding SARS-CoV cDNA was constructed to serve as a SARS-CoV genomic equivalence standard.", [["plasmid", "ANATOMY", 25, 32], ["SARS-CoV", "ORGANISM", 61, 69], ["recombinant plasmid", "DNA", 13, 32], ["3 -noncoding SARS-CoV cDNA", "DNA", 48, 74], ["SARS-CoV", "SPECIES", 61, 69], ["a recombinant plasmid", "TREATMENT", 11, 32], ["noncoding SARS", "PROBLEM", 51, 65], ["CoV cDNA", "TREATMENT", 66, 74], ["a SARS", "TEST", 103, 109]]], ["The recombinant plasmid, pHCV1 containing the SARS-CoV 3 -noncoding region was constructed and isolated as a possible SARS-CoV genomic reference standard (see Section 2).", [["plasmid", "ANATOMY", 16, 23], ["pHCV1", "GENE_OR_GENE_PRODUCT", 25, 30], ["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 46, 56], ["recombinant plasmid", "DNA", 4, 23], ["pHCV1", "DNA", 25, 30], ["SARS-CoV 3 -noncoding region", "DNA", 46, 74], ["SARS-CoV", "SPECIES", 46, 54], ["SARS-CoV", "SPECIES", 118, 126], ["The recombinant plasmid", "TREATMENT", 0, 23], ["pHCV1", "PROBLEM", 25, 30], ["the SARS", "TEST", 42, 50], ["SARS", "PROBLEM", 118, 122], ["recombinant", "OBSERVATION_MODIFIER", 4, 15], ["plasmid", "OBSERVATION", 16, 23]]], ["Fig. 1b demonstrated that the pHCV1 plasmid can be used as a SARS-CoV genomic copy number standard for the assay developed in this study.", [["pHCV1", "GENE_OR_GENE_PRODUCT", 30, 35], ["pHCV1 plasmid", "DNA", 30, 43], ["the pHCV1 plasmid", "TREATMENT", 26, 43], ["a SARS", "TEST", 59, 65], ["the assay", "TEST", 103, 112], ["this study", "TEST", 126, 136]]], ["The C T values of serially diluted plasmid concentration reflect a copy number dependent reaction.", [["plasmid", "ANATOMY", 35, 42], ["C T", "GENE_OR_GENE_PRODUCT", 4, 7], ["The C T values", "TEST", 0, 14], ["serially diluted plasmid concentration", "TREATMENT", 18, 56], ["a copy number dependent reaction", "PROBLEM", 65, 97]]], ["The slope of the pHCV1 standard curve (0.28) is identical to the slope of SARS-CoV viral standard curve (see Fig. 2 ).", [["SARS-CoV", "SPECIES", 74, 82], ["the pHCV1 standard curve", "TREATMENT", 13, 37], ["SARS", "PROBLEM", 74, 78], ["CoV viral standard curve", "TEST", 79, 103], ["slope", "OBSERVATION_MODIFIER", 4, 9]]], ["This illustrates that the pHCV1 DNA and viral cDNA can be amplified by the same method with the same amplification efficacy.", [["pHCV1", "GENE_OR_GENE_PRODUCT", 26, 31], ["DNA", "CELLULAR_COMPONENT", 32, 35], ["pHCV1 DNA", "DNA", 26, 35], ["viral cDNA", "DNA", 40, 50], ["pHCV1", "SPECIES", 26, 31], ["the pHCV1 DNA", "PROBLEM", 22, 35], ["viral cDNA", "PROBLEM", 40, 50], ["viral cDNA", "OBSERVATION", 40, 50]]], ["Comparison of quantitative SARS-CoV standard curves derived from direct viral cDNA preparation and the cloned 3 -NCR SARS-CoV plasmid DNA, pHCV1.", [["DNA", "CELLULAR_COMPONENT", 134, 137], ["cloned 3 -NCR SARS-CoV plasmid DNA", "DNA", 103, 137], ["pHCV1", "DNA", 139, 144], ["SARS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 117, 125], ["quantitative SARS", "PROBLEM", 14, 31], ["CoV standard curves", "TEST", 32, 51], ["direct viral cDNA preparation", "TREATMENT", 65, 94], ["NCR SARS", "TEST", 113, 121], ["CoV plasmid DNA", "TREATMENT", 122, 137], ["pHCV1", "PROBLEM", 139, 144]]], ["It was shown that both standard curves yield the same slope (two parallel lines taken from Fig. 1a and b) .", [["two parallel lines", "TREATMENT", 61, 79]]], ["The GE/pfu ratio of 1:1600 could be derived from the direct readout of intercepts difference at Y-(GE/pfu).", [["The GE/pfu ratio", "TEST", 0, 16]]], ["The GE/pfu ratio can also be calculated from the intercepts difference at X-(C t cycle) of 12.0 cycles between viral cDNA (pfu) and cloned plasmid (GE) standard curves as followings: GE/pfu = E 12 or 1.81 12.0 = 1239.Amplification efficiency and detection sensitivity of the SARS-CoV 3 -NCR based PCR cycling reactionThe ideal amplification efficiency of any given double helical cDNA substrate should yield a two-fold increase in PCR product during each amplification cycle.", [["viral cDNA", "DNA", 111, 121], ["SARS-CoV 3 -NCR", "DNA", 275, 290], ["SARS-CoV", "SPECIES", 275, 283], ["The GE/pfu ratio", "TEST", 0, 16], ["C t cycle)", "TREATMENT", 77, 87], ["viral cDNA", "TEST", 111, 121], ["standard curves", "TEST", 152, 167], ["GE/pfu", "TEST", 183, 189], ["Amplification efficiency", "TEST", 217, 241], ["detection sensitivity", "TEST", 246, 267], ["the SARS", "TEST", 271, 279], ["CoV", "TEST", 280, 283], ["NCR based PCR", "TEST", 287, 300], ["cycling reaction", "PROBLEM", 301, 317], ["double helical cDNA substrate", "TREATMENT", 365, 394], ["a two-fold increase in PCR product", "TREATMENT", 408, 442]]], ["The E value, PCR product increment per amplification cycle of any quantitative real-time PCR assay can be estimated from the slope of standard curves consisting of C T values of serially diluted target cDNA; either viral cDNA preparations or the cloned plasmid, pHCV1 may be used for this purpose (shown in Fig. 2) .", [["plasmid", "ANATOMY", 253, 260], ["C T", "GENE_OR_GENE_PRODUCT", 164, 167], ["pHCV1", "GENE_OR_GENE_PRODUCT", 262, 267], ["target cDNA", "DNA", 195, 206], ["viral cDNA preparations", "DNA", 215, 238], ["cloned plasmid", "DNA", 246, 260], ["pHCV1", "DNA", 262, 267], ["The E value", "TEST", 0, 11], ["PCR assay", "TEST", 89, 98], ["standard curves", "TEST", 134, 149], ["C T values", "TEST", 164, 174], ["serially diluted target cDNA", "TREATMENT", 178, 206], ["viral cDNA preparations", "TREATMENT", 215, 238], ["the cloned plasmid", "TREATMENT", 242, 260], ["pHCV1", "TREATMENT", 262, 267]]], ["The SARS-CoV 3 -NCR PCR assay consistently yielded standard curves with the slope of 0.28 producing an E value of 1.81 (\u22121/log(slope)) or amplification efficiency of E observed /E ideal \u00d7 100 = 91%.", [["SARS-CoV 3 -NCR PCR", "DNA", 4, 23], ["SARS-CoV", "SPECIES", 4, 12], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["NCR PCR assay", "TEST", 16, 29], ["standard curves", "TEST", 51, 66], ["the slope", "TEST", 72, 81], ["an E value", "TEST", 100, 110], ["amplification efficiency of E", "PROBLEM", 138, 167]]], ["It was demonstrated that the RT-PCR assay with 91% amplification efficiency could be used for consistent detect ion of the SARS-CoV viral RNA extracted from samples containing as little as 0.005 pfu per reaction with an anticipated C T value of 40 cycles (data not shown).", [["samples", "ANATOMY", 157, 164], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 123, 131], ["SARS-CoV viral RNA", "RNA", 123, 141], ["SARS-CoV", "SPECIES", 123, 131], ["the RT-PCR assay", "TEST", 25, 41], ["the SARS", "PROBLEM", 119, 127], ["CoV viral RNA", "PROBLEM", 128, 141]]], ["Fig. 2 illustrates that the assay could be used to detect viral cDNA preparations as well as the cloned SARS-CoV 3 -NCR at the same amplification efficacy.", [["SARS-CoV 3", "GENE_OR_GENE_PRODUCT", 104, 114], ["SARS-CoV 3 -NCR", "DNA", 104, 119], ["SARS-CoV", "SPECIES", 104, 112], ["the assay", "TEST", 24, 33], ["viral cDNA preparations", "TREATMENT", 58, 81], ["the cloned SARS", "TEST", 93, 108], ["CoV", "TEST", 109, 112], ["NCR", "PROBLEM", 116, 119]]], ["A linear regression model was used to determine the number of infectious units (pfu) present in a given SARS-CoV preparation and the results from this calculation indicates that the ratio of defective to infectious particles could be deduced from the difference of standard curves of assays using viral cDNA preparations as well as the cloned SARS-CoV 3 -NCR.", [["SARS", "DISEASE", 104, 108], ["viral cDNA preparations", "DNA", 297, 320], ["SARS-CoV 3 -NCR", "DNA", 343, 358], ["SARS-CoV", "SPECIES", 104, 112], ["SARS-CoV", "SPECIES", 343, 351], ["A linear regression model", "PROBLEM", 0, 25], ["SARS-CoV preparation", "TREATMENT", 104, 124], ["this calculation", "TEST", 146, 162], ["defective to infectious particles", "PROBLEM", 191, 224], ["assays", "TEST", 284, 290], ["viral cDNA preparations", "TREATMENT", 297, 320], ["the cloned SARS", "TEST", 332, 347], ["CoV", "TEST", 348, 351], ["NCR", "PROBLEM", 355, 358], ["infectious", "OBSERVATION", 62, 72]]], ["The GE/pfu ratio of 1:1600 was derived from the direct readout of intercepts difference at Y-(GE/pfu).", [["The GE/pfu ratio", "TEST", 0, 16]]], ["The GE/pfu ratio was calculated from the intercepts difference at X-(C t cycle) of 12.0 cycles between viral cDNA (pfu) and cloned plasmid (GE) standard curves as followings: GE/pfu = E 12 or 1.81 12.0 = 1239.Laboratory diagnosis of SARS-CoV infection from clinical specimens of probable and suspected SARS patients in TaiwanTo demonstrate the utility of the SARS-specific quantitative RT-PCR assay for diagnostic purposes, the assay was used for quantitative detection of SARS-CoV from nasopharyngeal aspirates obtained from patients that were diagnosed as probable or suspected SARS cases using clinical criteria.", [["specimens", "ANATOMY", 266, 275], ["nasopharyngeal aspirates", "ANATOMY", 487, 511], ["SARS-CoV infection", "DISEASE", 233, 251], ["SARS", "DISEASE", 302, 306], ["SARS", "DISEASE", 580, 584], ["SARS-CoV", "ORGANISM", 233, 241], ["patients", "ORGANISM", 307, 315], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 473, 481], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 487, 511], ["patients", "ORGANISM", 526, 534], ["viral cDNA", "DNA", 103, 113], ["patients", "SPECIES", 307, 315], ["patients", "SPECIES", 526, 534], ["SARS-CoV", "SPECIES", 233, 241], ["SARS-CoV", "SPECIES", 473, 481], ["The GE/pfu ratio", "TEST", 0, 16], ["C t cycle", "TREATMENT", 69, 78], ["viral cDNA", "TEST", 103, 113], ["standard curves", "TEST", 144, 159], ["GE/pfu", "TEST", 175, 181], ["SARS", "PROBLEM", 233, 237], ["CoV infection", "PROBLEM", 238, 251], ["clinical specimens", "TEST", 257, 275], ["the SARS", "TEST", 355, 363], ["diagnostic purposes", "TEST", 403, 422], ["the assay", "TEST", 424, 433], ["quantitative detection", "TEST", 447, 469], ["SARS", "PROBLEM", 473, 477], ["CoV", "PROBLEM", 478, 481], ["nasopharyngeal aspirates", "TEST", 487, 511], ["CoV infection", "OBSERVATION", 238, 251], ["nasopharyngeal", "ANATOMY", 487, 501], ["aspirates", "OBSERVATION", 502, 511]]], ["The assay used 5 l of extracted aspirate wash per reaction and the assay was set to run for 45 cycles of amplification.", [["The assay", "TEST", 0, 9], ["the assay", "TEST", 63, 72], ["45 cycles of amplification", "TREATMENT", 92, 118]]], ["CDC-PC was the SARS positive control RNA provided by the Taiwanese CDC, and BLANK served as the negative control.", [["CDC-PC", "CANCER", 0, 6], ["SARS positive control RNA", "RNA", 15, 40], ["BLANK", "PROTEIN", 76, 81], ["CDC", "TEST", 0, 3], ["PC", "PROBLEM", 4, 6], ["the SARS positive control RNA", "PROBLEM", 11, 40]]], ["The cloned pHCV1 template (STD2-10) was used as the SARS-CoV GE copy control. * Based on GE/pfu ration of 1200:1. * * Below the cutoff threshold (SARS negative).", [["STD2-10", "CHEMICAL", 27, 34], ["pHCV1", "GENE_OR_GENE_PRODUCT", 11, 16], ["pHCV1 template", "DNA", 11, 25], ["SARS-CoV", "SPECIES", 52, 60], ["The cloned pHCV1 template", "TREATMENT", 0, 25], ["STD2", "TEST", 27, 31], ["the SARS", "TEST", 48, 56], ["CoV GE copy control", "TREATMENT", 57, 76], ["GE/pfu ration", "TREATMENT", 89, 102], ["the cutoff threshold", "TEST", 124, 144]]], ["Table 1 indicates that the assay developed from this study could efficiently detect SARS-CoV from infected patients in Taiwan.", [["SARS-CoV from infected", "DISEASE", 84, 106], ["SARS-CoV", "ORGANISM", 84, 92], ["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["SARS-CoV", "SPECIES", 84, 92], ["the assay", "TEST", 23, 32], ["this study", "TEST", 48, 58], ["SARS", "PROBLEM", 84, 88]]], ["SARS-CoV RNA provided by the Center for Diseases Control (CDC) of the Ministry of Health, Taiwan and the cloned pHCV1 were used as positive controls.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["pHCV1", "GENE_OR_GENE_PRODUCT", 112, 117], ["SARS-CoV RNA", "RNA", 0, 12], ["cloned pHCV1", "DNA", 105, 117], ["SARS-CoV", "SPECIES", 0, 8], ["the cloned pHCV1", "TREATMENT", 101, 117]]], ["Five out of 16 samples tested were identified as SARS-CoV positive (31.2% positive rate for SARS identification).", [["samples", "ANATOMY", 15, 22], ["SARS", "DISEASE", 92, 96], ["samples", "CANCER", 15, 22], ["SARS-CoV", "ORGANISM", 49, 57], ["SARS-CoV", "SPECIES", 49, 57], ["16 samples", "TEST", 12, 22], ["SARS", "TEST", 49, 53], ["CoV", "TEST", 54, 57], ["SARS identification", "TEST", 92, 111]]], ["SARS-CoV RT-PCR positive samples indicated the presence of low concentrations of viral nucleic acid.", [["samples", "ANATOMY", 25, 32], ["nucleic acid", "CHEMICAL", 87, 99], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS", "TEST", 0, 4], ["CoV RT-PCR positive samples", "TEST", 5, 32], ["low concentrations of viral nucleic acid", "PROBLEM", 59, 99], ["low concentrations", "OBSERVATION_MODIFIER", 59, 77], ["viral nucleic acid", "OBSERVATION", 81, 99]]], ["Unfortunately, no other laboratory testing results, such as the rise of SARS-specific antibodies and SARS-CoV viral isolation were available to corroborate the RT-PCR data in this study.", [["SARS", "DISEASE", 72, 76], ["SARS-CoV", "ORGANISM", 101, 109], ["SARS-specific antibodies", "PROTEIN", 72, 96], ["SARS-CoV", "SPECIES", 101, 109], ["other laboratory testing", "TEST", 18, 42], ["SARS", "PROBLEM", 72, 76], ["specific antibodies", "TEST", 77, 96], ["SARS", "PROBLEM", 101, 105], ["CoV viral isolation", "PROBLEM", 106, 125], ["the RT-PCR data", "TEST", 156, 171], ["this study", "TEST", 175, 185]]], ["We further investigated and confirmed the specificity of SARS-CoV RT-PCR in this study.", [["SARS-CoV", "SPECIES", 57, 65], ["SARS", "TEST", 57, 61], ["CoV RT-PCR", "TEST", 62, 72], ["this study", "TEST", 76, 86]]], ["Twenty clinical samples derived from acute respiratory disease (ARD) patients caused by adenovirus in US were employed as negative controls for SARS-CoV assay (McNeill et al., 2000) None of these ARD samples yield any positive fluorescence signal for SARS-CoV (specificity = 100%).DiscussionsThe SARS-CoV genomic sequence differs significantly from other known coronaviruses, particularly in the 5 -and 3 -NCR (Marra et al., 2003; Ruan et al., 2003) .", [["samples", "ANATOMY", 16, 23], ["respiratory", "ANATOMY", 43, 54], ["samples", "ANATOMY", 200, 207], ["acute respiratory disease", "DISEASE", 37, 62], ["ARD", "DISEASE", 64, 67], ["patients", "ORGANISM", 69, 77], ["adenovirus", "ORGANISM", 88, 98], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 251, 259], ["coronaviruses", "ORGANISM", 361, 374], ["SARS-CoV genomic sequence", "DNA", 296, 321], ["patients", "SPECIES", 69, 77], ["adenovirus", "SPECIES", 88, 98], ["SARS-CoV", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 251, 259], ["SARS-CoV", "SPECIES", 296, 304], ["Twenty clinical samples", "PROBLEM", 0, 23], ["acute respiratory disease (ARD)", "PROBLEM", 37, 68], ["adenovirus", "PROBLEM", 88, 98], ["SARS", "PROBLEM", 144, 148], ["CoV assay", "TEST", 149, 158], ["these ARD samples", "TEST", 190, 207], ["fluorescence signal", "TEST", 227, 246], ["SARS", "TEST", 251, 255], ["CoV", "TEST", 256, 259], ["specificity", "TEST", 261, 272], ["The SARS", "TEST", 292, 300], ["CoV genomic sequence", "TEST", 301, 321], ["other known coronaviruses", "PROBLEM", 349, 374], ["acute", "OBSERVATION_MODIFIER", 37, 42], ["respiratory disease", "OBSERVATION", 43, 62], ["coronaviruses", "OBSERVATION", 361, 374]]], ["There are more than forty 3 -NCR SARS-CoV sequences deposited in the GenBank database, and a Blast search demonstrated 100% homology among various SARS-CoV isolates obtained from different parts of the world.", [["SARS-CoV", "ORGANISM", 147, 155], ["NCR SARS-CoV sequences", "DNA", 29, 51], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 147, 155], ["NCR SARS", "TEST", 29, 37], ["CoV sequences", "TEST", 38, 51], ["the GenBank database", "TEST", 65, 85], ["a Blast search", "TEST", 91, 105], ["various SARS", "TEST", 139, 151], ["CoV isolates", "TEST", 152, 164], ["GenBank", "ANATOMY", 69, 76]]], ["It was demonstrated that the 3 -NCR based fluorogoenic RT-PCR developed in this study could be used as an efficient diagnostic assay for laboratory grown SARS-CoV detection and quantification.", [["NCR", "DNA", 32, 35], ["SARS-CoV", "SPECIES", 154, 162], ["fluorogoenic RT-PCR", "TEST", 42, 61], ["this study", "TEST", 75, 85], ["laboratory grown SARS", "TEST", 137, 158], ["CoV detection", "TEST", 159, 172], ["quantification", "TEST", 177, 191]]], ["It was preliminarily illustrated that the assay has a wide dynamic range of detection (more than 4.9 logs) with excellent linearity (linear coefficient greater than 0.99) using cDNA templates derived from serial dilutions of viral RNA through reverse transcription (RT) reaction.", [["cDNA templates", "DNA", 177, 191], ["viral RNA", "RNA", 225, 234], ["the assay", "TEST", 38, 47], ["cDNA templates", "TREATMENT", 177, 191], ["serial dilutions", "TEST", 205, 221], ["viral RNA", "TREATMENT", 225, 234], ["reverse transcription", "TREATMENT", 243, 264]]], ["The data presented in Fig. 1 showed the detection range of SARS-CoV from 18,000 through 0.25 pfu per assay.", [["SARS", "DISEASE", 59, 63], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["SARS-CoV", "SPECIES", 59, 67], ["The data", "TEST", 0, 8], ["the detection", "TEST", 36, 49], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67]]], ["The C t value of 34 cycles obtained for the 0.25 pfu/assay did not represent the ultimate end point of the assay.", [["The C t value", "TEST", 0, 13], ["pfu/assay", "TEST", 49, 58]]], ["It was later demonstrated that the end point, or lower detection limit of the assay could reach as low as 0.005 pfu per assay with the C t value approximate at 40 cycles (data not shown).", [["the assay", "TEST", 74, 83], ["the C t value", "TEST", 131, 144], ["lower", "OBSERVATION_MODIFIER", 49, 54]]], ["The cloned 3 -NCR SARS-CoV cDNA pHCV1 was also established in this study as a molecular copy standard, or genomic equivalent standard for the SARS-CoV assay.", [["cloned 3 -NCR SARS-CoV cDNA pHCV1", "DNA", 4, 37], ["SARS-CoV", "SPECIES", 18, 26], ["SARS-CoV", "SPECIES", 142, 150], ["NCR SARS", "TEST", 14, 22], ["CoV cDNA pHCV1", "TEST", 23, 37], ["this study", "TEST", 62, 72], ["the SARS", "TEST", 138, 146], ["CoV assay", "TEST", 147, 156]]], ["It was demonstrated in this study that the cloned cDNA pHCV1 could mimic the viral cDNA derived from SARS-CoV RNA preparations as a copy number standard for the assay.", [["pHCV1", "GENE_OR_GENE_PRODUCT", 55, 60], ["SARS-CoV", "ORGANISM", 101, 109], ["cDNA pHCV1", "DNA", 50, 60], ["viral cDNA", "DNA", 77, 87], ["SARS-CoV RNA", "RNA", 101, 113], ["SARS-CoV", "SPECIES", 101, 109], ["this study", "TEST", 23, 33], ["the cloned cDNA pHCV1", "PROBLEM", 39, 60], ["the viral cDNA", "PROBLEM", 73, 87], ["CoV RNA preparations", "TREATMENT", 106, 126], ["the assay", "TEST", 157, 166]]], ["Fig. 2 showed the minimal detectable pHCV1 copy number of two GE per assay with C t value greater than 40 cycles.", [["Fig", "TEST", 0, 3], ["C t value", "TEST", 80, 89]]], ["However, the population size of cloned SARS-CoV standard at two copies per reaction was too small to be represented as a \"normal distribution\" (Gaussian distribution).", [["SARS", "DISEASE", 39, 43], ["SARS-CoV", "ORGANISM", 39, 47], ["SARS-CoV", "SPECIES", 39, 47], ["cloned SARS", "PROBLEM", 32, 43], ["population", "OBSERVATION_MODIFIER", 13, 23], ["size", "OBSERVATION_MODIFIER", 24, 28], ["too small to", "OBSERVATION_MODIFIER", 88, 100], ["normal", "OBSERVATION", 122, 128]]], ["Thus, multiple repeats of the same assay using such a low substrate copy number, two copies per assay would yield the result of \"hit or miss\" phenomenon.", [["\"hit or miss\" phenomenon", "PROBLEM", 128, 152]]], ["In order to obtain more reproducible results of the assay, the cutoff, or end point of pHCV1 for the assay was raised to 6-8 GE per assay with the C t value at 40 cycles.", [["pHCV1", "PROTEIN", 87, 92], ["the assay", "TEST", 48, 57], ["the cutoff", "TEST", 59, 69], ["pHCV1", "TEST", 87, 92], ["the assay", "TEST", 97, 106], ["the C t value", "TEST", 143, 156]]], ["Based on the calculated SARS-CoV GE/pfu ratio from Fig. 3 , and the actual experimental data using serial dilutions of viral cDNA preparations and cloned pHCV1, the lower detection limit of SARS-CoV assay could be conservatively defined as 0.005 pfu or 6-8 GE per assay.DiscussionsThe traditional expression for viral titer, plaque-forming unit (pfu) per ml must be determined through a conventional viral plaquing assay.", [["plaque", "ANATOMY", 325, 331], ["pHCV1", "GENE_OR_GENE_PRODUCT", 154, 159], ["pHCV1", "PROTEIN", 154, 159], ["SARS-CoV", "SPECIES", 190, 198], ["the calculated SARS", "TEST", 9, 28], ["CoV GE/pfu ratio", "TEST", 29, 45], ["serial dilutions", "TREATMENT", 99, 115], ["viral cDNA preparations", "TREATMENT", 119, 142], ["cloned pHCV1", "TEST", 147, 159], ["SARS", "PROBLEM", 190, 194], ["CoV assay", "TEST", 195, 204], ["viral titer", "TEST", 312, 323], ["a conventional viral plaquing assay", "TREATMENT", 385, 420]]], ["This culturing method identifies viable viruses that can generate cytopathic effects, or plaques, on the confluent lawn of susceptible host cells, such as Vero cells (Drosten et al., 2003) .", [["plaques", "ANATOMY", 89, 96], ["cells", "ANATOMY", 140, 145], ["Vero cells", "ANATOMY", 155, 165], ["host cells", "CELL", 135, 145], ["Vero cells", "CELL", 155, 165], ["susceptible host cells", "CELL_TYPE", 123, 145], ["Vero cells", "CELL_LINE", 155, 165], ["This culturing method", "TEST", 0, 21], ["viable viruses", "PROBLEM", 33, 47], ["cytopathic effects", "PROBLEM", 66, 84], ["plaques", "PROBLEM", 89, 96], ["susceptible host cells", "PROBLEM", 123, 145], ["viruses", "OBSERVATION", 40, 47], ["cytopathic", "OBSERVATION_MODIFIER", 66, 76], ["plaques", "OBSERVATION", 89, 96], ["confluent", "OBSERVATION_MODIFIER", 105, 114], ["lawn", "OBSERVATION_MODIFIER", 115, 119], ["susceptible host cells", "OBSERVATION", 123, 145], ["Vero cells", "OBSERVATION", 155, 165]]], ["The viral plaquing assay can only be used to score the total viable viruses that can infect the host cells.", [["cells", "ANATOMY", 101, 106], ["cells", "CELL", 101, 106], ["host cells", "CELL_TYPE", 96, 106], ["The viral plaquing assay", "TREATMENT", 0, 24], ["the total viable viruses", "PROBLEM", 51, 75], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["plaquing", "OBSERVATION", 10, 18], ["viruses", "OBSERVATION", 68, 75], ["host cells", "OBSERVATION", 96, 106]]], ["Thus, it cannot be used to distinguish, or detect any viral contaminants that are capable of infecting the host cells used for the plaquing assay (Porterfield, 1959; De Madrid and Porterfield, 1969) .", [["cells", "ANATOMY", 112, 117], ["cells", "CELL", 112, 117], ["host cells", "CELL_TYPE", 107, 117], ["any viral contaminants", "PROBLEM", 50, 72], ["host cells", "OBSERVATION", 107, 117]]], ["In contrast, the SRAR-CoV RT-PCR assay developed in this study is specific for the SARS-CoV detection.", [["SRAR-CoV", "GENE_OR_GENE_PRODUCT", 17, 25], ["SRAR", "DNA", 17, 21], ["SARS-CoV", "SPECIES", 83, 91], ["the SRAR", "TEST", 13, 21], ["CoV RT-PCR assay", "TEST", 22, 38], ["this study", "TEST", 52, 62], ["the SARS", "TEST", 79, 87], ["CoV detection", "TEST", 88, 101]]], ["However, the SARS-CoV PCR assay developed from this study cannot be used to differentiate among living versus dead viral particles (Freeman et al., 1999; Bae et al., 2003; MacKay et al., 2002) .", [["SARS-CoV", "SPECIES", 13, 21], ["the SARS", "TEST", 9, 17], ["CoV PCR assay", "TEST", 18, 31], ["this study", "TEST", 47, 57]]], ["Any viral particle or genomic segment containing intact PCR target sequence, such as the 3 -NCR SARS-CoV would be detected as one genomic equivalence (GE).", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 96, 104], ["genomic segment", "DNA", 22, 37], ["PCR target sequence", "DNA", 56, 75], ["3 -NCR SARS-CoV", "DNA", 89, 104], ["SARS-CoV", "SPECIES", 96, 104], ["Any viral particle or genomic segment containing intact PCR target sequence", "PROBLEM", 0, 75], ["CoV", "PROBLEM", 101, 104], ["viral particle", "OBSERVATION", 4, 18], ["segment", "ANATOMY_MODIFIER", 30, 37]]], ["The difference between pfu (viable viruses) and GE (total viral counts including defective and functional viruses) of SARS-CoV can be mathematically expressed as GE/pfu ratio (Freeman et al., 1999; Bae et al., 2003) .", [["SARS", "DISEASE", 118, 122], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 118, 126], ["SARS-CoV", "SPECIES", 118, 126], ["The difference between pfu (viable viruses", "PROBLEM", 0, 42], ["GE (total viral counts", "TEST", 48, 70], ["defective and functional viruses", "PROBLEM", 81, 113], ["SARS", "PROBLEM", 118, 122]]], ["The GE/pfu ratio of approximate 1200-1600:1obtained in this study only represents the GE/pfu ratio of the Vero cell derived SARS-CoV stock used in this study.", [["Vero cell", "ANATOMY", 106, 115], ["Vero cell", "CELL", 106, 115], ["SARS-CoV", "ORGANISM", 124, 132], ["SARS-CoV", "SPECIES", 124, 132], ["The GE/pfu ratio", "TEST", 0, 16], ["this study", "TEST", 55, 65], ["CoV stock", "TREATMENT", 129, 138], ["this study", "TEST", 147, 157], ["Vero cell", "OBSERVATION", 106, 115]]], ["The finding of high GE/pfu ratio from this study supported the hypothesis of SARS-CoV cultures and SARS-CoV infected clinical samples containing both infectious and defective (or subgenomic) viral RNA, i.e. each SARS-CoV infectious unit is represented by multiple viral RNA species.", [["samples", "ANATOMY", 126, 133], ["SARS", "DISEASE", 77, 81], ["SARS-CoV infected", "DISEASE", 99, 116], ["SARS", "DISEASE", 212, 216], ["SARS-CoV", "ORGANISM", 77, 85], ["SARS-CoV", "ORGANISM", 99, 107], ["SARS-CoV", "ORGANISM", 212, 220], ["infectious and defective (or subgenomic) viral RNA", "RNA", 150, 200], ["SARS-CoV infectious unit", "DNA", 212, 236], ["viral RNA species", "RNA", 264, 281], ["SARS-CoV", "SPECIES", 77, 85], ["SARS-CoV", "SPECIES", 99, 107], ["SARS-CoV", "SPECIES", 212, 220], ["high GE/pfu ratio", "PROBLEM", 15, 32], ["this study", "TEST", 38, 48], ["SARS", "PROBLEM", 77, 81], ["CoV cultures", "TEST", 82, 94], ["SARS", "PROBLEM", 99, 103], ["CoV infected clinical samples", "PROBLEM", 104, 133], ["both infectious and defective (or subgenomic) viral RNA", "PROBLEM", 145, 200], ["each SARS", "PROBLEM", 207, 216], ["multiple viral RNA species", "PROBLEM", 255, 281], ["infectious", "OBSERVATION_MODIFIER", 150, 160], ["viral RNA", "OBSERVATION", 191, 200], ["multiple", "OBSERVATION_MODIFIER", 255, 263], ["viral RNA species", "OBSERVATION", 264, 281]]], ["It is likely that the 3 -noncoding based SARS-CoV RT-PCR assay could detect both infectious and defective viral RNA from clinical samples (Poon et al., 2004) .", [["samples", "ANATOMY", 130, 137], ["viral RNA", "RNA", 106, 115], ["the 3 -noncoding based SARS", "PROBLEM", 18, 45], ["CoV RT-PCR assay", "TEST", 46, 62], ["both infectious and defective viral RNA", "PROBLEM", 76, 115], ["infectious", "OBSERVATION", 81, 91], ["viral RNA", "OBSERVATION", 106, 115]]], ["It is possible that viral stocks of different preparations might contain the same pfu per ml, but the total viral particles, or RNA copy numbers would be different (Bae et al., 2003; Peccoud and Jacob, 1996) .", [["viral stocks of different preparations", "TREATMENT", 20, 58], ["the total viral particles", "PROBLEM", 98, 123], ["viral stocks", "OBSERVATION", 20, 32]]], ["The pfu, infectious activity of any given viral stock is greatly affected by the percentage of viable virus.", [["viral stock", "PROBLEM", 42, 53], ["viable virus", "PROBLEM", 95, 107], ["infectious", "OBSERVATION", 9, 19], ["viral stock", "OBSERVATION", 42, 53], ["viable virus", "OBSERVATION", 95, 107]]], ["There are numerous factors that will determine, or affect the viability of each individual viral stock, such as culturing conditions (nutrients, ionic strength, incubation time and temperature), storage conditions (duration and temperature), and viral harvesting conditions.", [["viral harvesting conditions", "TREATMENT", 246, 273], ["viral harvesting", "OBSERVATION", 246, 262]]], ["It was demonstrated in this study that the cloned pHCV1 plasmid could be used to replace viral cDNA as a stable and rational SARS-CoV copy number standard for the SARS-CoV RT-PCR assay.DiscussionsThe practical application of the SARS-CoV RT-PCR developed in this study is to accurately identify SARS-CoV in suspected SARS patients.", [["SARS", "DISEASE", 295, 299], ["SARS", "DISEASE", 317, 321], ["pHCV1", "GENE_OR_GENE_PRODUCT", 50, 55], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 295, 303], ["patients", "ORGANISM", 322, 330], ["pHCV1 plasmid", "DNA", 50, 63], ["viral cDNA", "DNA", 89, 99], ["patients", "SPECIES", 322, 330], ["SARS-CoV", "SPECIES", 163, 171], ["SARS-CoV", "SPECIES", 295, 303], ["this study", "TEST", 23, 33], ["the cloned pHCV1 plasmid", "TREATMENT", 39, 63], ["viral cDNA", "TREATMENT", 89, 99], ["the SARS", "TEST", 159, 167], ["CoV RT-PCR assay", "TEST", 168, 184], ["the SARS", "TEST", 225, 233], ["CoV RT-PCR", "TEST", 234, 244], ["this study", "TEST", 258, 268], ["SARS", "PROBLEM", 295, 299], ["stable", "OBSERVATION_MODIFIER", 105, 111]]], ["The key to the successful control of SARS outbreaks is to identify SARS-CoV infected individuals in the early stages of infections.", [["SARS", "DISEASE", 37, 41], ["SARS-CoV infected", "DISEASE", 67, 84], ["infections", "DISEASE", 120, 130], ["SARS-CoV", "ORGANISM", 67, 75], ["SARS-CoV", "SPECIES", 67, 75], ["SARS outbreaks", "PROBLEM", 37, 51], ["SARS", "PROBLEM", 67, 71], ["CoV infected individuals", "PROBLEM", 72, 96], ["infections", "PROBLEM", 120, 130], ["early stages", "OBSERVATION_MODIFIER", 104, 116], ["infections", "OBSERVATION", 120, 130]]], ["This will allow public health officers to apply adequate physical quarantine measures before the SARS infected individuals become highly contagious.", [["SARS infected", "DISEASE", 97, 110], ["adequate physical quarantine measures", "TREATMENT", 48, 85], ["the SARS infected individuals", "PROBLEM", 93, 122]]], ["This requires the deployment of highly sensitive SARS-CoV diagnostics to detect low SARS-CoV titers.", [["SARS-CoV", "GENE_OR_GENE_PRODUCT", 84, 92], ["SARS-CoV", "SPECIES", 49, 57], ["SARS-CoV", "SPECIES", 84, 92], ["CoV diagnostics", "TEST", 54, 69], ["low SARS", "PROBLEM", 80, 88], ["CoV titers", "TEST", 89, 99]]], ["In this study, the assay was used to test a limited numbers of total RNA extracts derived from SARS suspected, or probable patients in Taiwan.", [["extracts", "ANATOMY", 73, 81], ["SARS", "DISEASE", 95, 99], ["patients", "ORGANISM", 123, 131], ["patients", "SPECIES", 123, 131], ["this study", "TEST", 3, 13], ["the assay", "TEST", 15, 24], ["total RNA extracts", "TREATMENT", 63, 81]]], ["The tested results indicated that it is feasible to use the developed assay to identify the SARS-CoV infected patients with viremia loads ranging from 3.59 pfu through 1608.29 pfu/ml.", [["SARS-CoV infected", "DISEASE", 92, 109], ["viremia", "DISEASE", 124, 131], ["SARS-CoV", "ORGANISM", 92, 100], ["patients", "ORGANISM", 110, 118], ["patients", "SPECIES", 110, 118], ["SARS-CoV", "SPECIES", 92, 100], ["assay", "TEST", 70, 75], ["the SARS", "PROBLEM", 88, 96], ["viremia loads", "PROBLEM", 124, 137]]], ["Even though only a limited numbers of samples were tested in this study, the assay was confirmed to be specific, i.e. none of 20 non-SARS ARD patients' samples tested positive using the SARS-CoV assay.", [["samples", "ANATOMY", 38, 45], ["samples", "ANATOMY", 152, 159], ["SARS", "DISEASE", 133, 137], ["samples", "CANCER", 38, 45], ["patients", "ORGANISM", 142, 150], ["samples", "CANCER", 152, 159], ["patients", "SPECIES", 142, 150], ["SARS-CoV", "SPECIES", 186, 194], ["this study", "TEST", 61, 71], ["the assay", "TEST", 73, 82], ["' samples", "TEST", 150, 159], ["the SARS", "TEST", 182, 190], ["CoV assay", "TEST", 191, 200]]], ["Even though we did not have specific information on the onset dates of disease for those clinical samples tested in this study.", [["disease", "PROBLEM", 71, 78], ["those clinical samples", "TEST", 83, 105], ["this study", "TEST", 116, 126]]], ["We demonstrated that the 3 -noncoding based RT-PCR developed in this study could be used to detect both infectious and defective viral RNA.", [["viral RNA", "RNA", 129, 138], ["the 3 -noncoding based RT-PCR", "PROBLEM", 21, 50], ["this study", "TEST", 64, 74], ["both infectious and defective viral RNA", "PROBLEM", 99, 138], ["infectious", "OBSERVATION", 104, 114], ["defective", "OBSERVATION_MODIFIER", 119, 128], ["viral RNA", "OBSERVATION", 129, 138]]], ["Thus, the assay should have fairly high diagnostic sensitivity of detecting SARS-CoV during the early stage of infections .", [["SARS", "DISEASE", 76, 80], ["infections", "DISEASE", 111, 121], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 76, 84], ["SARS-CoV", "SPECIES", 76, 84], ["the assay", "TEST", 6, 15], ["SARS", "PROBLEM", 76, 80], ["CoV", "PROBLEM", 81, 84], ["infections", "PROBLEM", 111, 121], ["infections", "OBSERVATION", 111, 121]]], ["It was previously reported that the mean time between onset of symptoms and sample collection ranged from 3.2 to 4.3 days for SARS-CoV detection directly from nasopharyngeal aspirate using real-time RT-PCR (Peiris et al., 2003a,b; Tsang et al., 2003) .", [["sample", "ANATOMY", 76, 82], ["nasopharyngeal aspirate", "ANATOMY", 159, 182], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 159, 182], ["SARS-CoV", "SPECIES", 126, 134], ["symptoms", "PROBLEM", 63, 71], ["sample collection", "TEST", 76, 93], ["SARS", "PROBLEM", 126, 130], ["CoV detection", "TEST", 131, 144], ["nasopharyngeal aspirate", "TEST", 159, 182], ["nasopharyngeal", "ANATOMY", 159, 173], ["aspirate", "OBSERVATION", 174, 182]]], ["It was proposed to further verify and validate the assay developed in this study by using careful selection panel of reference samples consisting of wide dynamic range of naturally infected SARS samples, i.e. from 10 6 to 1 pfu/ml as well as SARS negative control samples.", [["samples", "ANATOMY", 127, 134], ["samples", "ANATOMY", 195, 202], ["samples", "ANATOMY", 264, 271], ["SARS", "DISEASE", 190, 194], ["the assay", "TEST", 47, 56], ["this study", "TEST", 70, 80], ["careful selection panel", "TEST", 90, 113], ["reference samples", "TEST", 117, 134], ["naturally infected SARS samples", "PROBLEM", 171, 202]]], ["However, it is very difficult to obtain credible SARS reference samples with known infectious titers since there is no known major outbreak of SARS after the last multi-country outbreak in 2003.", [["SARS", "DISEASE", 143, 147], ["credible SARS reference samples", "PROBLEM", 40, 71], ["known infectious titers", "PROBLEM", 77, 100], ["SARS", "PROBLEM", 143, 147], ["infectious", "OBSERVATION_MODIFIER", 83, 93], ["no known", "UNCERTAINTY", 116, 124], ["major", "OBSERVATION_MODIFIER", 125, 130], ["outbreak", "OBSERVATION_MODIFIER", 131, 139]]], ["The conserved 3 -NCR feature of other RNA viruses, such as dengue viruses had been reported and utilized to develop type-specific RT-PCR assays for dengue virus identification and quantification throughout the world (Sudiro et al., 1997 (Sudiro et al., , 1998 Houng et al., 2000 Houng et al., , 2001 .", [["dengue viruses", "DISEASE", 59, 73], ["dengue viruses", "ORGANISM", 59, 73], ["conserved 3 -NCR feature", "DNA", 4, 28], ["dengue viruses", "SPECIES", 59, 73], ["dengue virus", "SPECIES", 148, 160], ["other RNA viruses", "PROBLEM", 32, 49], ["dengue viruses", "PROBLEM", 59, 73], ["type-specific RT-PCR assays", "TEST", 116, 143], ["dengue virus identification", "PROBLEM", 148, 175], ["RNA viruses", "OBSERVATION", 38, 49]]], ["Thus, it would be reasonable to predict that the 3 -NCR based SARS-CoV specific RT-PCR assay can be used to detect different SRAS-CoV originated from outbreaks of various geographic origins.", [["CoV", "ORGANISM", 67, 70], ["SRAS-CoV", "ORGANISM", 125, 133], ["SRAS-CoV", "DNA", 125, 133], ["SRAS-CoV", "SPECIES", 125, 133], ["CoV specific RT-PCR assay", "TEST", 67, 92], ["different SRAS", "PROBLEM", 115, 129], ["CoV", "PROBLEM", 130, 133], ["various", "OBSERVATION_MODIFIER", 163, 170], ["geographic origins", "OBSERVATION", 171, 189]]], ["It was demonstrated that the SARS-CoV 3 -NCR based assay using Canadian SARS-CoV Tor2 sequence could be used to detect laboratory grown SARS-CoV Urbani strain as well as various SARS-CoV infected samples in Taiwan.", [["samples", "ANATOMY", 196, 203], ["SARS-CoV infected", "DISEASE", 178, 195], ["CoV", "ORGANISM", 77, 80], ["SARS-CoV Urbani", "ORGANISM", 136, 151], ["SARS-CoV", "ORGANISM", 178, 186], ["SARS-CoV 3 -NCR", "DNA", 29, 44], ["Canadian SARS-CoV Tor2 sequence", "DNA", 63, 94], ["CoV Urbani", "SPECIES", 141, 151], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 72, 80], ["SARS-CoV Urbani", "SPECIES", 136, 151], ["SARS-CoV", "SPECIES", 178, 186], ["the SARS", "TEST", 25, 33], ["CoV", "TEST", 34, 37], ["Canadian SARS", "TEST", 63, 76], ["CoV Tor2 sequence", "TEST", 77, 94], ["laboratory grown SARS", "PROBLEM", 119, 140], ["CoV Urbani strain", "TREATMENT", 141, 158], ["various SARS", "PROBLEM", 170, 182]]], ["Based on the assay's excellent performance capacity (high detection sensitivity at 0.005 pfu/assay and robustness in detecting SARS-CoV of different origins and preparations including direct viral cDNA as well as cloned recombinant plasmid) and superior specifications (100% specificity and 91% amplification efficacy) shown in this report, the 3 -NCR based SARS-CoV RT-PCR should be able to serve as an efficient SARS-CoV diagnostics in the event of future outbreak.", [["plasmid", "ANATOMY", 232, 239], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 127, 135], ["viral cDNA", "DNA", 191, 201], ["cloned recombinant plasmid", "DNA", 213, 239], ["SARS-CoV", "SPECIES", 127, 135], ["the assay", "TEST", 9, 18], ["pfu/assay", "TEST", 89, 98], ["robustness", "TEST", 103, 113], ["SARS", "PROBLEM", 127, 131], ["preparations", "TREATMENT", 161, 173], ["direct viral cDNA", "TREATMENT", 184, 201], ["cloned recombinant plasmid", "TREATMENT", 213, 239], ["specificity", "TEST", 275, 286], ["CoV RT-PCR", "TREATMENT", 363, 373], ["CoV diagnostics", "TEST", 419, 434]]]], "PMC7302611": [], "ec7ca78a048ae3cfa7de0e59cc693bf563e7b75f": [["and in some cases thrombocytopenia.", [["thrombocytopenia", "DISEASE", 18, 34], ["some cases thrombocytopenia", "PROBLEM", 7, 34], ["thrombocytopenia", "OBSERVATION", 18, 34]]], ["About 20% of infected individuals will develop severe disease, including a pneumonia with acute respiratory distress syndrome (ARDS)-like process.", [["respiratory", "ANATOMY", 96, 107], ["pneumonia", "DISEASE", 75, 84], ["acute respiratory distress syndrome", "DISEASE", 90, 125], ["ARDS", "DISEASE", 127, 131], ["individuals", "ORGANISM", 22, 33], ["infected individuals", "PROBLEM", 13, 33], ["severe disease", "PROBLEM", 47, 61], ["a pneumonia", "PROBLEM", 73, 84], ["acute respiratory distress syndrome", "PROBLEM", 90, 125], ["ARDS)", "PROBLEM", 127, 132], ["severe", "OBSERVATION_MODIFIER", 47, 53], ["disease", "OBSERVATION", 54, 61], ["pneumonia", "OBSERVATION", 75, 84], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory distress syndrome", "OBSERVATION", 96, 125]]], ["7, 8 Those individuals develop pathognomonic findings on computed tomographic (CT) scan including ground glass abnormalities early in the disease course.", [["pathognomonic findings", "PROBLEM", 31, 53], ["computed tomographic (CT) scan", "TEST", 57, 87], ["ground glass abnormalities", "PROBLEM", 98, 124], ["ground glass abnormalities", "OBSERVATION", 98, 124], ["early", "OBSERVATION_MODIFIER", 125, 130]]], ["9 Emerging data also suggest that the virus can affect the heart, causing a viral myocarditis and associated cardiac injury in patients with or without underlying cardiac pathology.", [["heart", "ANATOMY", 59, 64], ["cardiac", "ANATOMY", 109, 116], ["cardiac", "ANATOMY", 163, 170], ["myocarditis", "DISEASE", 82, 93], ["cardiac injury", "DISEASE", 109, 123], ["heart", "ORGAN", 59, 64], ["cardiac", "ORGAN", 109, 116], ["patients", "ORGANISM", 127, 135], ["cardiac", "ORGAN", 163, 170], ["patients", "SPECIES", 127, 135], ["the virus", "PROBLEM", 34, 43], ["a viral myocarditis", "PROBLEM", 74, 93], ["associated cardiac injury", "PROBLEM", 98, 123], ["underlying cardiac pathology", "PROBLEM", 152, 180], ["virus", "OBSERVATION", 38, 43], ["heart", "ANATOMY", 59, 64], ["viral", "OBSERVATION_MODIFIER", 76, 81], ["myocarditis", "OBSERVATION", 82, 93], ["cardiac", "ANATOMY", 109, 116], ["injury", "OBSERVATION", 117, 123], ["cardiac", "ANATOMY", 163, 170], ["pathology", "OBSERVATION", 171, 180]]], ["10 At this time, COVID-19 does not appear to cause microangiopathy in the heart or in other vascular beds.", [["heart", "ANATOMY", 74, 79], ["vascular", "ANATOMY", 92, 100], ["microangiopathy", "DISEASE", 51, 66], ["COVID-19", "CHEMICAL", 17, 25], ["heart", "ORGAN", 74, 79], ["vascular beds", "MULTI-TISSUE_STRUCTURE", 92, 105], ["COVID-19", "DNA", 17, 25], ["COVID", "TEST", 17, 22], ["microangiopathy in the heart", "PROBLEM", 51, 79], ["microangiopathy", "OBSERVATION", 51, 66], ["heart", "ANATOMY", 74, 79], ["vascular beds", "ANATOMY", 92, 105]]], ["11 Mortality rates are varied, though appear to be between 0.6 and 4% depending on population, though as not all infected patients are tested, the true denominator is unknown.", [["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["Mortality rates", "TEST", 3, 18]]], ["11, 12 Older patients, those with underlying medical conditions, and those with bacterial superinfection in the lungs, are at higher risk adverse outcomes (\u25baFig. 1).", [["lungs", "ANATOMY", 112, 117], ["bacterial superinfection", "DISEASE", 80, 104], ["patients", "ORGANISM", 13, 21], ["lungs", "ORGAN", 112, 117], ["patients", "SPECIES", 13, 21], ["underlying medical conditions", "PROBLEM", 34, 63], ["bacterial superinfection in the lungs", "PROBLEM", 80, 117], ["bacterial", "OBSERVATION_MODIFIER", 80, 89], ["superinfection", "OBSERVATION", 90, 104], ["lungs", "ANATOMY", 112, 117]]], ["Specifically, as high as 6% for those with hypertension, 7.3% for those with diabetes, and 6.3% for those with chronic respiratory pathologies.", [["respiratory", "ANATOMY", 119, 130], ["hypertension", "DISEASE", 43, 55], ["diabetes", "DISEASE", 77, 85], ["respiratory pathologies", "DISEASE", 119, 142], ["hypertension", "PROBLEM", 43, 55], ["diabetes", "PROBLEM", 77, 85], ["chronic respiratory pathologies", "PROBLEM", 111, 142], ["high", "OBSERVATION_MODIFIER", 17, 21], ["hypertension", "OBSERVATION", 43, 55], ["chronic", "OBSERVATION_MODIFIER", 111, 118], ["respiratory", "ANATOMY", 119, 130], ["pathologies", "OBSERVATION", 131, 142]]], ["10, 14 Among hospitalized patients, mortality is as high as 13%.", [["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34]]], ["7 The median time from symptom onset to death is 13 days.", [["death", "DISEASE", 40, 45], ["symptom", "PROBLEM", 23, 30]]], ["1 At this time, no treatment for the virus exists.", [["treatment", "TREATMENT", 19, 28], ["the virus", "PROBLEM", 33, 42], ["virus", "OBSERVATION", 37, 42]]], ["Treatment in mild cases includes oral hydration and symptomatic relief.", [["oral", "ANATOMY", 33, 37], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["Treatment in mild cases", "TREATMENT", 0, 23], ["oral hydration", "TREATMENT", 33, 47], ["symptomatic relief", "TREATMENT", 52, 70], ["mild", "OBSERVATION_MODIFIER", 13, 17]]], ["For severe cases, supportive care is the standard of care.", [["severe cases", "PROBLEM", 4, 16], ["supportive care", "TREATMENT", 18, 33]]], ["The use of systemic corticosteroids for severe pneumonia has been associated with worse outcomes in influenza, SARS, and Middle East respiratory syndrome (MERS), and thus is not recommended at this time.", [["corticosteroids", "CHEMICAL", 20, 35], ["pneumonia", "DISEASE", 47, 56], ["influenza", "DISEASE", 100, 109], ["SARS", "DISEASE", 111, 115], ["Middle East respiratory syndrome", "DISEASE", 121, 153], ["systemic corticosteroids", "TREATMENT", 11, 35], ["severe pneumonia", "PROBLEM", 40, 56], ["influenza", "PROBLEM", 100, 109], ["SARS", "PROBLEM", 111, 115], ["Middle East respiratory syndrome", "PROBLEM", 121, 153], ["severe", "OBSERVATION_MODIFIER", 40, 46], ["pneumonia", "OBSERVATION", 47, 56], ["influenza", "OBSERVATION", 100, 109], ["Middle", "ANATOMY_MODIFIER", 121, 127], ["respiratory syndrome", "OBSERVATION", 133, 153]]], ["15 Though one small nonrandomized trial of hydroxychloroquine and azithromycin suggested a decrease in viral burden, this study only included those with mild disease.", [["hydroxychloroquine", "CHEMICAL", 43, 61], ["azithromycin", "CHEMICAL", 66, 78], ["hydroxychloroquine", "CHEMICAL", 43, 61], ["azithromycin", "CHEMICAL", 66, 78], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 43, 61], ["azithromycin", "SIMPLE_CHEMICAL", 66, 78], ["hydroxychloroquine", "TREATMENT", 43, 61], ["azithromycin", "TREATMENT", 66, 78], ["a decrease in viral burden", "PROBLEM", 89, 115], ["this study", "TEST", 117, 127], ["mild disease", "PROBLEM", 153, 165], ["small", "OBSERVATION_MODIFIER", 14, 19], ["decrease", "OBSERVATION_MODIFIER", 91, 99], ["viral burden", "OBSERVATION", 103, 115], ["mild", "OBSERVATION_MODIFIER", 153, 157], ["disease", "OBSERVATION", 158, 165]]], ["16 A recent systematic review on this topic found that chloroquine may be effective at treating COVID-19, but its use should only occur in clinical trials or as part of the monitored emergency use of unregistered interventions framework.", [["chloroquine", "CHEMICAL", 55, 66], ["chloroquine", "CHEMICAL", 55, 66], ["COVID-19", "CHEMICAL", 96, 104], ["chloroquine", "SIMPLE_CHEMICAL", 55, 66], ["chloroquine", "TREATMENT", 55, 66], ["COVID", "TEST", 96, 101], ["unregistered interventions framework", "TREATMENT", 200, 236]]], ["17 Though aggressive research efforts are underway, no vaccine is available at this time.", [["vaccine", "TREATMENT", 55, 62]]]], "PMC7222885": [["Being able to interpret the humanities within the context of clinical practice fortifies the ability of students to comprehend patients\u2019 experiences and to understand what they themselves undergo as clinicians.", [["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 127, 135]]], ["Also, excerpts from Michihiko Hachiya, Hiroshima Diary: The Journal of a Japanese Physician, August 6 - September 30, 1945, The University of North Carolina Press, 1995, Ben Shephard, A War of Nerves: Soldiers and Psychiatrists in the Twentieth Century Harvard University Press, 2003, Pearl S. Buck, \u201cThe Enemy,\u201d in Phyllis and Albert Blaustein, eds.", [["Nerves", "ANATOMY", 193, 199]]], ["Doctors\u2019 Choice, Wilfred Funk, 1957, pp. 40-59, and Last night I dreamed of peace: the diary of Dang Thuy Tram, Broadway Books, 2007.Endnotes3 The VHA is the largest integrated health care system in the United States with a network of 152 medical centers.Endnotes4 We discuss in detail the several relevant international agreements, from the Hague protocol in 1899, through the Geneva protocol of 1925, dealing with chemical warfare.", [["largest", "OBSERVATION_MODIFIER", 158, 165]]], ["Biological agents in partricular are developed by scientists, often including veterinarians and physicians.Endnotes5 The Hiroshima bomb, known as \"Little Boy\"\u2014 a reference to former President Roosevelt, contained the equivalent of between 12 and 15,000 tons of TNT and devastated an area of five square miles (13 square kilometres).", [["Hiroshima bomb", "OBSERVATION", 121, 135]]], ["Official Japanese figures at the time put the death toll at 118,661 civilians.", [["death", "DISEASE", 46, 51]]], ["Many have also suffered long-term sickness and disability.", [["sickness", "DISEASE", 34, 42], ["disability", "DISEASE", 47, 57], ["long-term sickness", "PROBLEM", 24, 42], ["disability", "PROBLEM", 47, 57], ["long-term sickness", "OBSERVATION_MODIFIER", 24, 42]]], ["The device known as \"Fat man,\" after Winston Churchill, weighed nearly 4,050 kg.Endnotes6 \u201cThe diary itself was a collection of pages sewn together with a cardboard cover, no bigger than a pack of cigarettes\u201d (xvi).", [["man", "SPECIES", 25, 28]]]], "PMC7166378": [["INTRODUCTIONHepatitis C virus (HCV) infection frequently leads to chronic hepatitis and may progress to liver cirrhosis and possibly hepatocellular carcinoma [1, 2, 3, \u20134].", [["liver", "ANATOMY", 104, 109], ["hepatocellular carcinoma", "ANATOMY", 133, 157], ["INTRODUCTIONHepatitis C virus (HCV) infection", "DISEASE", 0, 45], ["chronic hepatitis", "DISEASE", 66, 83], ["liver cirrhosis", "DISEASE", 104, 119], ["hepatocellular carcinoma", "DISEASE", 133, 157], ["INTRODUCTIONHepatitis C virus", "ORGANISM", 0, 29], ["HCV", "ORGANISM", 31, 34], ["liver", "ORGAN", 104, 109], ["hepatocellular carcinoma", "CANCER", 133, 157], ["C virus", "SPECIES", 22, 29], ["HCV", "SPECIES", 31, 34], ["INTRODUCTIONHepatitis C virus (HCV) infection", "PROBLEM", 0, 45], ["chronic hepatitis", "PROBLEM", 66, 83], ["liver cirrhosis", "PROBLEM", 104, 119], ["hepatocellular carcinoma", "PROBLEM", 133, 157], ["virus", "OBSERVATION", 24, 29], ["chronic", "OBSERVATION_MODIFIER", 66, 73], ["hepatitis", "OBSERVATION", 74, 83], ["liver", "ANATOMY", 104, 109], ["cirrhosis", "OBSERVATION", 110, 119], ["possibly", "UNCERTAINTY", 124, 132], ["hepatocellular", "ANATOMY", 133, 147], ["carcinoma", "OBSERVATION", 148, 157]]], ["HCV\u2010related end\u2010stage liver disease is currently one of the leading indications for liver transplantation.", [["liver", "ANATOMY", 22, 27], ["liver", "ANATOMY", 84, 89], ["liver disease", "DISEASE", 22, 35], ["HCV", "ORGANISM", 0, 3], ["liver", "ORGAN", 22, 27], ["liver", "ORGAN", 84, 89], ["HCV", "SPECIES", 0, 3], ["HCV", "PROBLEM", 0, 3], ["end\u2010stage liver disease", "PROBLEM", 12, 35], ["liver transplantation", "TREATMENT", 84, 105], ["liver", "ANATOMY", 22, 27], ["disease", "OBSERVATION", 28, 35], ["liver", "ANATOMY", 84, 89], ["transplantation", "OBSERVATION", 90, 105]]], ["Treatment with interferon\u2010\u03b1 (IFN\u2010\u03b1) alone leads only to a sustained viral clearance in approximately 15\u201320% of patients [5,6].", [["interferon\u2010\u03b1 (IFN\u2010\u03b1", "CHEMICAL", 15, 34], ["interferon\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 15, 27], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 29, 34], ["patients", "ORGANISM", 111, 119], ["interferon\u2010\u03b1", "PROTEIN", 15, 27], ["IFN\u2010\u03b1", "PROTEIN", 29, 34], ["patients", "SPECIES", 111, 119], ["Treatment with interferon\u2010\u03b1 (IFN\u2010\u03b1)", "TREATMENT", 0, 35], ["a sustained viral clearance", "PROBLEM", 56, 83]]], ["The addition of ribavirin to standard interferon\u2010\u03b1 treatment improves the sustained virological response rate to approximately 40% in previously untreated patients [7,8].INTRODUCTIONSeveral treatment strategies have been investigated in patients with chronic hepatitis C not responding to previous interferon\u2010\u03b1 monotherapy.", [["ribavirin", "CHEMICAL", 16, 25], ["interferon\u2010\u03b1", "CHEMICAL", 38, 50], ["chronic hepatitis C", "DISEASE", 251, 270], ["interferon\u2010\u03b1", "CHEMICAL", 298, 310], ["ribavirin", "CHEMICAL", 16, 25], ["interferon\u2010\u03b1", "CHEMICAL", 298, 310], ["ribavirin", "SIMPLE_CHEMICAL", 16, 25], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 38, 50], ["patients", "ORGANISM", 155, 163], ["patients", "ORGANISM", 237, 245], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 298, 310], ["patients", "SPECIES", 155, 163], ["patients", "SPECIES", 237, 245], ["ribavirin", "TREATMENT", 16, 25], ["standard interferon\u2010\u03b1 treatment", "TREATMENT", 29, 60], ["the sustained virological response rate", "PROBLEM", 70, 109], ["INTRODUCTIONSeveral treatment strategies", "TREATMENT", 170, 210], ["chronic hepatitis C", "PROBLEM", 251, 270], ["previous interferon\u2010\u03b1 monotherapy", "TREATMENT", 289, 322], ["ribavirin", "OBSERVATION", 16, 25], ["chronic", "OBSERVATION_MODIFIER", 251, 258], ["hepatitis", "OBSERVATION", 259, 268]]], ["However, retreatment of previous interferon\u2010\u03b1 nonresponders with standard regimens of interferon\u2010\u03b1 alone (3 \u00d7 3\u20136 MIU/week s.c.) or in combination with ribavirin (1000\u20131200 mg/day orally) showed only limited therapeutic efficacy with sustained viral response rates below 10% [9,10].INTRODUCTIONAmantadine (1\u2010aminoadamantanamine sulphate) is a tricyclic, symmetric amine with an antiviral activity against toga\u2010, myxo\u2010, arena\u2010, flavi\u2010 and coronaviruses [11, 12, 13, 14, \u201315].", [["interferon\u2010\u03b1", "CHEMICAL", 33, 45], ["interferon\u2010\u03b1", "CHEMICAL", 86, 98], ["ribavirin", "CHEMICAL", 152, 161], ["INTRODUCTIONAmantadine", "CHEMICAL", 282, 304], ["1\u2010aminoadamantanamine sulphate", "CHEMICAL", 306, 336], ["amine", "CHEMICAL", 364, 369], ["ribavirin", "CHEMICAL", 152, 161], ["INTRODUCTIONAmantadine", "CHEMICAL", 282, 304], ["1\u2010aminoadamantanamine sulphate", "CHEMICAL", 306, 336], ["tricyclic, symmetric amine", "CHEMICAL", 343, 369], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 33, 45], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 86, 98], ["ribavirin", "SIMPLE_CHEMICAL", 152, 161], ["INTRODUCTIONAmantadine", "SIMPLE_CHEMICAL", 282, 304], ["1\u2010aminoadamantanamine sulphate", "SIMPLE_CHEMICAL", 306, 336], ["symmetric amine", "SIMPLE_CHEMICAL", 354, 369], ["toga\u2010", "GENE_OR_GENE_PRODUCT", 405, 410], ["myxo\u2010", "GENE_OR_GENE_PRODUCT", 412, 417], ["arena\u2010", "ORGANISM", 419, 425], ["flavi\u2010", "CANCER", 427, 433], ["coronaviruses", "ORGANISM", 438, 451], ["retreatment", "TREATMENT", 9, 20], ["previous interferon\u2010\u03b1 nonresponders", "TREATMENT", 24, 59], ["standard regimens", "TREATMENT", 65, 82], ["interferon\u2010\u03b1 alone", "TREATMENT", 86, 104], ["ribavirin", "TREATMENT", 152, 161], ["sustained viral response rates", "PROBLEM", 234, 264], ["INTRODUCTIONAmantadine (1\u2010aminoadamantanamine sulphate", "TREATMENT", 282, 336], ["a tricyclic", "TREATMENT", 341, 352], ["symmetric amine", "TREATMENT", 354, 369], ["an antiviral activity", "TREATMENT", 375, 396], ["coronaviruses", "PROBLEM", 438, 451]]], ["The drug has been studied in detail in the influenza A virus infection and the antiviral activity was found to be related to inhibition of viral uncoating and viral budding by interaction with the viral M2 protein [16, 17, \u201318].", [["influenza A virus infection", "DISEASE", 43, 70], ["influenza A virus", "ORGANISM", 43, 60], ["viral M2 protein", "PROTEIN", 197, 213], ["influenza A virus", "SPECIES", 43, 60], ["influenza A virus", "SPECIES", 43, 60], ["the influenza A virus infection", "PROBLEM", 39, 70], ["the antiviral activity", "PROBLEM", 75, 97], ["viral uncoating", "PROBLEM", 139, 154], ["viral budding", "PROBLEM", 159, 172], ["the viral M2 protein", "TEST", 193, 213]]], ["The antiviral properties of amantadine have led to clinical trials evaluating the potential therapeutic role of amantadine alone or in combination with interferon\u2010\u03b1 in patients with chronic hepatitis C [19, 20, 21, 22, \u201323].", [["amantadine", "CHEMICAL", 28, 38], ["amantadine", "CHEMICAL", 112, 122], ["interferon\u2010\u03b1", "CHEMICAL", 152, 164], ["chronic hepatitis C", "DISEASE", 182, 201], ["amantadine", "CHEMICAL", 28, 38], ["amantadine", "CHEMICAL", 112, 122], ["amantadine", "SIMPLE_CHEMICAL", 28, 38], ["amantadine", "SIMPLE_CHEMICAL", 112, 122], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 152, 164], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["The antiviral properties", "TREATMENT", 0, 24], ["amantadine", "TREATMENT", 28, 38], ["clinical trials", "TREATMENT", 51, 66], ["amantadine", "TREATMENT", 112, 122], ["interferon\u2010\u03b1", "TREATMENT", 152, 164], ["chronic hepatitis C", "PROBLEM", 182, 201], ["chronic", "OBSERVATION_MODIFIER", 182, 189], ["hepatitis", "OBSERVATION", 190, 199]]], ["For retreatment of previous interferon\u2010\u03b1 nonresponders with chronic hepatitis C with the combination of interferon\u2010\u03b1 and amantadine, only data from a few uncontrolled studies with inconsistent response rates are available [24,25].INTRODUCTIONTherefore, the aims of the present study were to evaluate the therapeutic efficacy, tolerability and health\u2010related quality of life of interferon\u2010\u03b12a (IFN\u2010\u03b12a) plus amantadine sulphate in comparison with IFN\u2010\u03b12a plus placebo in patients with chronic hepatitis C not responding to previous IFN\u2010\u03b1 treatment.Patients ::: PATIENTS AND METHODSPatients with chronic hepatitis C not responding to previous IFN\u2010\u03b1 monotherapy with a minimal total IFN\u2010\u03b1 dose of 108 MIU and a treatment duration of at least 12 weeks were eligible for enrolment when they met all of the following inclusion criteria: (1) nonresponse to previous IFN\u2010\u03b1 monotherapy with persistence of serum HCV\u2010RNA and a treatment\u2010free interval of at least 24 weeks; (2) elevated alanine aminotransferase (ALT) levels; (3) a positive anti\u2010HCV test; (4) detectable serum HCV\u2010RNA; (5) compensated liver disease; (6) leukocyte count \u2265 2500/\u03bcL, platelets count \u2265 70000/\u03bcL; and (7) aged between 18 and 70 years.", [["serum", "ANATOMY", 897, 902], ["serum", "ANATOMY", 1060, 1065], ["liver", "ANATOMY", 1091, 1096], ["leukocyte", "ANATOMY", 1110, 1119], ["platelets", "ANATOMY", 1137, 1146], ["interferon\u2010\u03b1", "CHEMICAL", 28, 40], ["chronic hepatitis C", "DISEASE", 60, 79], ["interferon\u2010\u03b1", "CHEMICAL", 104, 116], ["amantadine", "CHEMICAL", 121, 131], ["interferon\u2010\u03b12a", "CHEMICAL", 377, 391], ["IFN\u2010\u03b12a", "CHEMICAL", 393, 400], ["amantadine sulphate", "CHEMICAL", 407, 426], ["IFN\u2010\u03b12a", "CHEMICAL", 446, 453], ["chronic hepatitis C", "DISEASE", 484, 503], ["IFN\u2010\u03b1", "CHEMICAL", 531, 536], ["chronic hepatitis C", "DISEASE", 594, 613], ["IFN\u2010\u03b1", "CHEMICAL", 641, 646], ["IFN\u2010\u03b1", "CHEMICAL", 859, 864], ["alanine", "CHEMICAL", 976, 983], ["liver disease", "DISEASE", 1091, 1104], ["interferon\u2010\u03b1", "CHEMICAL", 104, 116], ["amantadine", "CHEMICAL", 121, 131], ["amantadine sulphate", "CHEMICAL", 407, 426], ["alanine", "CHEMICAL", 976, 983], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 28, 40], ["interferon\u2010\u03b1", "SIMPLE_CHEMICAL", 104, 116], ["amantadine", "SIMPLE_CHEMICAL", 121, 131], ["interferon\u2010\u03b12a", "SIMPLE_CHEMICAL", 377, 391], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 393, 400], ["amantadine sulphate", "SIMPLE_CHEMICAL", 407, 426], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 446, 453], ["patients", "ORGANISM", 470, 478], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 531, 536], ["Patients", "ORGANISM", 547, 555], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 859, 864], ["serum", "ORGANISM_SUBSTANCE", 897, 902], ["HCV", "ORGANISM", 903, 906], ["alanine", "AMINO_ACID", 976, 983], ["aminotransferase", "GENE_OR_GENE_PRODUCT", 984, 1000], ["ALT", "SIMPLE_CHEMICAL", 1002, 1005], ["serum", "ORGANISM_SUBSTANCE", 1060, 1065], ["liver", "ORGAN", 1091, 1096], ["leukocyte", "CELL", 1110, 1119], ["platelets", "CELL", 1137, 1146], ["interferon\u2010\u03b12a", "PROTEIN", 377, 391], ["IFN", "PROTEIN", 393, 396], ["IFN", "PROTEIN", 446, 449], ["IFN", "PROTEIN", 531, 534], ["IFN", "PROTEIN", 641, 644], ["IFN", "PROTEIN", 680, 683], ["IFN", "PROTEIN", 859, 862], ["RNA", "RNA", 907, 910], ["alanine aminotransferase", "PROTEIN", 976, 1000], ["ALT", "PROTEIN", 1002, 1005], ["platelets", "CELL_TYPE", 1137, 1146], ["patients", "SPECIES", 470, 478], ["Patients", "SPECIES", 547, 555], ["HCV", "SPECIES", 903, 906], ["HCV", "SPECIES", 1066, 1069], ["retreatment", "TREATMENT", 4, 15], ["previous interferon\u2010\u03b1 nonresponders", "PROBLEM", 19, 54], ["chronic hepatitis C", "PROBLEM", 60, 79], ["interferon\u2010\u03b1", "TREATMENT", 104, 116], ["amantadine", "TREATMENT", 121, 131], ["a few uncontrolled studies", "TEST", 148, 174], ["inconsistent response rates", "PROBLEM", 180, 207], ["the present study", "TEST", 265, 282], ["amantadine sulphate", "TREATMENT", 407, 426], ["IFN", "TREATMENT", 446, 449], ["placebo", "TREATMENT", 459, 466], ["chronic hepatitis C", "PROBLEM", 484, 503], ["previous IFN\u2010\u03b1 treatment", "TREATMENT", 522, 546], ["chronic hepatitis C", "PROBLEM", 594, 613], ["previous IFN\u2010\u03b1 monotherapy", "TREATMENT", 632, 658], ["a minimal total IFN\u2010\u03b1 dose", "TREATMENT", 664, 690], ["a treatment duration", "TREATMENT", 706, 726], ["previous IFN\u2010\u03b1 monotherapy", "TREATMENT", 850, 876], ["serum HCV", "PROBLEM", 897, 906], ["a treatment\u2010free interval", "TREATMENT", 915, 940], ["elevated alanine aminotransferase (ALT) levels", "PROBLEM", 967, 1013], ["a positive anti\u2010HCV test", "PROBLEM", 1019, 1043], ["detectable serum HCV\u2010RNA", "PROBLEM", 1049, 1073], ["compensated liver disease", "PROBLEM", 1079, 1104], ["leukocyte count", "TEST", 1110, 1125], ["\u03bcL", "TEST", 1133, 1135], ["platelets count", "TEST", 1137, 1152], ["chronic", "OBSERVATION_MODIFIER", 60, 67], ["hepatitis", "OBSERVATION", 68, 77], ["chronic", "OBSERVATION_MODIFIER", 484, 491], ["hepatitis", "OBSERVATION", 492, 501], ["chronic", "OBSERVATION_MODIFIER", 594, 601], ["hepatitis", "OBSERVATION", 602, 611], ["liver", "ANATOMY", 1091, 1096], ["disease", "OBSERVATION", 1097, 1104]]], ["Demographic, biochemical, serological and virological pretreatment characteristics of the 55 enrolled patients are summarized in Table 1.", [["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110]]], ["Exclusion criteria were coinfection with hepatitis B virus or human immunodeficiency virus types 1 and 2, concomitant autoimmune disease, clinically significant cardiovascular, metabolic, renal, haematological, rheumatological, neurological or psychiatric disease, organ grafts, systemic infections, bleeding disorders, anaphylactic reactions, a history of neoplastic disease within the last 5 years, systemic immunosuppressive treatment, average daily intake of alcohol > 50 g, drug abuse within the previous year, pregnancy and lactation period.", [["cardiovascular", "ANATOMY", 161, 175], ["renal", "ANATOMY", 188, 193], ["neurological", "ANATOMY", 228, 240], ["organ grafts", "ANATOMY", 265, 277], ["neoplastic", "ANATOMY", 357, 367], ["coinfection", "DISEASE", 24, 35], ["hepatitis B", "DISEASE", 41, 52], ["human immunodeficiency virus", "DISEASE", 62, 90], ["autoimmune disease", "DISEASE", 118, 136], ["cardiovascular, metabolic, renal, haematological, rheumatological, neurological or psychiatric disease", "DISEASE", 161, 263], ["systemic infections", "DISEASE", 279, 298], ["bleeding disorders", "DISEASE", 300, 318], ["anaphylactic reactions", "DISEASE", 320, 342], ["neoplastic disease", "DISEASE", 357, 375], ["alcohol", "CHEMICAL", 463, 470], ["drug abuse", "DISEASE", 479, 489], ["alcohol", "CHEMICAL", 463, 470], ["hepatitis B virus", "ORGANISM", 41, 58], ["human immunodeficiency virus", "ORGANISM", 62, 90], ["renal", "ORGAN", 188, 193], ["organ grafts", "MULTI-TISSUE_STRUCTURE", 265, 277], ["alcohol", "SIMPLE_CHEMICAL", 463, 470], ["hepatitis B virus", "SPECIES", 41, 58], ["human immunodeficiency virus", "SPECIES", 62, 90], ["hepatitis B virus", "SPECIES", 41, 58], ["human immunodeficiency virus", "SPECIES", 62, 90], ["coinfection", "PROBLEM", 24, 35], ["hepatitis B virus", "PROBLEM", 41, 58], ["human immunodeficiency virus types", "PROBLEM", 62, 96], ["concomitant autoimmune disease", "PROBLEM", 106, 136], ["clinically significant cardiovascular, metabolic, renal, haematological, rheumatological", "PROBLEM", 138, 226], ["neurological or psychiatric disease", "PROBLEM", 228, 263], ["organ grafts", "TREATMENT", 265, 277], ["systemic infections", "PROBLEM", 279, 298], ["bleeding disorders", "PROBLEM", 300, 318], ["anaphylactic reactions", "PROBLEM", 320, 342], ["neoplastic disease", "PROBLEM", 357, 375], ["systemic immunosuppressive treatment", "TREATMENT", 401, 437], ["coinfection", "OBSERVATION", 24, 35], ["autoimmune disease", "OBSERVATION", 118, 136], ["renal", "ANATOMY", 188, 193], ["organ", "ANATOMY", 265, 270], ["grafts", "OBSERVATION", 271, 277], ["systemic", "OBSERVATION_MODIFIER", 279, 287], ["infections", "OBSERVATION", 288, 298], ["neoplastic", "OBSERVATION", 357, 367]]], ["Liver biopsy was performed in all patients 1\u20136 months before the initiation of the primary IFN\u2010\u03b1 therapy.", [["Liver", "ANATOMY", 0, 5], ["IFN", "CHEMICAL", 91, 94], ["Liver", "ORGAN", 0, 5], ["patients", "ORGANISM", 34, 42], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 91, 96], ["IFN", "PROTEIN", 91, 94], ["patients", "SPECIES", 34, 42], ["Liver biopsy", "TEST", 0, 12], ["the primary IFN\u2010\u03b1 therapy", "TREATMENT", 79, 104], ["biopsy", "OBSERVATION", 6, 12]]], ["According to the study protocol, additional liver biopsies before retreatment were not required for enrolment in the present study.Study design ::: PATIENTS AND METHODSIn the present prospective, randomized, double\u2010blind, placebo\u2010controlled trial, which was conducted at the University Hospitals of Berlin and Frankfurt, Germany, 55 eligible patients were randomly assigned to treatment with either the combination of IFN\u2010\u03b12a plus amantadine sulphate (n=26) or IFN\u2010\u03b12a plus placebo (n=29).", [["liver", "ANATOMY", 44, 49], ["IFN\u2010\u03b12a", "CHEMICAL", 418, 425], ["amantadine sulphate", "CHEMICAL", 431, 450], ["IFN\u2010\u03b12a", "CHEMICAL", 461, 468], ["amantadine sulphate", "CHEMICAL", 431, 450], ["liver biopsies", "MULTI-TISSUE_STRUCTURE", 44, 58], ["patients", "ORGANISM", 342, 350], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 418, 425], ["amantadine sulphate", "SIMPLE_CHEMICAL", 431, 450], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 461, 468], ["IFN", "PROTEIN", 418, 421], ["IFN", "PROTEIN", 461, 464], ["patients", "SPECIES", 342, 350], ["the study protocol", "TEST", 13, 31], ["additional liver biopsies", "TEST", 33, 58], ["retreatment", "TREATMENT", 66, 77], ["the present study", "TEST", 113, 130], ["placebo\u2010controlled trial", "TREATMENT", 222, 246], ["treatment", "TREATMENT", 377, 386], ["IFN", "TREATMENT", 418, 421], ["amantadine sulphate", "TREATMENT", 431, 450], ["liver", "ANATOMY", 44, 49], ["biopsies", "OBSERVATION", 50, 58]]], ["Randomization was performed with a random number generator in fixed blocks of four with a ratio of 1 : 1.", [["Randomization", "TREATMENT", 0, 13]]], ["All patients were treated with 6 MIU IFN\u2010\u03b12a (Roferon A\u00ae, Hoffmann La\u2010Roche AG, Grenzach\u2010Wyhlen, Germany) thrice weekly subcutaneously for 24 weeks followed by 3 MIU IFN\u2010\u03b12a thrice weekly subcutaneously for additional 24 weeks (Fig. 1).", [["subcutaneously", "ANATOMY", 120, 134], ["subcutaneously", "ANATOMY", 188, 202], ["MIU IFN\u2010\u03b12a", "CHEMICAL", 33, 44], ["\u03b12a", "CHEMICAL", 170, 173], ["patients", "ORGANISM", 4, 12], ["\u03b12a", "SIMPLE_CHEMICAL", 41, 44], ["Roferon A\u00ae", "SIMPLE_CHEMICAL", 46, 56], ["IFN", "PROTEIN", 37, 40], ["IFN", "PROTEIN", 166, 169], ["patients", "SPECIES", 4, 12], ["2a (Roferon A\u00ae", "TREATMENT", 42, 56], ["Hoffmann La\u2010Roche AG", "TREATMENT", 58, 78], ["Grenzach", "TREATMENT", 80, 88]]], ["A daily dose of 200 mg amantadine sulphate (Infex\u00ae, Merz + Co. GmbH & Co, Frankfurt/M., Germany) or matched placebo were given orally twice daily for 48 weeks.", [["amantadine sulphate", "CHEMICAL", 23, 42], ["Infex\u00ae", "CHEMICAL", 44, 50], ["amantadine sulphate", "CHEMICAL", 23, 42], ["Infex\u00ae", "CHEMICAL", 44, 50], ["Co", "CHEMICAL", 70, 72], ["amantadine", "SIMPLE_CHEMICAL", 23, 33], ["sulphate", "SIMPLE_CHEMICAL", 34, 42], ["Infex\u00ae", "SIMPLE_CHEMICAL", 44, 50], ["200 mg amantadine sulphate", "TREATMENT", 16, 42]]], ["Treatment was continued only in patients with undetectable serum HCV\u2010RNA (Amplicor HCV\u2122, Roche Diagnostic Systems, Branchburg, NJ; lower detection limit: 1000 copies/mL) at treatment week 12 [27].", [["serum", "ANATOMY", 59, 64], ["patients", "ORGANISM", 32, 40], ["serum", "ORGANISM_SUBSTANCE", 59, 64], ["patients", "SPECIES", 32, 40], ["HCV", "SPECIES", 65, 68], ["HCV", "SPECIES", 83, 86], ["Treatment", "TREATMENT", 0, 9], ["undetectable serum HCV", "PROBLEM", 46, 68], ["NJ; lower detection limit", "TREATMENT", 127, 152]]], ["The follow\u2010up period was 24 weeks in all patients.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["Clinical examination, haematological and biochemical tests were performed within 2\u201312 weeks before treatment, at initiation of treatment, every 2 weeks for the first 8 weeks of treatment, and every 4 weeks thereafter until the end of treatment.", [["Clinical examination", "TEST", 0, 20], ["haematological and biochemical tests", "TEST", 22, 58], ["treatment", "TREATMENT", 99, 108], ["treatment", "TREATMENT", 127, 136], ["treatment", "TREATMENT", 177, 186], ["treatment", "TREATMENT", 234, 243]]], ["During the follow\u2010up period patients were evaluated 4, 12 and 24 weeks after the end of treatment.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["treatment", "TREATMENT", 88, 97]]], ["Serum HCV\u2010RNA was determined in all patients quantitatively before treatment (Amplicor Monitor HCV\u2122, version 2.0, Roche Diagnostic Systems, Branchburg, NJ) and thereafter qualitatively at treatment weeks 4, 12, 24 and 48, and at the end of the follow\u2010up period.", [["Serum", "ANATOMY", 0, 5], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["HCV", "ORGANISM", 6, 9], ["patients", "ORGANISM", 36, 44], ["Serum HCV\u2010RNA", "RNA", 0, 13], ["patients", "SPECIES", 36, 44], ["HCV", "SPECIES", 6, 9], ["Serum HCV\u2010RNA", "PROBLEM", 0, 13], ["treatment", "TREATMENT", 67, 76], ["Amplicor", "TEST", 78, 86], ["HCV", "OBSERVATION", 6, 9]]], ["Genotyping was performed by a reverse hybridization assay (Inno LiPA HCV II, Innogenetics, Gent, Belgium) [28].Study design ::: PATIENTS AND METHODSInformed written consent was obtained from all patients before enrolment.", [["patients", "ORGANISM", 195, 203], ["patients", "SPECIES", 195, 203], ["Genotyping", "TEST", 0, 10], ["a reverse hybridization assay", "TREATMENT", 28, 57], ["Inno LiPA HCV II", "TREATMENT", 59, 75], ["Gent", "TREATMENT", 91, 95]]], ["The study was approved by the local ethics committees for medical research of the participating study centres and performed according to the Declaration of Helsinki, the German Drug Law, and the ICH guidelines of \u2018Good Clinical Practice\u2019.Assessment of health\u2010related quality of live (HRQOL) ::: PATIENTS AND METHODSIndividual emotional and psychological states were determined at baseline, at treatment week 16, and at the end of the 24 weeks follow\u2010up period by a German adapted and validated Profile of Mood States (POMS) scale assessing four factor scores for depression, fatigue, vigor and anger [29,30].", [["ICH", "DISEASE", 195, 198], ["depression", "DISEASE", 563, 573], ["fatigue", "DISEASE", 575, 582], ["The study", "TEST", 0, 9], ["depression", "PROBLEM", 563, 573], ["fatigue", "PROBLEM", 575, 582], ["vigor", "PROBLEM", 584, 589]]], ["This German\u2010validated questionnaire, related to the SF\u201036 Health Survey, assesses the following six subscales of health\u2010related quality\u2010of\u2010life for subjective health: body (e.g. make demands on body, concentrate on a task), mind (e.g. cope with illness, accept oneself), everyday life (e.g. solve daily problems, personal hygiene), social activity (e.g. get along with family, count on partner\u2019s help), zest for life (e.g. enjoy life) and medical treatment (e.g. believe in success of treatment).", [["body", "ANATOMY", 167, 171], ["body", "ANATOMY", 194, 198], ["illness", "DISEASE", 245, 252], ["body", "ORGANISM_SUBDIVISION", 167, 171], ["body", "ORGANISM_SUBDIVISION", 194, 198], ["medical treatment", "TREATMENT", 439, 456], ["treatment", "TREATMENT", 485, 494]]], ["Sum scores were determined for every patient.", [["patient", "ORGANISM", 37, 44], ["patient", "SPECIES", 37, 44]]], ["Missing items were replaced by the mean for the nonmissing items of the subscales.", [["Missing items", "PROBLEM", 0, 13]]], ["However, missing questionnaires were not replaced.Definition of response and study endpoints ::: PATIENTS AND METHODSThe primary efficacy endpoint of the present study was defined as a sustained virological response with undetectable serum HCV\u2010RNA by qualitative serum HCV\u2010RNA at the end of the follow\u2010up period.", [["serum", "ANATOMY", 234, 239], ["serum", "ANATOMY", 263, 268], ["serum", "ORGANISM_SUBSTANCE", 234, 239], ["serum", "ORGANISM_SUBSTANCE", 263, 268], ["RNA", "RNA", 244, 247], ["serum HCV\u2010RNA", "RNA", 263, 276], ["HCV", "SPECIES", 240, 243], ["HCV", "SPECIES", 269, 272], ["the present study", "TEST", 150, 167], ["a sustained virological response", "PROBLEM", 183, 215], ["undetectable serum HCV", "PROBLEM", 221, 243], ["qualitative serum HCV\u2010RNA", "PROBLEM", 251, 276]]], ["Secondary efficacy parameters included the virological response at treatment weeks 12, 24 and 48 as well as the corresponding biochemical response defined as a normalization of ALT.", [["ALT", "SIMPLE_CHEMICAL", 177, 180], ["ALT", "PROTEIN", 177, 180], ["Secondary efficacy parameters", "PROBLEM", 0, 29], ["ALT", "TEST", 177, 180]]], ["As an additional secondary efficacy parameter changes of HRQOL during and after treatment were evaluated.Statistical analysis ::: PATIENTS AND METHODSBased on an intent\u2010to\u2010treat analysis, 55 primary IFN\u2010\u03b1 nonresponders, who received at least one dose of the study medication, were included in the primary statistical analysis.", [["IFN", "PROTEIN", 199, 202], ["HRQOL", "TREATMENT", 57, 62], ["treatment", "TREATMENT", 80, 89], ["an intent\u2010to\u2010treat analysis", "TEST", 159, 186], ["the study medication", "TREATMENT", 254, 274]]], ["Virological response rates of the two treatment arms were compared with a one\u2010tailed Fisher\u2019s exact test on a significance level of \u03b1=10%.", [["Virological response rates", "TEST", 0, 26]]], ["Corresponding biochemical response rates were analysed with a two\u2010tailed Mann\u2013Whitney U\u2010test (\u03b1=0.05).", [["Corresponding biochemical response rates", "TEST", 0, 40], ["response rates", "OBSERVATION", 26, 40]]], ["Statistical procedures were performed using SAS procedures (version 6.12).", [["Statistical procedures", "TEST", 0, 22], ["SAS procedures", "TREATMENT", 44, 58]]], ["For the evaluation of HRQOL, the differences of the sum scores between the two treatment groups at treatment weeks 16 and 48, and at the end of follow\u2010up were compared with a two\u2010tailed Wilcoxon rank sum test (\u03b1=0.05) using StatXact4.Biochemical and virological response ::: RESULTSAn initial virological response with undetectable serum HCV\u2010RNA (< 1000 copies/mL) at treatment week 12 was achieved in five of 26 (19%) and in eight of 29 (28%) patients treated with IFN\u2010\u03b12a and amantadine sulphate or placebo, respectively (Table 2).", [["serum", "ANATOMY", 332, 337], ["IFN\u2010\u03b12a", "CHEMICAL", 466, 473], ["amantadine sulphate", "CHEMICAL", 478, 497], ["amantadine sulphate", "CHEMICAL", 478, 497], ["serum", "ORGANISM_SUBSTANCE", 332, 337], ["patients", "ORGANISM", 444, 452], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 466, 473], ["amantadine sulphate", "SIMPLE_CHEMICAL", 478, 497], ["serum HCV\u2010RNA", "RNA", 332, 345], ["IFN", "PROTEIN", 466, 469], ["patients", "SPECIES", 444, 452], ["HCV", "SPECIES", 338, 341], ["the evaluation", "TEST", 4, 18], ["HRQOL", "TREATMENT", 22, 27], ["StatXact4", "TREATMENT", 224, 233], ["undetectable serum HCV\u2010RNA", "PROBLEM", 319, 345], ["IFN", "TREATMENT", 466, 469], ["amantadine sulphate", "TREATMENT", 478, 497], ["placebo", "TREATMENT", 501, 508]]], ["According to the protocol the antiviral therapy was discontinued at treatment week 16 in 42 patients because of detectable serum HCV\u2010RNA at treatment week 12.", [["serum", "ANATOMY", 123, 128], ["patients", "ORGANISM", 92, 100], ["serum", "ORGANISM_SUBSTANCE", 123, 128], ["RNA", "RNA", 133, 136], ["patients", "SPECIES", 92, 100], ["HCV", "SPECIES", 129, 132], ["the antiviral therapy", "TREATMENT", 26, 47], ["detectable serum HCV", "PROBLEM", 112, 132], ["HCV", "OBSERVATION", 129, 132]]], ["Because of breakthrough events during treatment weeks 16\u201348, a virological end\u2010of\u2010treatment response was found only in one of 26 (4%) patients receiving combined IFN\u2010\u03b12a/amantadine sulphate treatment and in four of 29 (14%) patients on IFN\u2010\u03b12a and placebo.", [["IFN\u2010\u03b12a/amantadine sulphate", "CHEMICAL", 162, 189], ["IFN\u2010\u03b12a", "CHEMICAL", 236, 243], ["amantadine sulphate", "CHEMICAL", 170, 189], ["patients", "ORGANISM", 134, 142], ["\u03b12a", "SIMPLE_CHEMICAL", 166, 169], ["amantadine sulphate", "SIMPLE_CHEMICAL", 170, 189], ["patients", "ORGANISM", 224, 232], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 236, 243], ["IFN", "PROTEIN", 162, 165], ["IFN", "PROTEIN", 236, 239], ["patients", "SPECIES", 134, 142], ["patients", "SPECIES", 224, 232], ["breakthrough events", "PROBLEM", 11, 30], ["a virological end\u2010of\u2010treatment response", "TEST", 61, 100], ["combined IFN\u2010\u03b12a", "TREATMENT", 153, 169], ["amantadine sulphate treatment", "TREATMENT", 170, 199], ["IFN", "TREATMENT", 236, 239], ["placebo", "TREATMENT", 248, 255], ["breakthrough", "OBSERVATION_MODIFIER", 11, 23]]], ["At the end of follow\u2010up, a sustained virological response was observed in no patient treated with IFN\u2010\u03b12a and amantadine sulphate and in two patients treated with IFN\u2010\u03b12a plus placebo.Biochemical and virological response ::: RESULTSInitial biochemical responses with ALT values within the normal range at treatment week 12 were comparable in both groups (38% for each treatment arm, Table 2).", [["IFN\u2010\u03b12a", "CHEMICAL", 98, 105], ["amantadine sulphate", "CHEMICAL", 110, 129], ["IFN\u2010\u03b12a", "CHEMICAL", 163, 170], ["amantadine sulphate", "CHEMICAL", 110, 129], ["patient", "ORGANISM", 77, 84], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 98, 105], ["amantadine sulphate", "SIMPLE_CHEMICAL", 110, 129], ["patients", "ORGANISM", 141, 149], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 163, 170], ["placebo", "SIMPLE_CHEMICAL", 176, 183], ["ALT", "SIMPLE_CHEMICAL", 267, 270], ["IFN", "PROTEIN", 98, 101], ["IFN", "PROTEIN", 163, 166], ["ALT", "PROTEIN", 267, 270], ["patient", "SPECIES", 77, 84], ["patients", "SPECIES", 141, 149], ["a sustained virological response", "PROBLEM", 25, 57], ["IFN", "TREATMENT", 98, 101], ["amantadine sulphate", "TREATMENT", 110, 129], ["IFN", "TREATMENT", 163, 166], ["placebo", "TREATMENT", 176, 183], ["ALT values", "TEST", 267, 277], ["normal range", "OBSERVATION_MODIFIER", 289, 301]]], ["A sustained biochemical response was achieved in only one of the patients treated with IFN\u2010\u03b12a plus amantadine sulphate and in four of 29 patients receiving IFN\u2010\u03b12a plus placebo.Health\u2010related quality of life (HRQOL) ::: RESULTSAccording to the study protocol antiviral treatment was discontinued at week 16 in 42 of 55 patients with detectable serum HCV\u2010RNA at treatment week 12.", [["serum", "ANATOMY", 345, 350], ["IFN\u2010\u03b12a", "CHEMICAL", 87, 94], ["amantadine sulphate", "CHEMICAL", 100, 119], ["IFN\u2010\u03b12a", "CHEMICAL", 157, 164], ["amantadine sulphate", "CHEMICAL", 100, 119], ["patients", "ORGANISM", 65, 73], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 87, 94], ["amantadine sulphate", "SIMPLE_CHEMICAL", 100, 119], ["patients", "ORGANISM", 138, 146], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 157, 164], ["placebo", "SIMPLE_CHEMICAL", 170, 177], ["patients", "ORGANISM", 320, 328], ["serum", "ORGANISM_SUBSTANCE", 345, 350], ["HCV", "ORGANISM", 351, 354], ["IFN", "PROTEIN", 87, 90], ["IFN", "PROTEIN", 157, 160], ["RNA", "RNA", 355, 358], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 138, 146], ["patients", "SPECIES", 320, 328], ["HCV", "SPECIES", 351, 354], ["A sustained biochemical response", "PROBLEM", 0, 32], ["IFN", "TREATMENT", 87, 90], ["amantadine sulphate", "TREATMENT", 100, 119], ["IFN", "TREATMENT", 157, 160], ["placebo", "TREATMENT", 170, 177], ["the study", "TEST", 241, 250], ["antiviral treatment", "TREATMENT", 260, 279], ["detectable serum HCV", "PROBLEM", 334, 354], ["sustained", "OBSERVATION_MODIFIER", 2, 11], ["biochemical response", "OBSERVATION", 12, 32], ["HCV", "OBSERVATION", 351, 354]]], ["Therefore, health\u2010related quality of life during treatment was evaluated in all patients at treatment week 16.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["treatment", "TREATMENT", 49, 58]]], ["Assessment of health\u2010related quality of live during treatment revealed a deterioration of the mean of all four factor scores of the POMS scale in the patients treated with IFN\u2010\u03b1 plus placebo and in three of the four factor scores (depression, fatigue and anger) in patients treated with combined IFN\u2010\u03b1/amantadine sulphate (Fig. 2a).", [["IFN\u2010\u03b1", "CHEMICAL", 172, 177], ["depression", "DISEASE", 231, 241], ["fatigue", "DISEASE", 243, 250], ["IFN\u2010\u03b1/amantadine sulphate", "CHEMICAL", 296, 321], ["amantadine sulphate", "CHEMICAL", 302, 321], ["patients", "ORGANISM", 150, 158], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 172, 177], ["patients", "ORGANISM", 265, 273], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 296, 301], ["amantadine sulphate", "SIMPLE_CHEMICAL", 302, 321], ["Fig. 2a", "SIMPLE_CHEMICAL", 323, 330], ["IFN", "PROTEIN", 172, 175], ["IFN", "PROTEIN", 296, 299], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 265, 273], ["treatment", "TREATMENT", 52, 61], ["a deterioration", "PROBLEM", 71, 86], ["the POMS scale", "TEST", 128, 142], ["IFN\u2010\u03b1", "TREATMENT", 172, 177], ["placebo", "TREATMENT", 183, 190], ["depression", "PROBLEM", 231, 241], ["fatigue", "PROBLEM", 243, 250], ["combined IFN\u2010\u03b1", "TREATMENT", 287, 301], ["amantadine sulphate", "TREATMENT", 302, 321]]], ["The extent of the observed impairment of the POMS scale was less pronounced for the subscales depression and fatigue in patients treated with IFN\u2010\u03b12a plus amantadine sulphate.", [["depression", "DISEASE", 94, 104], ["fatigue", "DISEASE", 109, 116], ["IFN\u2010\u03b12a", "CHEMICAL", 142, 149], ["amantadine sulphate", "CHEMICAL", 155, 174], ["amantadine sulphate", "CHEMICAL", 155, 174], ["patients", "ORGANISM", 120, 128], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 142, 149], ["amantadine sulphate", "SIMPLE_CHEMICAL", 155, 174], ["IFN", "PROTEIN", 142, 145], ["patients", "SPECIES", 120, 128], ["the POMS scale", "TEST", 41, 55], ["the subscales depression", "PROBLEM", 80, 104], ["fatigue", "PROBLEM", 109, 116], ["IFN", "TREATMENT", 142, 145], ["amantadine sulphate", "TREATMENT", 155, 174], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["observed", "OBSERVATION_MODIFIER", 18, 26], ["impairment", "OBSERVATION", 27, 37]]], ["At the end of follow\u2010up, a sustained improvement of the mean factor scores for depression (P=n.s.), fatigue (P=0.023), and vigor (P=0.025) in comparison with baseline levels was observed only in patients receiving combined treatment with IFN\u2010\u03b12a plus amantadine sulphate.Health\u2010related quality of life (HRQOL) ::: RESULTSIrrespective of treatment, the evaluation of the \u2018Everyday Life\u2019 questionnaire at treatment week 16 showed an impairment in the means of most subscales in our patients compared with the corresponding pretreatment scores (Fig. 2b).", [["depression", "DISEASE", 79, 89], ["fatigue", "DISEASE", 100, 107], ["IFN\u2010\u03b12a", "CHEMICAL", 238, 245], ["amantadine sulphate", "CHEMICAL", 251, 270], ["amantadine sulphate", "CHEMICAL", 251, 270], ["patients", "ORGANISM", 195, 203], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 238, 245], ["amantadine sulphate", "SIMPLE_CHEMICAL", 251, 270], ["patients", "ORGANISM", 480, 488], ["IFN", "PROTEIN", 238, 241], ["patients", "SPECIES", 195, 203], ["patients", "SPECIES", 480, 488], ["the mean factor scores", "PROBLEM", 52, 74], ["depression", "PROBLEM", 79, 89], ["fatigue", "PROBLEM", 100, 107], ["P", "TEST", 109, 110], ["IFN", "TREATMENT", 238, 241], ["amantadine sulphate", "TREATMENT", 251, 270], ["treatment", "TREATMENT", 337, 346], ["the evaluation", "TEST", 348, 362], ["an impairment", "PROBLEM", 428, 441], ["impairment", "OBSERVATION", 431, 441]]], ["At the end of the follow\u2010up period, a sustained improvement in the means of all subscales was observed only in patients receiving treatment with IFN\u2010\u03b1 plus amantadine sulphate.", [["IFN\u2010\u03b1", "CHEMICAL", 145, 150], ["amantadine sulphate", "CHEMICAL", 156, 175], ["amantadine sulphate", "CHEMICAL", 156, 175], ["patients", "ORGANISM", 111, 119], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 145, 150], ["amantadine sulphate", "SIMPLE_CHEMICAL", 156, 175], ["IFN", "PROTEIN", 145, 148], ["patients", "SPECIES", 111, 119], ["treatment", "TREATMENT", 130, 139], ["IFN", "TREATMENT", 145, 148], ["amantadine sulphate", "TREATMENT", 156, 175], ["sustained", "OBSERVATION_MODIFIER", 38, 47], ["improvement", "OBSERVATION_MODIFIER", 48, 59]]], ["In the group of patients treated with IFN\u2010\u03b1 plus placebo the means of all subscales at the end of the follow\u2010up period was worse than the corresponding pretreatment scores.Adverse events ::: RESULTSAdverse events (n=269) occurred in a similar frequency in both treatment arms and were mostly related to IFN.", [["IFN\u2010\u03b1", "CHEMICAL", 38, 43], ["patients", "ORGANISM", 16, 24], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 38, 43], ["IFN", "GENE_OR_GENE_PRODUCT", 303, 306], ["IFN", "PROTEIN", 38, 41], ["IFN", "PROTEIN", 303, 306], ["patients", "SPECIES", 16, 24], ["IFN\u2010\u03b1", "TREATMENT", 38, 43], ["placebo", "TREATMENT", 49, 56], ["Adverse events", "PROBLEM", 172, 186], ["RESULTSAdverse events", "PROBLEM", 191, 212]]], ["The spectrum and frequency of the observed adverse events in relation to treatment are listed in detail in Table 3.", [["the observed adverse events", "PROBLEM", 30, 57], ["treatment", "TREATMENT", 73, 82]]], ["Serious adverse events were not observed in this study.", [["Serious adverse events", "PROBLEM", 0, 22], ["this study", "TEST", 44, 54]]], ["However, one patient treated with IFN\u2010\u03b12a plus placebo was discontinued prematurely from antiviral treatment at week 20 due to depression.Adverse events ::: RESULTSA slight decrease of mean leukocyte and thrombocyte count was found in most patients irrespective of the treatment group from baseline to treatment week 4 (5.8 \u00b1 1.6/nL to 4.3 \u00b1 1.4/nL, and 197 \u00b1 77/nL to 153 \u00b1 83/nL, respectively).", [["leukocyte", "ANATOMY", 190, 199], ["thrombocyte", "ANATOMY", 204, 215], ["IFN\u2010\u03b12a", "CHEMICAL", 34, 41], ["depression", "DISEASE", 127, 137], ["patient", "ORGANISM", 13, 20], ["\u03b12a", "SIMPLE_CHEMICAL", 38, 41], ["leukocyte", "CELL", 190, 199], ["thrombocyte", "CELL", 204, 215], ["patients", "ORGANISM", 240, 248], ["IFN", "PROTEIN", 34, 37], ["patient", "SPECIES", 13, 20], ["patients", "SPECIES", 240, 248], ["IFN", "TREATMENT", 34, 37], ["placebo", "TREATMENT", 47, 54], ["antiviral treatment", "TREATMENT", 89, 108], ["depression", "PROBLEM", 127, 137], ["RESULTSA", "TEST", 157, 165], ["mean leukocyte", "TEST", 185, 199], ["thrombocyte count", "TEST", 204, 221], ["slight", "OBSERVATION_MODIFIER", 166, 172], ["decrease", "OBSERVATION_MODIFIER", 173, 181], ["mean leukocyte", "OBSERVATION", 185, 199], ["thrombocyte count", "OBSERVATION", 204, 221]]], ["At the end of the follow\u2010up period leukocyte and thrombocyte counts returned to baseline levels with no significant differences between the treatment groups.", [["leukocyte", "ANATOMY", 35, 44], ["thrombocyte", "ANATOMY", 49, 60], ["leukocyte", "CELL", 35, 44], ["thrombocyte", "CELL", 49, 60], ["the follow\u2010up period leukocyte", "TEST", 14, 44], ["thrombocyte counts", "TEST", 49, 67], ["baseline levels", "TEST", 80, 95], ["the treatment groups", "TREATMENT", 136, 156], ["thrombocyte counts", "OBSERVATION", 49, 67], ["no", "UNCERTAINTY", 101, 103], ["significant", "OBSERVATION_MODIFIER", 104, 115]]], ["Hyperthyroidism developed in one patient treated with IFN\u2010\u03b12a alone and in five patients receiving IFN\u2010\u03b12a plus amantadine sulphate.", [["Hyperthyroidism", "DISEASE", 0, 15], ["IFN\u2010\u03b12a", "CHEMICAL", 54, 61], ["IFN\u2010\u03b12a", "CHEMICAL", 99, 106], ["amantadine sulphate", "CHEMICAL", 112, 131], ["amantadine sulphate", "CHEMICAL", 112, 131], ["patient", "ORGANISM", 33, 40], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 54, 61], ["patients", "ORGANISM", 80, 88], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 99, 106], ["amantadine sulphate", "SIMPLE_CHEMICAL", 112, 131], ["IFN", "PROTEIN", 54, 57], ["\u03b12a", "PROTEIN", 58, 61], ["IFN", "PROTEIN", 99, 102], ["patient", "SPECIES", 33, 40], ["patients", "SPECIES", 80, 88], ["Hyperthyroidism", "PROBLEM", 0, 15], ["IFN", "TREATMENT", 54, 57], ["IFN", "TREATMENT", 99, 102], ["amantadine sulphate", "TREATMENT", 112, 131]]], ["In one patient, diabetes mellitus developed and in another patient diabetes mellitus was aggravated during treatment.", [["diabetes mellitus", "DISEASE", 16, 33], ["diabetes mellitus", "DISEASE", 67, 84], ["patient", "ORGANISM", 7, 14], ["patient", "ORGANISM", 59, 66], ["patient", "SPECIES", 7, 14], ["patient", "SPECIES", 59, 66], ["diabetes mellitus", "PROBLEM", 16, 33], ["another patient diabetes mellitus", "PROBLEM", 51, 84], ["treatment", "TREATMENT", 107, 116], ["mellitus", "OBSERVATION", 25, 33], ["mellitus", "OBSERVATION", 76, 84]]], ["Both patients received IFN\u2010\u03b12a plus amantadine sulphate.DISCUSSIONDuring the last decade IFN\u2010\u03b1 therapy has been established as the standard treatment for chronic hepatitis C. Sustained viral clearance can be achieved by IFN\u2010\u03b1 monotherapy and IFN\u2010\u03b1/ribavirin combination therapy in 5\u201320% and 38\u201341% of treatment naive patients, respectively [5, 6, 7, \u20138].", [["IFN\u2010\u03b12a", "CHEMICAL", 23, 30], ["amantadine sulphate", "CHEMICAL", 36, 55], ["IFN\u2010\u03b1", "CHEMICAL", 89, 94], ["hepatitis", "DISEASE", 162, 171], ["IFN\u2010\u03b1", "CHEMICAL", 220, 225], ["IFN\u2010\u03b1", "CHEMICAL", 242, 247], ["ribavirin", "CHEMICAL", 248, 257], ["amantadine sulphate", "CHEMICAL", 36, 55], ["ribavirin", "CHEMICAL", 248, 257], ["patients", "ORGANISM", 5, 13], ["IFN\u2010\u03b12a", "SIMPLE_CHEMICAL", 23, 30], ["amantadine sulphate", "SIMPLE_CHEMICAL", 36, 55], ["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 89, 94], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 220, 225], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 242, 247], ["ribavirin", "SIMPLE_CHEMICAL", 248, 257], ["patients", "ORGANISM", 317, 325], ["IFN", "PROTEIN", 23, 26], ["IFN", "PROTEIN", 89, 92], ["IFN", "PROTEIN", 220, 223], ["IFN", "PROTEIN", 242, 245], ["patients", "SPECIES", 5, 13], ["patients", "SPECIES", 317, 325], ["IFN", "TREATMENT", 23, 26], ["amantadine sulphate", "TREATMENT", 36, 55], ["IFN\u2010\u03b1 therapy", "TREATMENT", 89, 102], ["the standard treatment", "TREATMENT", 127, 149], ["chronic hepatitis C.", "PROBLEM", 154, 174], ["IFN\u2010\u03b1 monotherapy", "TREATMENT", 220, 237], ["IFN\u2010\u03b1", "TREATMENT", 242, 247], ["ribavirin combination therapy", "TREATMENT", 248, 277], ["chronic", "OBSERVATION_MODIFIER", 154, 161], ["hepatitis", "OBSERVATION", 162, 171]]], ["With respect to the low sustained response rates to retreatment with IFN\u2010\u03b1 alone or in combination with ribavirin in IFN\u2010\u03b1 nonresponder, the need for the development of alternative, effective retreatment regimens in this subgroup of patients became apparent.", [["IFN\u2010\u03b1", "CHEMICAL", 69, 74], ["ribavirin", "CHEMICAL", 104, 113], ["ribavirin", "CHEMICAL", 104, 113], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 69, 74], ["ribavirin", "SIMPLE_CHEMICAL", 104, 113], ["patients", "ORGANISM", 233, 241], ["IFN", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 117, 120], ["patients", "SPECIES", 233, 241], ["the low sustained response rates", "PROBLEM", 16, 48], ["retreatment", "TREATMENT", 52, 63], ["IFN\u2010\u03b1", "TREATMENT", 69, 74], ["ribavirin", "TREATMENT", 104, 113], ["IFN", "TREATMENT", 117, 120], ["alternative, effective retreatment regimens", "TREATMENT", 169, 212]]], ["In a 1997 published pilot study, a beneficial therapeutic effect of six months amantadine retreatment in IFN\u2010\u03b1 nonresponders with chronic hepatitis C was reported with a sustained biochemical and virological response in four of 22 patients (18%) after a 24 week follow\u2010up period [19].", [["amantadine", "CHEMICAL", 79, 89], ["IFN\u2010\u03b1", "CHEMICAL", 105, 110], ["chronic hepatitis C", "DISEASE", 130, 149], ["amantadine", "CHEMICAL", 79, 89], ["amantadine", "SIMPLE_CHEMICAL", 79, 89], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 105, 110], ["patients", "ORGANISM", 231, 239], ["IFN", "PROTEIN", 105, 108], ["patients", "SPECIES", 231, 239], ["pilot study", "TEST", 20, 31], ["six months amantadine retreatment", "TREATMENT", 68, 101], ["IFN", "TREATMENT", 105, 108], ["chronic hepatitis C", "PROBLEM", 130, 149], ["chronic", "OBSERVATION_MODIFIER", 130, 137], ["hepatitis", "OBSERVATION", 138, 147]]], ["The postulated antiviral effect of amantadine was supported in vitro by a dose\u2010dependent decrease of HCV\u2010RNA in the supernatant of isolated blood mononuclear cells from patients with chronic hepatitis C cultured with amantadine [33].", [["supernatant", "ANATOMY", 116, 127], ["blood mononuclear cells", "ANATOMY", 140, 163], ["amantadine", "CHEMICAL", 35, 45], ["chronic hepatitis C", "DISEASE", 183, 202], ["amantadine", "CHEMICAL", 217, 227], ["amantadine", "CHEMICAL", 35, 45], ["amantadine", "CHEMICAL", 217, 227], ["amantadine", "SIMPLE_CHEMICAL", 35, 45], ["HCV", "ORGANISM", 101, 104], ["blood mononuclear cells", "CELL", 140, 163], ["patients", "ORGANISM", 169, 177], ["amantadine", "SIMPLE_CHEMICAL", 217, 227], ["HCV\u2010RNA", "RNA", 101, 108], ["isolated blood mononuclear cells", "CELL_TYPE", 131, 163], ["patients", "SPECIES", 169, 177], ["HCV", "SPECIES", 101, 104], ["The postulated antiviral effect", "TREATMENT", 0, 31], ["amantadine", "TREATMENT", 35, 45], ["HCV\u2010RNA", "TREATMENT", 101, 108], ["isolated blood mononuclear cells", "PROBLEM", 131, 163], ["chronic hepatitis C", "PROBLEM", 183, 202], ["amantadine", "TREATMENT", 217, 227], ["antiviral effect", "OBSERVATION", 15, 31], ["HCV", "OBSERVATION", 101, 104], ["blood mononuclear cells", "OBSERVATION", 140, 163], ["chronic", "OBSERVATION_MODIFIER", 183, 190], ["hepatitis", "OBSERVATION", 191, 200]]], ["However, in vivo determination of hepatitis C viral load failed to show a direct synergistic antiviral effect of amantadine sulphate during combined IFN\u2010\u03b1/amantadine treatment in previously untreated patients with chronic hepatitis C [23].DISCUSSIONSubsequently, mainly uncontrolled clinical trials of amantadine monotherapy in small cohorts of nonresponders with chronic hepatitis C showed conflicting results with sustained virological response rates varying from 0% to 15%.", [["amantadine sulphate", "CHEMICAL", 113, 132], ["IFN\u2010\u03b1", "CHEMICAL", 149, 154], ["amantadine", "CHEMICAL", 155, 165], ["chronic hepatitis C", "DISEASE", 214, 233], ["amantadine", "CHEMICAL", 302, 312], ["chronic hepatitis C", "DISEASE", 364, 383], ["amantadine sulphate", "CHEMICAL", 113, 132], ["amantadine", "CHEMICAL", 155, 165], ["amantadine", "CHEMICAL", 302, 312], ["hepatitis C viral", "ORGANISM", 34, 51], ["amantadine sulphate", "SIMPLE_CHEMICAL", 113, 132], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 149, 154], ["amantadine", "SIMPLE_CHEMICAL", 155, 165], ["patients", "ORGANISM", 200, 208], ["amantadine", "SIMPLE_CHEMICAL", 302, 312], ["IFN", "PROTEIN", 149, 152], ["patients", "SPECIES", 200, 208], ["hepatitis C viral load", "PROBLEM", 34, 56], ["a direct synergistic antiviral effect", "TREATMENT", 72, 109], ["amantadine sulphate", "TREATMENT", 113, 132], ["combined IFN\u2010\u03b1", "TREATMENT", 140, 154], ["amantadine treatment", "TREATMENT", 155, 175], ["chronic hepatitis C", "PROBLEM", 214, 233], ["amantadine monotherapy", "TREATMENT", 302, 324], ["small cohorts of nonresponders", "PROBLEM", 328, 358], ["chronic hepatitis C", "PROBLEM", 364, 383], ["sustained virological response rates", "TEST", 416, 452], ["chronic", "OBSERVATION_MODIFIER", 214, 221], ["hepatitis", "OBSERVATION", 222, 231], ["small", "OBSERVATION_MODIFIER", 328, 333]]], ["As indicated by a recently published pilot study, the combination of IFN\u2010\u03b1 with amantadine may lead to an improvement of virological response rates in nonresponders with chronic hepatitis C [25].DISCUSSIONThe present study is the first randomized, double\u2010blind, placebo\u2010controlled trial evaluating the efficacy of retreatment with IFN\u2010\u03b1 plus amantadine sulphate compared with IFN\u2010\u03b1 alone in previous IFN\u2010\u03b1 nonresponders with chronic hepatitis C. Considering the demographic, biochemical, virological and histological patients\u2019 characteristics, significant differences between both treatment groups were not present.", [["IFN\u2010\u03b1", "CHEMICAL", 69, 74], ["amantadine", "CHEMICAL", 80, 90], ["chronic hepatitis C", "DISEASE", 170, 189], ["IFN\u2010\u03b1", "CHEMICAL", 331, 336], ["amantadine sulphate", "CHEMICAL", 342, 361], ["IFN\u2010\u03b1", "CHEMICAL", 376, 381], ["chronic hepatitis C.", "DISEASE", 425, 445], ["amantadine", "CHEMICAL", 80, 90], ["amantadine sulphate", "CHEMICAL", 342, 361], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 69, 74], ["amantadine", "SIMPLE_CHEMICAL", 80, 90], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 331, 336], ["amantadine sulphate", "SIMPLE_CHEMICAL", 342, 361], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 376, 381], ["patients", "ORGANISM", 517, 525], ["IFN", "PROTEIN", 69, 72], ["IFN", "PROTEIN", 331, 334], ["IFN\u2010\u03b1", "PROTEIN", 376, 381], ["IFN", "PROTEIN", 400, 403], ["patients", "SPECIES", 517, 525], ["pilot study", "TEST", 37, 48], ["IFN\u2010\u03b1", "TREATMENT", 69, 74], ["amantadine", "TREATMENT", 80, 90], ["virological response rates", "TEST", 121, 147], ["chronic hepatitis C", "PROBLEM", 170, 189], ["The present study", "TEST", 205, 222], ["placebo\u2010controlled trial", "TREATMENT", 262, 286], ["retreatment", "TREATMENT", 314, 325], ["IFN", "TREATMENT", 331, 334], ["amantadine sulphate", "TREATMENT", 342, 361], ["IFN", "TREATMENT", 376, 379], ["chronic hepatitis C.", "PROBLEM", 425, 445], ["both treatment groups", "TREATMENT", 576, 597], ["chronic", "OBSERVATION_MODIFIER", 170, 177], ["hepatitis", "OBSERVATION", 178, 187], ["chronic", "OBSERVATION_MODIFIER", 425, 432], ["hepatitis", "OBSERVATION", 433, 442], ["significant", "OBSERVATION_MODIFIER", 544, 555]]], ["The sustained virological response rates were similar in both treatment groups.", [["The sustained virological response rates", "PROBLEM", 0, 40], ["sustained", "OBSERVATION_MODIFIER", 4, 13], ["virological response", "OBSERVATION", 14, 34]]], ["Thus, with respect to the results of the present controlled study, the addition of amantadine sulphate to IFN\u2010\u03b1 does not improve the sustained virological response rates in nonresponders with chronic hepatitis C. These results confirm a larger controlled trial in 119 treatment naive patients with chronic hepatitis C which also showed no beneficial virological effect of the addition of amantadine sulphate to IFN\u2010\u03b1 treatment in these patients [23].", [["amantadine sulphate", "CHEMICAL", 83, 102], ["IFN\u2010\u03b1", "CHEMICAL", 106, 111], ["chronic hepatitis C.", "DISEASE", 192, 212], ["chronic hepatitis C", "DISEASE", 298, 317], ["amantadine sulphate", "CHEMICAL", 388, 407], ["IFN\u2010\u03b1", "CHEMICAL", 411, 416], ["amantadine sulphate", "CHEMICAL", 83, 102], ["amantadine sulphate", "CHEMICAL", 388, 407], ["amantadine sulphate", "SIMPLE_CHEMICAL", 83, 102], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 106, 111], ["patients", "ORGANISM", 284, 292], ["amantadine sulphate", "SIMPLE_CHEMICAL", 388, 407], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 411, 416], ["patients", "ORGANISM", 436, 444], ["IFN\u2010\u03b1", "PROTEIN", 106, 111], ["IFN", "PROTEIN", 411, 414], ["patients", "SPECIES", 284, 292], ["patients", "SPECIES", 436, 444], ["the present controlled study", "TEST", 37, 65], ["amantadine sulphate", "TREATMENT", 83, 102], ["IFN", "TREATMENT", 106, 109], ["the sustained virological response rates in nonresponders", "PROBLEM", 129, 186], ["chronic hepatitis C.", "PROBLEM", 192, 212], ["a larger controlled trial in 119 treatment", "TREATMENT", 235, 277], ["chronic hepatitis C", "PROBLEM", 298, 317], ["amantadine sulphate", "TREATMENT", 388, 407], ["IFN\u2010\u03b1 treatment", "TREATMENT", 411, 426], ["larger", "OBSERVATION_MODIFIER", 237, 243], ["chronic", "OBSERVATION_MODIFIER", 298, 305], ["hepatitis", "OBSERVATION", 306, 315], ["no", "UNCERTAINTY", 336, 338]]], ["In contrast, a recently published study in 60 nonresponders, treated with IFN\u2010\u03b1, ribavirin and amantadine or IFN\u2010\u03b1 and amantadine, could demonstrate increased virological response rates in nonresponders with chronic hepatitis C who received amantadine [34].", [["IFN\u2010\u03b1", "CHEMICAL", 74, 79], ["ribavirin", "CHEMICAL", 81, 90], ["amantadine", "CHEMICAL", 95, 105], ["IFN\u2010\u03b1", "CHEMICAL", 109, 114], ["amantadine", "CHEMICAL", 119, 129], ["chronic hepatitis C", "DISEASE", 208, 227], ["amantadine", "CHEMICAL", 241, 251], ["IFN\u2010\u03b1", "CHEMICAL", 74, 79], ["ribavirin", "CHEMICAL", 81, 90], ["amantadine", "CHEMICAL", 95, 105], ["amantadine", "CHEMICAL", 119, 129], ["amantadine", "CHEMICAL", 241, 251], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 74, 79], ["ribavirin", "SIMPLE_CHEMICAL", 81, 90], ["amantadine", "SIMPLE_CHEMICAL", 95, 105], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 109, 114], ["amantadine", "SIMPLE_CHEMICAL", 119, 129], ["IFN", "PROTEIN", 109, 112], ["a recently published study", "TEST", 13, 39], ["IFN\u2010\u03b1", "TREATMENT", 74, 79], ["ribavirin", "TREATMENT", 81, 90], ["amantadine", "TREATMENT", 95, 105], ["IFN\u2010\u03b1", "TREATMENT", 109, 114], ["amantadine", "TREATMENT", 119, 129], ["increased virological response rates", "PROBLEM", 149, 185], ["chronic hepatitis C", "PROBLEM", 208, 227], ["amantadine", "TREATMENT", 241, 251], ["increased", "OBSERVATION_MODIFIER", 149, 158], ["virological response", "OBSERVATION", 159, 179], ["chronic", "OBSERVATION_MODIFIER", 208, 215], ["hepatitis", "OBSERVATION", 216, 225]]], ["However, these data have to be confirmed by larger randomized, double\u2010blind, placebo\u2010controlled trials in nonresponders with chronic hepatitis C.DISCUSSIONDespite a similar number of adverse events in both treatment groups, additional analysis of the individual emotional and psychological state as well as the evaluation of health\u2010related quality of live revealed an improved outcome in patients treated with the combination of IFN\u2010\u03b1 plus amantadine sulphate compared with those patients receiving IFN\u2010\u03b1 alone.", [["chronic hepatitis C.DISCUSSIONDespite", "DISEASE", 125, 162], ["IFN\u2010\u03b1", "CHEMICAL", 429, 434], ["amantadine sulphate", "CHEMICAL", 440, 459], ["IFN\u2010\u03b1", "CHEMICAL", 499, 504], ["amantadine sulphate", "CHEMICAL", 440, 459], ["patients", "ORGANISM", 388, 396], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 429, 434], ["amantadine sulphate", "SIMPLE_CHEMICAL", 440, 459], ["patients", "ORGANISM", 480, 488], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 499, 504], ["IFN", "PROTEIN", 429, 432], ["IFN\u2010\u03b1", "PROTEIN", 499, 504], ["patients", "SPECIES", 388, 396], ["patients", "SPECIES", 480, 488], ["placebo\u2010controlled trials", "TREATMENT", 77, 102], ["chronic hepatitis", "PROBLEM", 125, 142], ["adverse events", "PROBLEM", 183, 197], ["both treatment groups", "TREATMENT", 201, 222], ["the evaluation", "TEST", 307, 321], ["IFN\u2010\u03b1", "TREATMENT", 429, 434], ["amantadine sulphate", "TREATMENT", 440, 459], ["IFN\u2010\u03b1", "TREATMENT", 499, 504], ["larger", "OBSERVATION_MODIFIER", 44, 50], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["hepatitis", "OBSERVATION", 133, 142]]], ["In the POMS scale all four subscores deteriorated during treatment with IFN\u2010\u03b1 alone in comparison with the corresponding baseline levels and remained impaired during the follow\u2010up period.", [["IFN\u2010\u03b1", "CHEMICAL", 72, 77], ["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 72, 77], ["IFN\u2010\u03b1", "PROTEIN", 72, 77], ["treatment", "TREATMENT", 57, 66], ["IFN\u2010\u03b1", "TREATMENT", 72, 77], ["impaired", "OBSERVATION", 150, 158]]], ["The combined retreatment with IFN\u2010\u03b1 plus amantadine sulphate led to a smaller reduction of three of the four subscores, i.e. depression, vigor, and fatigue during treatment and interestingly, to a sustained improvement of the corresponding subscores in comparison with baseline levels at the end of the 24 week follow\u2010up period.", [["IFN\u2010\u03b1", "CHEMICAL", 30, 35], ["amantadine sulphate", "CHEMICAL", 41, 60], ["depression", "DISEASE", 125, 135], ["fatigue", "DISEASE", 148, 155], ["amantadine sulphate", "CHEMICAL", 41, 60], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 30, 35], ["amantadine sulphate", "SIMPLE_CHEMICAL", 41, 60], ["IFN", "PROTEIN", 30, 33], ["The combined retreatment", "TREATMENT", 0, 24], ["IFN", "TREATMENT", 30, 33], ["amantadine sulphate", "TREATMENT", 41, 60], ["depression", "PROBLEM", 125, 135], ["vigor", "PROBLEM", 137, 142], ["fatigue", "PROBLEM", 148, 155], ["treatment", "TREATMENT", 163, 172], ["retreatment", "OBSERVATION_MODIFIER", 13, 24], ["smaller", "OBSERVATION_MODIFIER", 70, 77], ["reduction", "OBSERVATION_MODIFIER", 78, 87], ["depression", "OBSERVATION", 125, 135]]], ["A similar improvement during amantadine sulphate treatment has also been shown for patients with central nervous disease, including multiple sclerosis and Parkinson\u2019s disease [35].", [["central nervous", "ANATOMY", 97, 112], ["amantadine sulphate", "CHEMICAL", 29, 48], ["central nervous disease", "DISEASE", 97, 120], ["multiple sclerosis", "DISEASE", 132, 150], ["Parkinson\u2019s disease", "DISEASE", 155, 174], ["amantadine sulphate", "CHEMICAL", 29, 48], ["amantadine sulphate", "SIMPLE_CHEMICAL", 29, 48], ["patients", "ORGANISM", 83, 91], ["nervous", "ANATOMICAL_SYSTEM", 105, 112], ["patients", "SPECIES", 83, 91], ["amantadine sulphate treatment", "TREATMENT", 29, 58], ["central nervous disease", "PROBLEM", 97, 120], ["multiple sclerosis", "PROBLEM", 132, 150], ["Parkinson\u2019s disease", "PROBLEM", 155, 174], ["similar", "OBSERVATION_MODIFIER", 2, 9], ["improvement", "OBSERVATION_MODIFIER", 10, 21], ["central nervous disease", "OBSERVATION", 97, 120], ["multiple", "OBSERVATION_MODIFIER", 132, 140], ["sclerosis", "OBSERVATION", 141, 150]]], ["In the present study, analysis of the SF\u201036 health\u2010related \u2018Everyday Life\u2019 questionnaire showed a sustained improvement of all six subscores in the group of patients treated with IFN\u2010\u03b1 plus amantadine sulphate at the end of the follow\u2010up period in comparison with the corresponding baseline scores while five of six subscores remained impaired in patients treated with IFN\u2010\u03b1 alone.", [["IFN\u2010\u03b1", "CHEMICAL", 179, 184], ["amantadine sulphate", "CHEMICAL", 190, 209], ["IFN\u2010\u03b1", "CHEMICAL", 369, 374], ["amantadine sulphate", "CHEMICAL", 190, 209], ["patients", "ORGANISM", 157, 165], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 179, 184], ["amantadine sulphate", "SIMPLE_CHEMICAL", 190, 209], ["patients", "ORGANISM", 347, 355], ["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 369, 374], ["IFN", "PROTEIN", 179, 182], ["IFN\u2010\u03b1", "PROTEIN", 369, 374], ["patients", "SPECIES", 157, 165], ["patients", "SPECIES", 347, 355], ["the present study", "TEST", 3, 20], ["the SF", "TEST", 34, 40], ["IFN", "TREATMENT", 179, 182], ["amantadine sulphate", "TREATMENT", 190, 209], ["IFN\u2010\u03b1", "TREATMENT", 369, 374], ["sustained", "OBSERVATION_MODIFIER", 98, 107], ["improvement", "OBSERVATION_MODIFIER", 108, 119]]], ["A sustained improvement for the POMS scale and the SF\u201036 health\u2010related \u2018Everyday Life\u2019 questionnaire has also been reported in a previously published study in naive patients with chronic hepatitis C receiving IFN\u2010\u03b1/amantadine sulphate combination therapy compared with those treated with IFN\u2010\u03b1 alone [23].DISCUSSIONIn summary, retreatment with IFN\u2010\u03b1 in combination with amantadine sulphate does not increase the low sustained virological response rates of IFN\u2010\u03b1 monotherapy in primary IFN\u2010\u03b1 nonresponders with chronic hepatitis C, but may lead to a sustained improvement of health\u2010related quality of life.", [["chronic hepatitis C", "DISEASE", 180, 199], ["IFN\u2010\u03b1/amantadine sulphate", "CHEMICAL", 210, 235], ["IFN\u2010\u03b1", "CHEMICAL", 289, 294], ["IFN\u2010\u03b1", "CHEMICAL", 345, 350], ["amantadine sulphate", "CHEMICAL", 371, 390], ["IFN\u2010\u03b1", "CHEMICAL", 457, 462], ["chronic hepatitis C", "DISEASE", 511, 530], ["amantadine sulphate", "CHEMICAL", 216, 235], ["IFN\u2010\u03b1", "CHEMICAL", 289, 294], ["amantadine sulphate", "CHEMICAL", 371, 390], ["patients", "ORGANISM", 166, 174], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 210, 215], ["amantadine sulphate", "SIMPLE_CHEMICAL", 216, 235], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 289, 294], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 345, 350], ["amantadine sulphate", "SIMPLE_CHEMICAL", 371, 390], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 457, 462], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 486, 491], ["IFN", "PROTEIN", 210, 213], ["IFN\u2010\u03b1", "PROTEIN", 345, 350], ["IFN", "PROTEIN", 457, 460], ["IFN", "PROTEIN", 486, 489], ["patients", "SPECIES", 166, 174], ["the POMS scale", "TEST", 28, 42], ["chronic hepatitis C", "PROBLEM", 180, 199], ["IFN\u2010\u03b1", "TREATMENT", 210, 215], ["amantadine sulphate combination therapy", "TREATMENT", 216, 255], ["retreatment", "TREATMENT", 328, 339], ["IFN\u2010\u03b1", "TREATMENT", 345, 350], ["amantadine sulphate", "TREATMENT", 371, 390], ["IFN\u2010\u03b1 monotherapy", "TREATMENT", 457, 474], ["chronic hepatitis C", "PROBLEM", 511, 530], ["sustained", "OBSERVATION_MODIFIER", 2, 11], ["improvement", "OBSERVATION", 12, 23], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["hepatitis", "OBSERVATION", 188, 197], ["chronic", "OBSERVATION_MODIFIER", 511, 518], ["hepatitis", "OBSERVATION", 519, 528]]], ["The recently suggested improved antiviral effect of triple retreatment with IFN\u2010\u03b1, ribavirin and amantadine in previous IFN\u2010\u03b1 nonresponders has to be confirmed in larger randomized, double\u2010blind, placebo\u2010controlled trials.", [["IFN\u2010\u03b1", "CHEMICAL", 76, 81], ["ribavirin", "CHEMICAL", 83, 92], ["amantadine", "CHEMICAL", 97, 107], ["IFN", "CHEMICAL", 120, 123], ["IFN\u2010\u03b1", "CHEMICAL", 76, 81], ["ribavirin", "CHEMICAL", 83, 92], ["amantadine", "CHEMICAL", 97, 107], ["IFN\u2010\u03b1", "SIMPLE_CHEMICAL", 76, 81], ["ribavirin", "SIMPLE_CHEMICAL", 83, 92], ["amantadine", "SIMPLE_CHEMICAL", 97, 107], ["IFN\u2010\u03b1", "GENE_OR_GENE_PRODUCT", 120, 125], ["IFN", "PROTEIN", 120, 123], ["triple retreatment", "TREATMENT", 52, 70], ["IFN\u2010\u03b1", "TREATMENT", 76, 81], ["ribavirin", "TREATMENT", 83, 92], ["amantadine", "TREATMENT", 97, 107], ["placebo\u2010controlled trials", "TREATMENT", 196, 221], ["improved", "OBSERVATION_MODIFIER", 23, 31], ["antiviral effect", "OBSERVATION", 32, 48]]]], "b25230722ffaa58072459788c6dfd69664885476": [["IntroductionIn the last two decades the wavelet transform has positioned itself as a powerful tool for digital signal processing complementing the Fourier transform and in some cases more powerful, since the wavelet transform performs an analysis both in time and in the frequency at the same time.", [["IntroductionIn", "TREATMENT", 0, 14], ["digital signal processing", "TEST", 103, 128], ["an analysis", "TEST", 235, 246]]], ["In relation to the combined use of the Wavelet transform and the ICA, some related publications are shown below.IntroductionIn [1] , an adaptive hybrid algorithm based on DWT and ICA is proposed to remove noise from images obtained by means of magnetic resonance imaging, where this combined technique is compared to conventional techniques, such as DWT, undecimated discrete wavelet transforms (UDWT) and ICA.", [["DWT", "DNA", 171, 174], ["the Wavelet transform", "TREATMENT", 35, 56], ["an adaptive hybrid algorithm", "TREATMENT", 133, 161], ["images", "TEST", 216, 222], ["magnetic resonance imaging", "TEST", 244, 270], ["DWT", "TEST", 350, 353], ["ICA", "ANATOMY", 65, 68], ["publications", "OBSERVATION", 83, 95]]], ["In [2] , the idea of energy efficiency state identification is proposed and the monitoring strategy of energy efficiency state is established for a metal cutting process.", [["a metal cutting process", "TREATMENT", 146, 169], ["energy efficiency", "OBSERVATION", 21, 38]]], ["A combined application method of continuous wavelet transform (CWT) and fast independent component analysis (FICA) is proposed for feature extraction of low or high energy efficiency state.", [["A combined application method", "TREATMENT", 0, 29], ["continuous wavelet transform", "TREATMENT", 33, 61], ["fast independent component analysis", "TEST", 72, 107], ["low or high energy efficiency state", "PROBLEM", 153, 188], ["high energy efficiency", "OBSERVATION", 160, 182]]], ["On the other hand in [3] an electrocardiogram (ECG) signal noise elimination method is proposed based on wavelet transformation and ICA.", [["an electrocardiogram", "TEST", 25, 45], ["ECG", "TEST", 47, 50]]], ["First, two-channel ECG signals are acquired.", [["two-channel ECG signals", "TEST", 7, 30]]], ["We decompose these two ECG signals by wavelet and adding the useful wavelet coefficients separately, obtaining two-channel ECG signals with fewer interference components.", [["fewer interference components", "PROBLEM", 140, 169]]], ["Second, these two-channel ECG signals are processed and a channel signal constructed to perform an additional process with ICA, obtaining the separate ECG signal.", [["a channel signal", "TEST", 56, 72], ["the separate ECG signal", "TEST", 138, 161]]], ["Forensic speaker verification systems show severe performance degradation in the presence of noise when the signal to noise ratio (SNR) is low.", [["Forensic speaker verification systems", "TEST", 0, 37], ["severe performance degradation", "PROBLEM", 43, 73], ["noise ratio", "TEST", 118, 129], ["SNR", "TEST", 131, 134], ["severe", "OBSERVATION_MODIFIER", 43, 49]]], ["Also use a combination of feature warped Mel frequency Cepstral coefficients (MFCCs) and feature warped MFCC extracted from the DWT of the enhanced speech signals as the feature extraction.", [["MFCC", "PROTEIN", 104, 108], ["feature warped Mel frequency Cepstral coefficients (MFCCs)", "TREATMENT", 26, 84], ["feature warped MFCC", "PROBLEM", 89, 108], ["the feature extraction", "TREATMENT", 166, 188]]], ["In [5] , a method for separation of mixed signals using ICA and Wavelet transform is proposed.", [["ICA and Wavelet transform", "TREATMENT", 56, 81]]], ["This problem is solved using DWT based parallel architecture, which is a combined system consisting of two sub-over complete ICA.", [["ICA", "PROTEIN", 125, 128], ["parallel", "OBSERVATION_MODIFIER", 39, 47], ["architecture", "OBSERVATION_MODIFIER", 48, 60]]], ["One process takes the high-frequency wavelet part of observations as its inputs and the other process takes the low-frequency part.", [["high-frequency", "OBSERVATION_MODIFIER", 22, 36], ["low-frequency part", "OBSERVATION_MODIFIER", 112, 130]]], ["In [6] , authors proposed a new wavelet based ICA method using Kurtosis for blind audio source separation.", [["a new wavelet based ICA method", "TREATMENT", 26, 56], ["Kurtosis", "TEST", 63, 71], ["blind audio source separation", "PROBLEM", 76, 105]]], ["In this method, the observations are transformed into an adequate representation using wavelet packets decomposition and Kurtosis criterion.Independent Component Analysis (ICA)There is an essentially statistical method for signals which simulates the way that human brain is able to differentiate a particular signal when it is listening to several signals at the same time ( Fig. 1) .", [["brain", "ANATOMY", 266, 271], ["human", "ORGANISM", 260, 265], ["brain", "ORGAN", 266, 271], ["human", "SPECIES", 260, 265], ["human", "SPECIES", 260, 265], ["wavelet packets decomposition", "TREATMENT", 87, 116], ["Kurtosis criterion", "TEST", 121, 139], ["brain", "ANATOMY", 266, 271]]], ["It means the signals are mixed with a noise which has a probability function and subsequently through ICA to obtain the original independent signals.Operation of the ICA MethodUsually when there is a social meeting and two persons are talking, the brain of the person who is listening only concentrates on the voice of the person with whom he is talking and keeping his main characteristics of the signal [7] .", [["brain", "ANATOMY", 248, 253], ["persons", "ORGANISM", 223, 230], ["brain", "ORGAN", 248, 253], ["ICA", "PROTEIN", 102, 105], ["persons", "SPECIES", 223, 230], ["person", "SPECIES", 261, 267], ["person", "SPECIES", 323, 329], ["a noise", "PROBLEM", 36, 43], ["mixed", "OBSERVATION_MODIFIER", 25, 30], ["ICA", "ANATOMY", 166, 169]]], ["The human brain is able to isolate and separate the different sounds that it is listening in order to concentrate only on the voice that is interested (Fig. 2) .", [["brain", "ANATOMY", 10, 15], ["human", "ORGANISM", 4, 9], ["brain", "ORGAN", 10, 15], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 4, 9], ["brain", "ANATOMY", 10, 15]]], ["This acoustic phenomenon of human psychology was initially proposed by Colin Cherry [8] .Operation of the ICA MethodIn the following example there are two speakers A and B that each of them is speaking independently.", [["human", "ORGANISM", 28, 33], ["human", "SPECIES", 28, 33], ["human", "SPECIES", 28, 33], ["Operation", "TREATMENT", 89, 98], ["the ICA Method", "TREATMENT", 102, 116], ["ICA", "ANATOMY", 106, 109]]], ["The signals are separated by a mathematical process where two acoustic signals s a and s b are generated.", [["a mathematical process", "PROBLEM", 29, 51]]], ["Also, The signals are mixed and next to them there is a microphone that record these signals independently [9] .", [["mixed", "OBSERVATION_MODIFIER", 22, 27]]], ["The ICA method takes these signals (generated independently) which are mixed with random noise and then using a statistical process (ICA) to recover the two original signals separately (Fig. 2) .Operation of the ICA MethodThis process can be observed in greater detail when the signals A and B (Fig. 3 ) are mixed linearly through a linear function s \u00bc 0:7 \u00c3 A \u00c0 0:11 \u00c3 B to generate two new mixed signals M A and M B [10] .", [["0:11 \u00c3 B", "PROTEIN", 363, 371], ["Operation", "TREATMENT", 195, 204], ["the ICA Method", "TREATMENT", 208, 222], ["mixed", "OBSERVATION_MODIFIER", 71, 76], ["ICA", "ANATOMY", 212, 215]]], ["Once they are separated, the ICA method is applied to the processed signals M A and M B .", [["M B", "GENE_OR_GENE_PRODUCT", 84, 87], ["the ICA method", "TREATMENT", 25, 39]]], ["When the process is finished, it is recovered with the two independent signals except for a very low noise factor called scalar which can be positive or negative (Fig. 4 ).Formulation of the ICA Method for Discrete Signalsas a vector of n components that are the samples of a signal.", [["noise factor", "PROTEIN", 101, 113], ["a very low noise factor", "PROBLEM", 90, 113], ["Discrete Signalsas a vector of n components", "PROBLEM", 206, 249], ["ICA", "ANATOMY", 191, 194]]], ["Then, it can be described using matrix notation as:Formulation of the ICA Method for Discrete SignalsIn practice, only the vector of mixtures x that is generated when sampling a dialogue event for example is known.", [["the vector of mixtures", "TREATMENT", 119, 141]]], ["Therefore, the ICA method consists in applying the algorithm that allows to find a mixed desiccation matrix W in such a way that y \u00bc Wx is a good approximation of the vector s (y \u224c s).Wavelets ProcessThe wavelet transform has as main characteristics that is low computational and algorithmic complexity and the high probability of recovering small details in the inverse transformation [11] .", [["the ICA method", "TEST", 11, 25], ["a mixed desiccation matrix W", "TREATMENT", 81, 109], ["low computational and algorithmic complexity", "PROBLEM", 258, 302], ["good", "OBSERVATION_MODIFIER", 141, 145], ["main", "OBSERVATION_MODIFIER", 229, 233], ["low", "OBSERVATION_MODIFIER", 258, 261], ["high", "OBSERVATION_MODIFIER", 311, 315], ["small", "OBSERVATION_MODIFIER", 342, 347]]], ["These are very interesting characteristics for human voice signals.", [["human", "ORGANISM", 47, 52], ["human", "SPECIES", 47, 52], ["human", "SPECIES", 47, 52], ["human voice signals", "TEST", 47, 66]]], ["In addition, the process for the compression of the sampled data is the most efficient to optimize the computation time of the ICA method [12] .", [["the sampled data", "TEST", 48, 64]]], ["Another reason why wavelet was selected for use in research is its conduction in the areas of medicine, especially for the separation of brain signals where have good results [13] in combination with ICA.", [["brain", "ANATOMY", 137, 142], ["brain", "ORGAN", 137, 142], ["brain signals", "TEST", 137, 150]]], ["The mother wavelet that is selected for this work is the HAAR because it is appropriate to look for the points of inflection and discontinuities in the signals [14] .HAAR Wavelet TransformThe HAAR wavelet functions provides an optimal balance between the resolutions in time and frequency spaces.", [["HAAR", "PROTEIN", 166, 170], ["HAAR", "PROTEIN", 192, 196]]], ["This wavelet is the most used since it is reduced to calculate averages (sums) and changes (differences) between the data.", [["reduced", "OBSERVATION_MODIFIER", 42, 49]]], ["In the case of the HAAR wavelet, the scale function is represented as:HAAR Wavelet TransformThe mother scale function is defined as:HAAR Wavelet TransformUsing the same scale function, the basic HAAR wavelet function is considered as:HAAR Wavelet TransformThese two previous definitions multiplied by the coefficients 1 and 2 allow to generate the wavelet coefficients with the data of our sample in a way using only averages and differences between the data.", [["HAAR wavelet", "DNA", 19, 31], ["HAAR", "PROTEIN", 70, 74], ["HAAR", "PROTEIN", 132, 136], ["HAAR", "PROTEIN", 195, 199], ["HAAR", "PROTEIN", 234, 238], ["the scale function", "TEST", 33, 51], ["the basic HAAR wavelet function", "TEST", 185, 216]]], ["If we have a vector s of m data with m = 2n, we calculate the first level of wavelet coefficients as:HAAR Wavelet TransformIt is shown that the vector c 1 is divided into two parts.", [["c 1", "GENE_OR_GENE_PRODUCT", 151, 154], ["HAAR", "PROTEIN", 101, 105], ["vector c 1", "DNA", 144, 154]]], ["The first part corresponds only to the averages of two elements of s and the second section corresponds to the differences two of the elements of s.HAAR Wavelet TransformFor the next wavelet level, the first section of the vector c 1 is taken and the previous procedure is repeated.", [["vector c 1", "DNA", 223, 233], ["the previous procedure", "TREATMENT", 247, 269], ["two", "OBSERVATION_MODIFIER", 51, 54], ["elements", "OBSERVATION_MODIFIER", 55, 63]]], ["We notice the elements of c 1 as the next level of wavelet coefficients will be the vector c 2 contains in the first quarter, the averages of the elements of s in the second quarter, and the differences of the averages of s and the second half only the differences of the elements of s.HAAR Wavelet TransformThe procedure can be repeated up to n times, which is the number of subdivisions in half that can be made from the vector s.", [["c 1", "GENE_OR_GENE_PRODUCT", 26, 29], ["c 1", "DNA", 26, 29], ["vector c 2", "DNA", 84, 94], ["HAAR", "PROTEIN", 286, 290], ["The procedure", "TREATMENT", 308, 321]]], ["In the following, the algorithm for calculating the coefficients of the wavelet HAAR is presented.Inverse Wavelet HAARIt is possible to return by performing simple addition and subtraction operations again in terms of the mother wavelet function and the mother scale function, when calculating the wavelet coefficients up to some level t.", [["the algorithm", "TEST", 18, 31], ["subtraction operations", "TREATMENT", 177, 199]]], ["To obtain the original data again, it can be expressed through:Inverse Wavelet HAARIn terms of the data generated by performing a wavelet level (c 1 ), we obtained the data as:Inverse Wavelet HAARThe original data is also recovered as:Inverse Wavelet HAARThis process can be repeated with all the data of a c t vector until all the data of the previous wavelet level is recovered.Data Compression Process Through WaveletThe simple way is known as the wavelet HAAR allows to calculate wavelet coefficients.", [["c t vector", "DNA", 307, 317], ["HAAR", "PROTEIN", 459, 463], ["the original data", "TEST", 10, 27], ["Inverse Wavelet HAARThis process", "PROBLEM", 235, 267], ["a c t vector", "TREATMENT", 305, 317], ["the previous wavelet level", "TEST", 340, 366], ["Data Compression Process", "TREATMENT", 380, 404]]], ["It is possible to perform a compression of the data without losing relevant information of them [15] .", [["a compression of the data", "TEST", 26, 51]]], ["As was explained, in the HAAR wavelet, additions and subtractions are made.", [["subtractions", "TREATMENT", 53, 65]]], ["As several c t levels of wavelet coefficients are calculated, the energy of the signal s is concentrated in the first section of the vector c t and to the left of the vector.", [["vector c t", "DNA", 133, 143], ["wavelet coefficients", "TEST", 25, 45], ["concentrated", "OBSERVATION_MODIFIER", 92, 104], ["left", "ANATOMY_MODIFIER", 155, 159], ["vector", "ANATOMY", 167, 173]]], ["The result of the vector c 8 shows (8 wavelet levels) the coefficients decay approach to zero (Fig. 5 ).Data Compression Process Through WaveletOnce these two techniques are described (wavelet transform and the ICA technique), they must combined in an optimal way for a better compression of the sampled data and trying to avoid the loss of information in the communication between these processes.", [["vector c 8", "DNA", 18, 28], ["the vector c", "TEST", 14, 26], ["the ICA technique", "TEST", 207, 224]]], ["To obtain the two virtual data streams, an arithmetic mean between data is applied by means of such a way to generate two equal data streams in their creation and an independent requirement to be able to use the ICA process.", [["an arithmetic mean", "TEST", 40, 58]]], ["At the time of processing the information through ICA and in order to reduce the amount of sampled data that have to be calculated by the ICA algorithm, the HAAR wavelet algorithm was applied to further reduce the data that ICA needs.Process of Generation of Data TrainsThis process must be done using the sample taken from a data source and must create two equal samples, but linearly independent between them (Fig. 6) .Process of Generation of Data TrainsFor this process we should look for the sampled elements that are missing in each of the data streams.", [["sampled data", "TEST", 91, 103], ["the HAAR wavelet algorithm", "TEST", 153, 179], ["the sample", "TEST", 302, 312], ["the sampled elements", "PROBLEM", 493, 513]]], ["The algorithm complexity evaluation technique is used to calculate the number of required operations.", [["The algorithm complexity evaluation technique", "TEST", 0, 45], ["required operations", "TREATMENT", 81, 100]]], ["It focuses on classifying the complexity of the processes and performing the algorithm of the ICA method.", [["the ICA method", "TREATMENT", 90, 104]]], ["It determines that the order is 120m6n6 where n is the number of signals received and m the number of iterations of the algorithm.", [["the algorithm", "TEST", 116, 129]]], ["The number of operations necessary for the data reduction process using wavelet HAAR is of the order mn (6t\u221212*2t), where t is the number of wavelet levels processed [16] .", [["the data reduction process", "TREATMENT", 39, 65]]], ["The calculation of the total number of operations for the wavelet analysis was made, but it is negligible compared to the operations necessary for ICA.", [["the wavelet analysis", "TEST", 54, 74], ["total", "OBSERVATION_MODIFIER", 23, 28]]], ["These results give a linear polynomial as explained above.", [["a linear polynomial", "TREATMENT", 19, 38]]], ["They show the potential of wavelet analysis to generate good performance, reducing the computational cost.Graphic InterfaceFor this work two algorithms were implemented, one for signal separation using ICA and another wavelet supported by the platform of a graphical interface that allows to visualize and compare part of the compression process of audio signals.", [["ICA", "PROTEIN", 202, 205], ["wavelet analysis", "TEST", 27, 43], ["compression", "OBSERVATION", 326, 337]]], ["The related process is illustrated through a graph to determine the similarity of the signals.", [["a graph", "TEST", 43, 50]]], ["However, to compare the transformations and their application in each reading it is more practical to develop each of the steps and display them visually through a graphic.Process Time Between AlgorithmsThe result of the algorithms (the running time in micro second) are presented in Table 1 .", [["the algorithms", "TEST", 217, 231]]], ["As seen in this Table, the used time by wavelet is better in larger files and in smaller files the ICA is better.", [["ICA", "MULTI-TISSUE_STRUCTURE", 99, 102], ["smaller", "OBSERVATION_MODIFIER", 81, 88], ["ICA", "ANATOMY", 99, 102], ["better", "OBSERVATION_MODIFIER", 106, 112]]], ["It can be deduced that for a large data the ICA has more calculations to perform, but if the compression of the data with the wavelet technique is used, it has fewer calculations.", [["the wavelet technique", "TREATMENT", 122, 143]]], ["The ICA method is a very effective tool for the blind separation of signals, especially if it is combined with other techniques such as the wavelet transform.", [["ICA", "ANATOMY", 4, 7]]], ["In the present study, this statistical mathematical model was developed to separate audio signals using the ICA method, which are generated independently.", [["the present study", "TEST", 3, 20], ["the ICA method", "TEST", 104, 118]]], ["So that these signals do not have a statistical dependency.", [["a statistical dependency", "PROBLEM", 34, 58]]], ["The integration of these methods is performed for the separation of audio signals in which the processing time is optimized using previously the wavelet technique before the use of the ICA algorithm.", [["these methods", "TEST", 19, 32], ["audio signals", "TEST", 68, 81], ["the ICA algorithm", "TEST", 181, 198]]], ["In this way, the problem is faced where the human being listens to several sound sources at the same time, having the ability to pay attention to the signal coming from one in particular.", [["human", "ORGANISM", 44, 49], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 44, 49]]], ["These signals, which are transported through the ear canal, can be separated and identified by the human being.", [["ear canal", "ANATOMY", 49, 58], ["ear canal", "MULTI-TISSUE_STRUCTURE", 49, 58], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["ear canal", "ANATOMY", 49, 58]]]], "3e8286a0531a46c267f34d20e60a4754c2391a09": [["IntroductionTravel medicine is the branch of medicine that deals with the prevention and management of health problems of international travelers [1] [2] [3] [4] .", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 146, 161]]], ["We presented the case of a child with central hypoventilation syndrome (CHS) to highlight issues that need to be considered in planning long-haul flight and problems that may arise during the flight.CaseIn the summer of 2013, the pediatric intensive care unit (PICU) of a hospital in Hong Kong received an 8-year-old boy with central hypoventilation with respiratory infection and decompensation en route to Hong Kong on a make-a-wish campaign.", [["respiratory", "ANATOMY", 355, 366], ["central hypoventilation syndrome", "DISEASE", 38, 70], ["CHS", "DISEASE", 72, 75], ["hypoventilation", "DISEASE", 334, 349], ["respiratory infection", "DISEASE", 355, 376], ["boy", "ORGANISM", 317, 320], ["child", "SPECIES", 27, 32], ["boy", "SPECIES", 317, 320], ["central hypoventilation syndrome", "PROBLEM", 38, 70], ["central hypoventilation", "PROBLEM", 326, 349], ["respiratory infection", "PROBLEM", 355, 376], ["decompensation", "PROBLEM", 381, 395], ["central", "OBSERVATION", 38, 45], ["hypoventilation syndrome", "OBSERVATION", 46, 70], ["central", "ANATOMY_MODIFIER", 326, 333], ["hypoventilation", "OBSERVATION", 334, 349], ["respiratory", "ANATOMY", 355, 366], ["infection", "OBSERVATION", 367, 376]]], ["He was diagnosed with central hypoventilation (medullary atrophy) or Ondine's curse and had been well managed in Toronto, Canada.", [["medullary", "ANATOMY", 47, 56], ["hypoventilation", "DISEASE", 30, 45], ["medullary atrophy", "DISEASE", 47, 64], ["medullary", "ORGAN", 47, 56], ["central hypoventilation (medullary atrophy", "PROBLEM", 22, 64], ["Ondine's curse", "TREATMENT", 69, 83], ["central", "ANATOMY_MODIFIER", 22, 29], ["hypoventilation", "OBSERVATION", 30, 45], ["medullary atrophy", "OBSERVATION", 47, 64]]], ["He was ambulatory, only needed home ventilatory support at night via tracheostomy, and inhaled salbutamol puffs on a prn basis, and he was on PEG (percutaneous endoscopic gastrostomy) feeding with puree food.", [["percutaneous", "ANATOMY", 147, 159], ["salbutamol", "CHEMICAL", 95, 105], ["PEG", "CHEMICAL", 142, 145], ["salbutamol", "CHEMICAL", 95, 105], ["PEG", "CHEMICAL", 142, 145], ["salbutamol", "SIMPLE_CHEMICAL", 95, 105], ["PEG", "SIMPLE_CHEMICAL", 142, 145], ["home ventilatory support", "TREATMENT", 31, 55], ["tracheostomy", "TREATMENT", 69, 81], ["inhaled salbutamol puffs", "TREATMENT", 87, 111], ["PEG (percutaneous endoscopic gastrostomy) feeding", "TREATMENT", 142, 191], ["tracheostomy", "OBSERVATION", 69, 81]]], ["Advanced fitness for air-travel arrangement was well negotiated with the respective commercial airline.", [["air-travel arrangement", "TREATMENT", 21, 43], ["air", "OBSERVATION", 21, 24]]], ["However, he developed symptoms of respiratory infections with intermittent fever (up to 39 \u2218 C), cough, and sputum for 2 days prior to departure.", [["respiratory", "ANATOMY", 34, 45], ["sputum", "ANATOMY", 108, 114], ["respiratory infections", "DISEASE", 34, 56], ["intermittent fever", "DISEASE", 62, 80], ["cough", "DISEASE", 97, 102], ["symptoms", "PROBLEM", 22, 30], ["respiratory infections", "PROBLEM", 34, 56], ["intermittent fever", "PROBLEM", 62, 80], ["cough", "PROBLEM", 97, 102], ["sputum", "PROBLEM", 108, 114], ["respiratory", "ANATOMY", 34, 45], ["infections", "OBSERVATION", 46, 56], ["intermittent", "OBSERVATION_MODIFIER", 62, 74], ["fever", "OBSERVATION", 75, 80]]], ["The child was seen at the emergency department of a children's hospital in Toronto and was treated with an oral course of cefuroxime.", [["oral", "ANATOMY", 107, 111], ["cefuroxime", "CHEMICAL", 122, 132], ["cefuroxime", "CHEMICAL", 122, 132], ["child", "ORGANISM", 4, 9], ["children", "ORGANISM", 52, 60], ["oral", "ORGANISM_SUBDIVISION", 107, 111], ["cefuroxime", "SIMPLE_CHEMICAL", 122, 132], ["children", "SPECIES", 52, 60], ["cefuroxime", "TREATMENT", 122, 132]]], ["During the long-haul flight, symptoms of respiratory infections persisted and desaturations (86%) developed.", [["respiratory", "ANATOMY", 41, 52], ["respiratory infections", "DISEASE", 41, 63], ["desaturations", "DISEASE", 78, 91], ["symptoms", "PROBLEM", 29, 37], ["respiratory infections", "PROBLEM", 41, 63], ["desaturations", "PROBLEM", 78, 91], ["respiratory", "ANATOMY", 41, 52], ["infections", "OBSERVATION", 53, 63]]], ["The patient had his own oxygen monitoring and air compressor on board which needed to be increased to 1 L/min.", [["oxygen", "CHEMICAL", 24, 30], ["oxygen", "CHEMICAL", 24, 30], ["patient", "ORGANISM", 4, 11], ["oxygen", "SIMPLE_CHEMICAL", 24, 30], ["patient", "SPECIES", 4, 11], ["his own oxygen monitoring", "TEST", 16, 41], ["air compressor", "TREATMENT", 46, 60]]], ["His vital signs were as follows: tympanic temperature 38.6 \u2218 C, heart rate 157/min, and SpO 2 98% on own ventilator with flow 1 L/min.", [["tympanic", "ANATOMY", 33, 41], ["heart", "ANATOMY", 64, 69], ["heart", "ORGAN", 64, 69], ["His vital signs", "TEST", 0, 15], ["tympanic temperature", "TEST", 33, 53], ["C", "TEST", 61, 62], ["heart rate", "TEST", 64, 74], ["SpO", "TEST", 88, 91], ["own ventilator", "TREATMENT", 101, 115], ["heart", "ANATOMY", 64, 69]]], ["The home ventilator's electric plug was in Canadian style and did not fit the Hong Kong standard socket.", [["The home ventilator's electric plug", "TREATMENT", 0, 35], ["plug", "OBSERVATION", 31, 35], ["socket", "OBSERVATION", 97, 103]]], ["Chest radiograph revealed mild right sided haziness.", [["Chest radiograph", "TEST", 0, 16], ["mild right sided haziness", "PROBLEM", 26, 51], ["mild", "OBSERVATION_MODIFIER", 26, 30], ["right", "ANATOMY_MODIFIER", 31, 36], ["sided", "ANATOMY_MODIFIER", 37, 42], ["haziness", "OBSERVATION", 43, 51]]], ["He was admitted to PICU for management.", [["He", "ORGANISM", 0, 2], ["management", "TREATMENT", 28, 38]]], ["He weighed 23.2 kg and his vital signs were as follows: temperature 36.5 \u2218 C, heart rate 121/min, respiratory rate 23/min, BP 97/57 mmHg, and SpO 2 97% in room air on arrival at PICU.", [["heart", "ANATOMY", 78, 83], ["He", "ORGANISM", 0, 2], ["heart", "ORGAN", 78, 83], ["his vital signs", "TEST", 23, 38], ["temperature", "TEST", 56, 67], ["C", "TEST", 75, 76], ["heart rate", "TEST", 78, 88], ["respiratory rate", "TEST", 98, 114], ["BP", "TEST", 123, 125], ["SpO", "TEST", 142, 145], ["heart", "ANATOMY", 78, 83]]], ["The child received physiotherapy and the tracheostomy was temporarily connected to the ICU ventilator on SIMV mode with pressure control (PC) and pressure support (PS).", [["child", "ORGANISM", 4, 9], ["physiotherapy", "TREATMENT", 19, 32], ["the tracheostomy", "TREATMENT", 37, 53], ["the ICU ventilator", "TREATMENT", 83, 101], ["SIMV mode", "TREATMENT", 105, 114], ["pressure control (PC)", "TREATMENT", 120, 141], ["pressure support (PS", "TREATMENT", 146, 166], ["tracheostomy", "OBSERVATION", 41, 53]]], ["Settings were FiO 2 0.25, inspiratory time (Ti) 0.9 seconds, intermittent mandatory ventilation (IMV) rate 20/min, positive end expiratory pressure (PEEP) 5 cm H 2 O, pressure control 15 cm H 2 O above PEEP, and PS 13 cm H 2 O above PEEP.", [["FiO", "TEST", 14, 17], ["inspiratory time", "TEST", 26, 42], ["intermittent mandatory ventilation", "TREATMENT", 61, 95], ["rate", "TEST", 102, 106], ["positive end expiratory pressure", "TEST", 115, 147], ["PEEP", "TEST", 149, 153], ["pressure control", "TREATMENT", 167, 183], ["PEEP", "TREATMENT", 202, 206], ["PS", "TEST", 212, 214], ["PEEP", "TREATMENT", 233, 237], ["expiratory pressure", "OBSERVATION", 128, 147]]], ["There was no further desaturation, and the settings were gradually reduced to IMV 10/min and FiO 2 of 0.21.", [["desaturation", "DISEASE", 21, 33], ["further desaturation", "PROBLEM", 13, 33], ["IMV", "TREATMENT", 78, 81], ["FiO", "TEST", 93, 96], ["no", "UNCERTAINTY", 10, 12], ["further", "OBSERVATION_MODIFIER", 13, 20], ["desaturation", "OBSERVATION", 21, 33]]], ["The child gave a history of drug allergy to Ativan (lorazepam) and gluten sensitivity.", [["drug allergy", "DISEASE", 28, 40], ["Ativan", "CHEMICAL", 44, 50], ["lorazepam", "CHEMICAL", 52, 61], ["Ativan", "CHEMICAL", 44, 50], ["lorazepam", "CHEMICAL", 52, 61], ["child", "ORGANISM", 4, 9], ["Ativan", "SIMPLE_CHEMICAL", 44, 50], ["lorazepam", "SIMPLE_CHEMICAL", 52, 61], ["child", "SPECIES", 4, 9], ["drug allergy", "PROBLEM", 28, 40], ["Ativan", "TREATMENT", 44, 50], ["lorazepam", "TREATMENT", 52, 61], ["gluten sensitivity", "PROBLEM", 67, 85]]], ["Sedation was not needed.", [["Sedation", "TREATMENT", 0, 8]]], ["He received a course of intravenous amoxicillin/clavulanate (30 mg/kg/dose, 8 hourly).", [["intravenous", "ANATOMY", 24, 35], ["amoxicillin/clavulanate", "CHEMICAL", 36, 59], ["amoxicillin", "CHEMICAL", 36, 47], ["clavulanate", "CHEMICAL", 48, 59], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 24, 35], ["amoxicillin", "SIMPLE_CHEMICAL", 36, 47], ["clavulanate", "SIMPLE_CHEMICAL", 48, 59], ["intravenous amoxicillin", "TREATMENT", 24, 47], ["clavulanate", "TREATMENT", 48, 59]]], ["The patient remained playful, talkative, and not in distress.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["distress", "PROBLEM", 52, 60]]], ["Laboratory data were normal complete blood count with white blood cell count of 16.1 \u00d7 10 9 /L, neutrophil differential of 77%, and elevated C-reactive protein of 44.1 (normal < 9.9 mg/L).", [["blood", "ANATOMY", 37, 42], ["white blood cell", "ANATOMY", 54, 70], ["neutrophil", "ANATOMY", 96, 106], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["white blood cell", "CELL", 54, 70], ["neutrophil", "CELL", 96, 106], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 141, 159], ["neutrophil", "CELL_TYPE", 96, 106], ["C-reactive protein", "PROTEIN", 141, 159], ["Laboratory data", "TEST", 0, 15], ["blood count", "TEST", 37, 48], ["white blood cell count", "TEST", 54, 76], ["neutrophil differential", "TEST", 96, 119], ["elevated C-reactive protein", "PROBLEM", 132, 159]]], ["There was no bacterial or respiratory viral isolation in the tracheal aspirate.", [["tracheal aspirate", "ANATOMY", 61, 78], ["tracheal aspirate", "MULTI-TISSUE_STRUCTURE", 61, 78], ["bacterial or respiratory viral isolation in the tracheal aspirate", "PROBLEM", 13, 78], ["no", "UNCERTAINTY", 10, 12], ["bacterial", "OBSERVATION_MODIFIER", 13, 22], ["respiratory", "OBSERVATION", 26, 37], ["viral isolation", "OBSERVATION", 38, 53], ["tracheal", "ANATOMY", 61, 69], ["aspirate", "OBSERVATION", 70, 78]]], ["Blood culture was negative.", [["Blood", "ANATOMY", 0, 5], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["Blood culture", "TEST", 0, 13], ["negative", "OBSERVATION", 18, 26]]], ["The patient was discharged from the PICU 2 days later and went on with his make-a-wish journey to Disneyland in Hong Kong prior to returning home.DiscussionOndine's curse, also called congenital central hypoventilation syndrome (CCHS) or primary alveolar hypoventilation, is a serious form of central nervous system failure, involving an inborn failure of autonomic control of breathing.", [["alveolar", "ANATOMY", 246, 254], ["central nervous system", "ANATOMY", 293, 315], ["congenital central hypoventilation syndrome", "DISEASE", 184, 227], ["CCHS", "DISEASE", 229, 233], ["primary alveolar hypoventilation", "DISEASE", 238, 270], ["central nervous system failure", "DISEASE", 293, 323], ["inborn failure of autonomic control of breathing", "DISEASE", 338, 386], ["patient", "ORGANISM", 4, 11], ["alveolar", "MULTI-TISSUE_STRUCTURE", 246, 254], ["central nervous system", "ANATOMICAL_SYSTEM", 293, 315], ["patient", "SPECIES", 4, 11], ["congenital central hypoventilation syndrome", "PROBLEM", 184, 227], ["CCHS", "PROBLEM", 229, 233], ["primary alveolar hypoventilation", "PROBLEM", 238, 270], ["central nervous system failure", "PROBLEM", 293, 323], ["an inborn failure", "PROBLEM", 335, 352], ["autonomic control of breathing", "PROBLEM", 356, 386], ["central", "ANATOMY_MODIFIER", 195, 202], ["hypoventilation syndrome", "OBSERVATION", 203, 227], ["primary", "OBSERVATION_MODIFIER", 238, 245], ["alveolar hypoventilation", "OBSERVATION", 246, 270], ["central", "ANATOMY_MODIFIER", 293, 300], ["nervous system", "ANATOMY", 301, 315], ["failure", "OBSERVATION", 316, 323], ["autonomic control", "OBSERVATION", 356, 373]]], ["Patients generally require tracheotomies and lifetime mechanical ventilator support.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["tracheotomies", "TREATMENT", 27, 40], ["lifetime mechanical ventilator support", "TREATMENT", 45, 83], ["tracheotomies", "OBSERVATION", 27, 40], ["mechanical ventilator", "OBSERVATION", 54, 75]]], ["With advances of home ventilatory support, patients with central hypoventilation are no longer \"cursed.\"", [["hypoventilation", "DISEASE", 65, 80], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["home ventilatory support", "TREATMENT", 17, 41], ["central hypoventilation", "PROBLEM", 57, 80], ["central hypoventilation", "OBSERVATION", 57, 80], ["no longer", "UNCERTAINTY", 85, 94]]], ["They can live a relative normal life at home, as reported by Hon et al., even in the remote countryside setting in one case report [5] [6] [7] .DiscussionTravel medicine is the branch of medicine that deals with the prevention and management of health problems of international travelers [1] [2] [3] [4] .", [["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 288, 303]]], ["The field of travel medicine encompasses a wide variety of disciplines including epidemiology, infectious disease, public health, tropical medicine, high altitude physiology, travel related obstetrics, psychiatry, occupational medicine, military and migration medicine, and environmental health.", [["infectious disease", "DISEASE", 95, 113], ["tropical medicine", "TREATMENT", 130, 147], ["high altitude physiology", "PROBLEM", 149, 173], ["migration medicine", "TREATMENT", 250, 268]]], ["In our case, potential problems that may arise during travel include cardiopulmonary disease mortality, injury, and accident.", [["cardiopulmonary disease mortality", "DISEASE", 69, 102], ["injury", "DISEASE", 104, 110], ["cardiopulmonary disease mortality", "PROBLEM", 69, 102], ["injury", "PROBLEM", 104, 110], ["cardiopulmonary", "ANATOMY", 69, 84], ["disease", "OBSERVATION", 85, 92]]], ["Infectious disease accounts for about 2.8-4% of deaths during/from travel [1] [2] [3] [4] [8] [9] [10] .", [["Infectious disease", "DISEASE", 0, 18], ["deaths", "DISEASE", 48, 54], ["[1] [2] [3] [4] [8] [9] [10]", "CHEMICAL", 74, 102], ["[1] [2] [3] [4] [8] [9] [10]", "SIMPLE_CHEMICAL", 74, 102]]], ["In terms of morbidity, traveler's diarrhea is the most common problem encountered [9, 10] .DiscussionIn this day and age, international travel is made possible even for patients who need ventilatory support.", [["diarrhea", "DISEASE", 34, 42], ["patients", "ORGANISM", 169, 177], ["patients", "SPECIES", 169, 177], ["morbidity", "PROBLEM", 12, 21], ["traveler's diarrhea", "PROBLEM", 23, 42], ["ventilatory support", "TREATMENT", 187, 206], ["morbidity", "OBSERVATION", 12, 21]]], ["Prior to a long-haul air travel, parents should negotiate with airline to detail the transport and inflight plans [8, 11, 12] .", [["a long-haul air travel", "TREATMENT", 9, 31]]], ["The following part gives 4 website addresses of checklists for commercial air-travel preparation for ventilated children.", [["children", "ORGANISM", 112, 120], ["children", "SPECIES", 112, 120], ["commercial air-travel preparation", "TREATMENT", 63, 96]]], ["In our case of CCHS with specific needs for ventilatory support, the patient, family, and the airline collaborated well.", [["CCHS", "DISEASE", 15, 19], ["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["CCHS", "PROBLEM", 15, 19], ["ventilatory support", "TREATMENT", 44, 63]]], ["In general, the patient's usual emergency medication such as inhaled salbutamol should be readily accompanying the patient.", [["salbutamol", "CHEMICAL", 69, 79], ["salbutamol", "CHEMICAL", 69, 79], ["patient", "ORGANISM", 16, 23], ["salbutamol", "SIMPLE_CHEMICAL", 69, 79], ["patient", "ORGANISM", 115, 122], ["patient", "SPECIES", 16, 23], ["patient", "SPECIES", 115, 122], ["emergency medication", "TREATMENT", 32, 52], ["inhaled salbutamol", "TREATMENT", 61, 79]]], ["Additional space is required to station the ventilator, air compressor, and monitor.", [["the ventilator", "TREATMENT", 40, 54], ["air compressor", "TREATMENT", 56, 70], ["space", "OBSERVATION", 11, 16]]], ["An international travel insurance policy is mandatory in this age of unexpected and unavoidable disasters [8] .DiscussionWebsites of checklists for commercial air-travel preparation for ventilated children are as follows:Discussion(1) A Special Needs Preflight Checklist: 16 Things You Need to Do before Heading to the Airport (http:// www.friendshipcircle.org/blog/2012/01/09/a-specialneeds-pre-flight-checklist/).", [["children", "ORGANISM", 197, 205], ["children", "SPECIES", 197, 205], ["commercial air-travel preparation", "TREATMENT", 148, 181]]], ["This website gives some tips about travelling with a ventilator.DiscussionOne more issue pertinent to the discussion of travel medicine is advice regarding feasibility of long-haul travel in a patient with acute or intercurrent respiratory infection.", [["respiratory", "ANATOMY", 228, 239], ["respiratory infection", "DISEASE", 228, 249], ["patient", "ORGANISM", 193, 200], ["patient", "SPECIES", 193, 200], ["a ventilator", "TREATMENT", 51, 63], ["intercurrent respiratory infection", "PROBLEM", 215, 249], ["tips", "OBSERVATION_MODIFIER", 24, 28], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["respiratory", "ANATOMY", 228, 239], ["infection", "OBSERVATION", 240, 249]]], ["Since the days of SARS (severe acute respiratory syndrome) and recently MERS (Middle East respiratory syndrome) and SARI (severe acute respiratory infection), travel transmission of novel respiratory infections has become hot issues [13] [14] [15] .", [["respiratory", "ANATOMY", 135, 146], ["respiratory", "ANATOMY", 188, 199], ["SARS", "DISEASE", 18, 22], ["acute respiratory syndrome", "DISEASE", 31, 57], ["Middle East respiratory syndrome", "DISEASE", 78, 110], ["SARI", "DISEASE", 116, 120], ["acute respiratory infection", "DISEASE", 129, 156], ["respiratory infections", "DISEASE", 188, 210], ["SARS (severe acute respiratory syndrome", "PROBLEM", 18, 57], ["recently MERS (Middle East respiratory syndrome", "PROBLEM", 63, 110], ["SARI (severe acute respiratory infection", "PROBLEM", 116, 156], ["novel respiratory infections", "PROBLEM", 182, 210], ["hot issues", "PROBLEM", 222, 232], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["acute", "OBSERVATION_MODIFIER", 31, 36], ["respiratory syndrome", "OBSERVATION", 37, 57], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["acute", "OBSERVATION_MODIFIER", 129, 134], ["respiratory", "ANATOMY", 135, 146], ["infection", "OBSERVATION", 147, 156], ["respiratory", "ANATOMY", 188, 199], ["infections", "OBSERVATION", 200, 210]]], ["Ideally, patients with an acute respiratory infection should not be travelling for the patient's own sake as well as for the sake of other passengers.", [["respiratory", "ANATOMY", 32, 43], ["acute respiratory infection", "DISEASE", 26, 53], ["patients", "ORGANISM", 9, 17], ["patient", "ORGANISM", 87, 94], ["patients", "SPECIES", 9, 17], ["patient", "SPECIES", 87, 94], ["an acute respiratory infection", "PROBLEM", 23, 53], ["acute", "OBSERVATION_MODIFIER", 26, 31], ["respiratory", "ANATOMY", 32, 43], ["infection", "OBSERVATION", 44, 53]]], ["However, travel may be once-in-a-lifetime opportunity for a young person with chronic illness as was in our case.", [["chronic illness", "DISEASE", 78, 93], ["person", "SPECIES", 66, 72], ["chronic illness", "PROBLEM", 78, 93]]], ["This may be inhumane to the child if his/her opportunity was removed from him/her due to a non-life threatening chest infection.", [["chest", "ANATOMY", 112, 117], ["chest infection", "DISEASE", 112, 127], ["chest", "ORGAN", 112, 117], ["a non-life threatening chest infection", "PROBLEM", 89, 127], ["chest", "ANATOMY", 112, 117], ["infection", "OBSERVATION", 118, 127]]], ["On the other hand, the risk has to be weighed between a seemingly minor infection which may predispose a major decompensation during long-haul travel in a child with already compromised respiratory health.DiscussionNo published literature on mortality and morbidity in children travelling with central hypoventilation syndrome or Ondine's curse is available.", [["respiratory", "ANATOMY", 186, 197], ["infection", "DISEASE", 72, 81], ["decompensation", "DISEASE", 111, 125], ["central hypoventilation syndrome", "DISEASE", 294, 326], ["children", "ORGANISM", 269, 277], ["children", "SPECIES", 269, 277], ["a seemingly minor infection", "PROBLEM", 54, 81], ["a major decompensation", "PROBLEM", 103, 125], ["already compromised respiratory health", "PROBLEM", 166, 204], ["central hypoventilation syndrome", "PROBLEM", 294, 326], ["Ondine's curse", "TREATMENT", 330, 344], ["minor", "OBSERVATION_MODIFIER", 66, 71], ["infection", "OBSERVATION", 72, 81], ["major", "OBSERVATION_MODIFIER", 105, 110], ["decompensation", "OBSERVATION", 111, 125], ["respiratory health", "OBSERVATION", 186, 204], ["hypoventilation syndrome", "OBSERVATION", 302, 326]]], ["Critically ill children are transported safely via medical evacuation teams [16, 17] .", [["Critically ill", "DISEASE", 0, 14], ["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23]]], ["However, critically ill children cannot be transported via commercial airlines.", [["critically ill", "DISEASE", 9, 23], ["children", "ORGANISM", 24, 32], ["children", "SPECIES", 24, 32]]], ["Our case illustrates that children who are ventilator dependent may travel in commercial airlines if they are stable.", [["children", "ORGANISM", 26, 34], ["children", "SPECIES", 26, 34], ["ventilator dependent", "PROBLEM", 43, 63], ["stable", "OBSERVATION_MODIFIER", 110, 116]]], ["The issue of quarantine to prevent international transmission of SARI is a much more complicated issue that is likely to remain a contemporary controversy.", [["SARI", "DISEASE", 65, 69], ["quarantine", "TREATMENT", 13, 23], ["SARI", "PROBLEM", 65, 69]]], ["This case illustrates the many issues associated with long-haul flight in a pediatric patient with a chronic respiratory disorder.", [["respiratory", "ANATOMY", 109, 120], ["respiratory disorder", "DISEASE", 109, 129], ["patient", "ORGANISM", 86, 93], ["patient", "SPECIES", 86, 93], ["a chronic respiratory disorder", "PROBLEM", 99, 129], ["chronic", "OBSERVATION_MODIFIER", 101, 108], ["respiratory disorder", "OBSERVATION", 109, 129]]], ["Air travel is possible for children with respiratory compromise if anticipatory preparation is timely arranged.", [["respiratory", "ANATOMY", 41, 52], ["children", "ORGANISM", 27, 35], ["children", "SPECIES", 27, 35], ["respiratory compromise", "PROBLEM", 41, 63], ["anticipatory preparation", "TREATMENT", 67, 91]]]], "PMC7395218": [["IntroductionThe risk of pathogen transmission can be reduced by using a disposable filter respiratory protection against particles and aerosols [1].", [["pathogen transmission", "TREATMENT", 24, 45], ["a disposable filter respiratory protection", "TREATMENT", 70, 112]]], ["There are several types of single-use masks providing different levels of protection.", [["masks", "TREATMENT", 38, 43], ["different levels of protection", "TREATMENT", 54, 84], ["several", "OBSERVATION_MODIFIER", 10, 17], ["types", "OBSERVATION_MODIFIER", 18, 23]]], ["Surgical masks stop at least 80% of aerosols and protect the people around the user.", [["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["Surgical masks", "TREATMENT", 0, 14]]], ["N95 filtering facepiece respirators (American equivalent of European FFP2 masks) stop at least 94% of aerosols and protect the wearer against infections.", [["infections", "DISEASE", 142, 152], ["N95 filtering facepiece respirators", "TREATMENT", 0, 35], ["European FFP2 masks", "TREATMENT", 60, 79], ["aerosols", "TREATMENT", 102, 110], ["infections", "PROBLEM", 142, 152]]], ["However, the COVID-19 pandemic has led to a drastic shortage of personal protective equipment worldwide [2].IntroductionFollowing the H1N1 influenza epidemic health crisis in 2009, France constituted a safety stock of one billion surgical masks and of 799.9 million FFP2 masks (equivalent to N95).", [["influenza", "DISEASE", 139, 148], ["the COVID", "TEST", 9, 18], ["million FFP2 masks", "TREATMENT", 258, 276], ["drastic", "OBSERVATION_MODIFIER", 44, 51]]], ["In 2013, there was a change of approach to stock management which was found to be too expensive.", [["stock management", "TREATMENT", 43, 59]]], ["The new management approach generated a shortage of surgical and FFP2 masks in hospitals right from the beginning of the COVID-19 health crisis, exposing caregivers to the highest risk of contamination.IntroductionDriven by the urgent need for masks to prevent the spread of COVID-19, stockpiled FFP2/N95 and surgical masks that had passed their manufacturer-designated shelf-life were released.", [["COVID", "DISEASE", 275, 280], ["The new management approach", "TREATMENT", 0, 27], ["surgical and FFP2 masks", "TREATMENT", 52, 75], ["contamination", "PROBLEM", 188, 201], ["masks", "TREATMENT", 244, 249], ["COVID", "TEST", 275, 280], ["surgical masks", "TREATMENT", 309, 323], ["new", "OBSERVATION_MODIFIER", 4, 7], ["contamination", "OBSERVATION", 188, 201]]], ["Given the prevailing emergency, the usual standards for the control of medical devices were adapted to the financial and material resources available.IntroductionIn the USA, the Center for Disease Control and Prevention (CDC) published recommendations [3] stating that prior to using the respirator in the workplace, users should take four precautionary measures: three visual tests, and one user seal check.", [["medical devices", "TREATMENT", 71, 86], ["Disease Control", "TREATMENT", 189, 204], ["visual tests", "TEST", 370, 382], ["one user seal check", "TEST", 388, 407]]], ["CDC is also currently conducting a study to evaluate stockpiled N95 from several geographically scattered facilities.IntroductionIn France, the release of expired batches of FFP2/N95 and surgical masks was the responsibility of the Agence R\u00e9gionale de Sant\u00e9 (ARS, the regional public authority responsible for the implementation of health policy in a given region).", [["FFP2", "CHEMICAL", 174, 178], ["stockpiled N95", "CELL_LINE", 53, 67], ["a study", "TEST", 33, 40], ["FFP2/N95", "TREATMENT", 174, 182], ["surgical masks", "TREATMENT", 187, 201], ["scattered", "OBSERVATION_MODIFIER", 96, 105]]], ["According to French Health Ministry directives [4], four verifications, similar to the CDC tests, were required on the FFP2 mask batches before release: packaging integrity verification, mask appearance verification, breaking strength test on elastic ties and strength test on nose clip, and face-fit test.", [["nose", "ANATOMY", 277, 281], ["nose", "ORGANISM_SUBDIVISION", 277, 281], ["the CDC tests", "TEST", 83, 96], ["the FFP2 mask batches", "TREATMENT", 115, 136], ["mask appearance verification", "TEST", 187, 215], ["breaking strength test", "TEST", 217, 239], ["strength test", "TEST", 260, 273], ["nose clip", "TEST", 277, 286], ["fit test", "TEST", 297, 305], ["nose", "ANATOMY", 277, 281]]], ["These tests, contrary to CDC recommendations, were not to be performed by the users.", [["These tests", "TEST", 0, 11]]], ["Ministerial directives recommended that health structures use existing resources such as quality-control laboratories to perform the tests.IntroductionOur laboratory was commissioned by the ARS of Provence Alpes C\u00f4te d\u2019Azur region to develop and apply a protocol of the various assessments of compliance with standards for the expired batches of masks.Materials and MethodsBetween 12th March 2020 and 16th April 2020, 175 batches of FFP2/N95 masks and 31 batches of surgical masks were checked.", [["Ministerial directives", "TREATMENT", 0, 22], ["existing resources", "TREATMENT", 62, 80], ["the tests", "TEST", 129, 138], ["a protocol", "TREATMENT", 252, 262], ["the expired batches of masks", "TREATMENT", 323, 351], ["FFP2", "TREATMENT", 433, 437], ["N95 masks", "TREATMENT", 438, 447], ["surgical masks", "TREATMENT", 466, 480], ["surgical masks", "OBSERVATION", 466, 480]]], ["Batches were sent from 12 different establishments and produced by 42 different companies.", [["Batches", "TEST", 0, 7]]], ["There was no expiry date for 25% of FFP2/N95 mask batches and 45% of surgical mask batches.Materials and MethodsFrom each batch, a sample of 15 FFP2/N95 masks and 12 surgical masks was taken for testing.", [["FFP2", "TREATMENT", 36, 40], ["N95 mask batches", "TREATMENT", 41, 57], ["surgical mask batches", "TREATMENT", 69, 90], ["a sample", "TEST", 129, 137], ["15 FFP2/N95 masks", "TREATMENT", 141, 158], ["12 surgical masks", "TREATMENT", 163, 180], ["testing", "TEST", 195, 202], ["no", "UNCERTAINTY", 10, 12]]], ["Some samples were used for several tests.", [["samples", "ANATOMY", 5, 12], ["Some samples", "TEST", 0, 12], ["several tests", "TEST", 27, 40]]], ["Except for the face-fit test performed only on three FFP2/N95 masks by batch, identical testing was carried out on both types of masks.", [["FFP2", "PROTEIN", 53, 57], ["the face-fit test", "TEST", 11, 28], ["three FFP2/N95 masks", "TREATMENT", 47, 67], ["identical testing", "TEST", 78, 95]]], ["For each batch, three masks were kept stored in the laboratory.Materials and MethodsThe primary and secondary producers\u2019 packaging integrity was visually verified, searching in particular for alterations (discoloration, cracks, moisture, tears) in the packaging.", [["each batch", "TREATMENT", 4, 14], ["three masks", "TREATMENT", 16, 27], ["Methods", "TREATMENT", 77, 84], ["alterations (discoloration", "PROBLEM", 192, 218], ["cracks", "PROBLEM", 220, 226], ["tears", "PROBLEM", 238, 243], ["the packaging", "TREATMENT", 248, 261], ["discoloration", "OBSERVATION_MODIFIER", 205, 218], ["cracks", "OBSERVATION_MODIFIER", 220, 226]]], ["For each batch, 10 samples were checked when possible.Materials and MethodsMask appearance verification was inspected visually under an inspection machine with black and white background.", [["samples", "ANATOMY", 19, 26], ["each batch", "TREATMENT", 4, 14], ["an inspection machine", "TEST", 133, 154], ["black and white background", "PROBLEM", 160, 186]]], ["A check for deterioration (discoloration, tears, decomposition) was carried out on 10 samples which could then be used for other tests.Materials and MethodsThe breaking strength of the elastic ties was evaluated with an Instron 3343 dynamometer and strength transducer (INSTRON 02062 Massachusetts, USA) with a capacity of 100 N. The apparatus was connected to a DELL Optiplex GX520 computer equipped with data processing software (Bluehill).", [["samples", "ANATOMY", 86, 93], ["A check", "TEST", 0, 7], ["deterioration", "PROBLEM", 12, 25], ["discoloration", "PROBLEM", 27, 40], ["tears", "PROBLEM", 42, 47], ["other tests", "TEST", 123, 134], ["Methods", "TREATMENT", 149, 156], ["an Instron 3343 dynamometer and strength transducer", "TREATMENT", 217, 268], ["discoloration", "OBSERVATION_MODIFIER", 27, 40], ["breaking", "OBSERVATION_MODIFIER", 160, 168], ["strength", "OBSERVATION_MODIFIER", 169, 177]]], ["The mask was placed between fixed jaws of the dynamometer and the elastic ties between movable jaws.", [["jaws", "ANATOMY", 34, 38], ["jaws", "ANATOMY", 95, 99], ["jaws", "ORGAN", 34, 38], ["jaws", "ORGAN", 95, 99], ["The mask", "TREATMENT", 0, 8], ["movable", "ANATOMY_MODIFIER", 87, 94], ["jaws", "ANATOMY", 95, 99]]], ["Elastic strain was applied at a speed of 500 mm/min, as soon as an elastic broke under the extension, a measurement was recorded and the breakage site noted.", [["Elastic strain", "PROBLEM", 0, 14], ["a measurement", "TEST", 102, 115], ["the breakage site", "PROBLEM", 133, 150], ["strain", "OBSERVATION", 8, 14], ["elastic", "OBSERVATION", 67, 74], ["breakage site", "OBSERVATION", 137, 150]]], ["Before each measurement set, three reference masks (from valid batches) were tested.", [["valid batches", "TREATMENT", 57, 70]]], ["For each batch, nine samples were checked.Materials and MethodsThe strength of the nose clip was tested manually by performing 10 twists along the full length of the clip.", [["samples", "ANATOMY", 21, 28], ["nose", "ANATOMY", 83, 87], ["nose", "ORGAN", 83, 87], ["each batch", "TEST", 4, 14], ["nine samples", "TEST", 16, 28], ["Methods", "TREATMENT", 56, 63], ["the nose clip", "TREATMENT", 79, 92], ["the clip", "TREATMENT", 162, 170], ["strength", "OBSERVATION_MODIFIER", 67, 75], ["nose", "ANATOMY", 83, 87], ["clip", "OBSERVATION", 88, 92], ["clip", "OBSERVATION", 166, 170]]], ["The same nine samples per batch and for the elastic tie breaking strength test were checked, and are valid reference mask was tested per batch.Materials and MethodsThe face-fit test was performed using three ultrasonic nebulizers (model 1: SYSTAM LS290; model 2: Shinmed SW966 ORKYN; model 3: Europe Medical NU52).", [["samples", "ANATOMY", 14, 21], ["the elastic tie breaking strength test", "TEST", 40, 78], ["valid reference mask", "TREATMENT", 101, 121], ["Methods", "TREATMENT", 157, 164], ["fit test", "TEST", 173, 181], ["three ultrasonic nebulizers", "TREATMENT", 202, 229], ["face", "ANATOMY", 168, 172]]], ["A sodium saccharin (Cooper 7700 Melun, France) solution was employed for control.", [["sodium saccharin", "CHEMICAL", 2, 18], ["sodium saccharin", "CHEMICAL", 2, 18], ["sodium saccharin", "SIMPLE_CHEMICAL", 2, 18], ["A sodium saccharin", "TREATMENT", 0, 18], ["France) solution", "TREATMENT", 39, 55]]], ["This test followed an adapted ED 6273 protocol [5] from the Institut National de Recherche et de S\u00e9curit\u00e9 (INRS: reference organization in occupational health and risk prevention in France) relating to breathing protection.", [["This test", "TEST", 0, 9], ["risk prevention", "TREATMENT", 163, 178], ["breathing protection", "TREATMENT", 202, 222]]], ["The ultrasonic nebulizer was filled with 8 mL of a 415-g/L sodium saccharin solution.", [["sodium saccharin", "CHEMICAL", 59, 75], ["sodium saccharin", "CHEMICAL", 59, 75], ["sodium saccharin", "SIMPLE_CHEMICAL", 59, 75], ["The ultrasonic nebulizer", "TREATMENT", 0, 24], ["a 415-g/L sodium saccharin solution", "TREATMENT", 49, 84]]], ["The experimenter was placed in an airtight environment with a plastic bag, covering his upper body and the nebulizer hose placed nearby, within this environment.", [["upper body", "ANATOMY", 88, 98], ["upper body", "ORGANISM_SUBDIVISION", 88, 98], ["a plastic bag", "TREATMENT", 60, 73], ["the nebulizer hose", "TREATMENT", 103, 121], ["plastic bag", "OBSERVATION", 62, 73], ["upper body", "ANATOMY_MODIFIER", 88, 98], ["nebulizer", "ANATOMY", 107, 116]]], ["The breathing exercises performed by the experimenter consisted of 1 min of normal breathing, 1 min of deep breathing, 30 s of head movements from right to left, 30 s of head movements from top to bottom and 1 mi of talking.", [["head", "ANATOMY", 127, 131], ["head", "ANATOMY", 170, 174], ["head", "ORGANISM_SUBDIVISION", 127, 131], ["head", "ORGANISM_SUBDIVISION", 170, 174], ["The breathing exercises", "TREATMENT", 0, 23], ["head movements", "TEST", 127, 141], ["right", "ANATOMY_MODIFIER", 147, 152], ["left", "ANATOMY_MODIFIER", 156, 160]]], ["A 10-s nebulization of the sodium saccharin solution was performed at 1-min intervals.", [["sodium saccharin", "CHEMICAL", 27, 43], ["sodium saccharin", "CHEMICAL", 27, 43], ["sodium saccharin", "SIMPLE_CHEMICAL", 27, 43], ["A 10-s nebulization of the sodium saccharin solution", "TREATMENT", 0, 52]]], ["Each exercise set ended with a positive control, where the experimenter removed the mask in the airtight environment.", [["a positive control", "TREATMENT", 29, 47], ["the mask", "TREATMENT", 80, 88]]], ["Compliance was validated if experimenter did not experience any sweet taste while wearing the mask but experienced a sweet taste during the positive control.", [["the mask", "TREATMENT", 90, 98], ["a sweet taste", "PROBLEM", 115, 128], ["the positive control", "TREATMENT", 136, 156]]], ["For each batch, three independent experimenters tested one mask each.ResultsForty-nine per cent of FFP2/N95 mask batches were compliant according to the different tests, 32% of batches were compliant with concerns and 19% of batches were non-compliant with the ministerial directive (Table I).", [["FFP2", "ORGANISM", 99, 103], ["each batch", "TREATMENT", 4, 14], ["ResultsForty", "TEST", 69, 81], ["FFP2", "TREATMENT", 99, 103], ["N95 mask batches", "TREATMENT", 104, 120], ["the different tests", "TEST", 149, 168]]], ["Non-compliance was based on various factions: packaging integrity (1% of batches), visual appearance (7% of batches), breaking of the elastic ties (37% of batches), breaking of the nose clip (9% of batches), and fit problems (16% of batches).", [["nose", "ANATOMY", 181, 185], ["nose", "ORGANISM_SUBDIVISION", 181, 185], ["packaging integrity", "TREATMENT", 46, 65], ["the elastic ties", "TREATMENT", 130, 146], ["the nose clip", "TREATMENT", 177, 190], ["fit problems", "PROBLEM", 212, 224], ["nose", "ANATOMY", 181, 185]]], ["The decisive criteria for batch non-compliance were both the appearance and the face fit.", [["batch non-compliance", "PROBLEM", 26, 46]]], ["The concerns expressed for 32% of compliant batches relate to the fragility of the elastic ties and the nose clip.", [["nose", "ANATOMY", 104, 108], ["nose", "ORGANISM_SUBDIVISION", 104, 108], ["compliant batches", "TREATMENT", 34, 51], ["the elastic ties", "TREATMENT", 79, 95], ["the nose clip", "TREATMENT", 100, 113], ["elastic ties", "OBSERVATION", 83, 95], ["nose", "ANATOMY", 104, 108], ["clip", "OBSERVATION", 109, 113]]], ["For surgical masks, 58% of batches were found to be compliant, 39% of batches compliant but with concerns about the fragility of the elastic ties and 3% of batches non-compliant.ResultsThe primary and secondary packaging verifications did not reveal non-compliance with the ministerial directives, except for 1% of FFP2 mask batches.", [["surgical masks", "TREATMENT", 4, 18], ["batches", "TREATMENT", 27, 34], ["secondary packaging verifications", "TEST", 201, 234], ["FFP2 mask batches", "TREATMENT", 315, 332]]], ["However, 36% of batches from different establishments and different producers were not sent in their secondary packaging, but simply placed in plastic bags, still in their primary packaging.", [["their primary packaging", "TREATMENT", 166, 189], ["plastic bags", "OBSERVATION", 143, 155], ["primary packaging", "OBSERVATION", 172, 189]]], ["Thus, it cannot be concluded that primary and secondary packing criteria were fulfilled.", [["secondary packing criteria", "TEST", 46, 72]]], ["Moreover, primary packaging differed from one manufacturer to another: some manufacturers packaged their masks in individual plastic bags, others in batches of 20 units per plastic bag or 50 units per cardboard box.ResultsThe visual inspection of masks revealed a non-compliance with the ministerial directives for 7% of FFP2 mask batches and 3% of surgical mask batches.", [["individual plastic bags", "TREATMENT", 114, 137], ["plastic bag", "TREATMENT", 173, 184], ["The visual inspection of masks", "TEST", 222, 252], ["FFP2 mask batches", "TREATMENT", 321, 338], ["surgical mask batches", "TREATMENT", 349, 370], ["plastic bags", "OBSERVATION", 125, 137]]], ["In the majority of these batches, the nose foam crumbled easily when touched (Figure 1).", [["nose foam", "ANATOMY", 38, 47], ["nose", "ORGANISM_SUBDIVISION", 38, 42], ["these batches", "TREATMENT", 19, 32], ["the nose foam", "TREATMENT", 34, 47], ["nose", "ANATOMY", 38, 42]]], ["At the establishment\u2019s request, compliance testing on its batches stopped when this result was obtained.", [["compliance testing", "TEST", 32, 50], ["its batches", "TREATMENT", 54, 65]]], ["Another establishment asked us to cover the foam with adhesive tape and to continue testing.", [["the foam", "TREATMENT", 40, 48], ["adhesive tape", "TREATMENT", 54, 67], ["testing", "TEST", 84, 91]]], ["An N95 mask has to carry a brand name, a National Institute for Occupational Safety and Health (NIOSH) logo, a TC approval number, a filter class and filter efficiency level and a model number [6].", [["An N95 mask", "TREATMENT", 0, 11], ["a filter class", "TREATMENT", 131, 145], ["filter efficiency level", "TEST", 150, 173], ["N95 mask", "OBSERVATION", 3, 11], ["filter efficiency", "OBSERVATION", 150, 167]]], ["On the suspect batch, all the required data except the NIOSH logo and the filter class and efficiency level were missing (Figure 2).", [["the filter class", "TREATMENT", 70, 86], ["efficiency level", "PROBLEM", 91, 107]]], ["The face-fit test was also negative for this batch.ResultsThe breaking strength test of the elastic ties showed that 63% of the FFP2/N95 mask batches were compliant and 37% were non-compliant with the ministerial directives.", [["The face-fit test", "TEST", 0, 17], ["this batch", "TREATMENT", 40, 50], ["The breaking strength test", "TEST", 58, 84], ["the elastic ties", "TEST", 88, 104], ["the FFP2", "TEST", 124, 132], ["N95 mask batches", "TREATMENT", 133, 149], ["face", "ANATOMY", 4, 8]]], ["Among the non-compliant batches, there were three categories: 17% of batches with one to three non-compliant samples, 7% of batches with four to six non-compliant samples and 13% of batches with seven to nine non-compliant samples (Table I).", [["samples", "ANATOMY", 109, 116], ["batches", "TREATMENT", 69, 76], ["batches", "TREATMENT", 124, 131], ["batches", "TREATMENT", 182, 189]]], ["Two different break points were observed and noted: junction point between elastic and mask, and middle of elastic.", [["Two different break points", "PROBLEM", 0, 26], ["elastic and mask", "TREATMENT", 75, 91], ["different", "OBSERVATION_MODIFIER", 4, 13], ["break points", "OBSERVATION", 14, 26], ["elastic", "OBSERVATION_MODIFIER", 75, 82], ["mask", "OBSERVATION_MODIFIER", 87, 91], ["middle", "ANATOMY_MODIFIER", 97, 103], ["elastic", "OBSERVATION_MODIFIER", 107, 114]]], ["For the surgical masks, this test revealed non-compliance with the ministerial directives: there were 10% of batches with one to three non-compliant samples, 6% of batches with four to six non-compliant samples and 23% of batches with seven to nine non-compliant samples.ResultsThe strength test on the nose clip test revealed that 9% of batches were non-compliant with the ministerial directives: either the nose clip broke from the first twists, or the nose clip broke during the last twists.", [["samples", "ANATOMY", 149, 156], ["samples", "ANATOMY", 203, 210], ["samples", "ANATOMY", 263, 270], ["nose", "ANATOMY", 303, 307], ["nose", "ANATOMY", 409, 413], ["nose", "ANATOMY", 455, 459], ["nose", "ORGANISM_SUBDIVISION", 303, 307], ["nose", "ORGANISM_SUBDIVISION", 409, 413], ["nose", "ORGANISM_SUBDIVISION", 455, 459], ["the surgical masks", "TREATMENT", 4, 22], ["this test", "TEST", 24, 33], ["batches", "TREATMENT", 109, 116], ["batches", "TREATMENT", 164, 171], ["batches", "TREATMENT", 222, 229], ["The strength test", "TEST", 278, 295], ["the nose clip test", "TEST", 299, 317], ["the nose clip", "TREATMENT", 405, 418], ["the nose clip", "PROBLEM", 451, 464], ["nose", "ANATOMY", 409, 413], ["clip", "OBSERVATION", 414, 418], ["nose", "ANATOMY", 455, 459], ["clip", "OBSERVATION", 460, 464]]], ["Moreover, 2% of the batches had no nose clip and therefore were not checked for this criterion.ResultsOn the face-fit test, 16% batches were non-compliant with the ministerial directives.", [["nose", "ORGANISM_SUBDIVISION", 35, 39], ["nose clip", "TREATMENT", 35, 44], ["fit test", "TEST", 114, 122], ["16% batches", "TREATMENT", 124, 135], ["no", "UNCERTAINTY", 32, 34], ["nose", "ANATOMY", 35, 39], ["clip", "OBSERVATION", 40, 44]]], ["Batches were considered non-compliant as soon as the experimenter experienced a sweet taste during at least one exercise of the test.", [["the test", "TEST", 124, 132]]], ["For 1% of the batches, a fourth experimenter performed the test to avoid errors.DiscussionSince the beginning of the COVID-19 health crisis, there has been a dramatic shortage of surgical and FFP2/N95 masks, leaving health caregivers exposed to a high risk of infection.", [["infection", "DISEASE", 260, 269], ["the batches", "TREATMENT", 10, 21], ["the test", "TEST", 55, 63], ["surgical and FFP2/N95 masks", "TREATMENT", 179, 206], ["infection", "PROBLEM", 260, 269], ["infection", "OBSERVATION", 260, 269]]], ["In response to these directives, our laboratory specially designed several tests and adapted INRS guidelines [5] for the face-fit test.DiscussionOf the 206 batches assessed, 81% of FFP2/N95 mask batches and 97% of surgical mask batches were found sufficiently compliant with the ministerial directives.", [["several tests", "TEST", 67, 80], ["INRS guidelines", "TEST", 93, 108], ["the face-fit test", "TEST", 117, 134], ["FFP2", "TREATMENT", 181, 185], ["N95 mask batches", "TREATMENT", 186, 202], ["surgical mask batches", "TREATMENT", 214, 235]]], ["Most cases of non-compliance involved the nose clip and elastic ties, but were not considered to preclude use.", [["nose", "ANATOMY", 42, 46], ["nose", "ORGANISM_SUBDIVISION", 42, 46], ["the nose clip", "TREATMENT", 38, 51]]], ["However, non-compliance involving the face-fit could lead to contamination, non-compliance involving mask appearance would indicate poor state of preservation.DiscussionThe test on elastic tie to breaking strength yielded three categories of batches.", [["contamination", "PROBLEM", 61, 74], ["non-compliance involving mask appearance", "PROBLEM", 76, 116], ["The test", "TEST", 169, 177]]], ["Batches containing one to three non-compliant samples needed to be considered fragile in terms of their elastic ties.", [["Batches", "TREATMENT", 0, 7], ["elastic ties", "OBSERVATION", 104, 116]]], ["Batches containing four to six non-compliant samples warranted precautionary measures.", [["Batches", "TREATMENT", 0, 7], ["precautionary measures", "TREATMENT", 63, 85]]], ["Batches containing seven to nine non-compliant samples were not recommended for use.", [["samples", "ANATOMY", 47, 54], ["Batches", "TREATMENT", 0, 7]]], ["Nevertheless, depending on the breaking point of the elastic, establishments may still be able to use the mask: if the breaking point is at the junction between the elastic and the mask, the mask can be used provided this point is reinforced with staples.DiscussionIn addition to revealing batches that were insufficiently airtight, the face-fit test revealed other characteristics that could make them unsatisfactory.", [["the mask", "TREATMENT", 102, 110], ["the elastic and the mask", "TREATMENT", 161, 185], ["the mask", "TREATMENT", 187, 195], ["staples", "TREATMENT", 247, 254], ["the face-fit test", "TEST", 333, 350], ["elastic", "OBSERVATION_MODIFIER", 165, 172], ["staples", "OBSERVATION", 247, 254]]], ["Some batches had strong musty odours or strong chemical odours which could indicate poor storage conditions.", [["strong musty odours", "PROBLEM", 17, 36], ["strong chemical odours", "PROBLEM", 40, 62], ["poor storage conditions", "PROBLEM", 84, 107]]], ["One batch had very poor breathability, preventing its use.DiscussionGiven the health emergency represented by this crisis, a compromise had to be made between performing lengthy tests to the usual standards and the speed to obtain rapid results.", [["very poor breathability", "PROBLEM", 14, 37], ["this crisis", "PROBLEM", 110, 121], ["very", "OBSERVATION_MODIFIER", 14, 18], ["poor", "OBSERVATION_MODIFIER", 19, 23], ["breathability", "OBSERVATION", 24, 37]]], ["To avoid cases such as that of Reunion Island, where masks appearing moldy were delivered to hospitals, meticulous testing must be applied.", [["meticulous testing", "TEST", 104, 122]]], ["In our laboratory, although utmost care was given to all tests, each result was obtained within 6 working hours.DiscussionThe fact that all testing required by the ministerial directives was grouped together in the same laboratory provided a comprehensive picture.", [["all tests", "TEST", 53, 62], ["all testing", "TEST", 136, 147]]], ["Thus, counterfeit masks were quickly suspected, then confirmed by the absence of regulatory data.DiscussionBecause of the lack of comprehensive guidelines for assessing the quality and efficiency of these masks, the Health Ministry published its two directives with low requirements in a crisis context.", [["counterfeit masks", "TREATMENT", 6, 23]]], ["It would be wise to take advantage of this experience to create a national standard protocol that would harmonize quality controls by different laboratories and enhance the rapid response to such testing accords in a health crisis.", [["a national standard protocol", "TREATMENT", 64, 92]]], ["The Ministry should also take advantage of this critical situation to modify the national stock management policy in two directions: by increasing safety stocks as well as production autonomy to reduce worldwide dependence in one manufactory country.", [["the national stock management", "TREATMENT", 77, 106]]], ["This would avoid recourse to inadequate solutions appearing during health crises, such as manufacturing paper or cloth masks, not officially recommended for use due to scientific evidence that they do not protect against viral contamination [7,8].DiscussionThis work has several limitations.", [["inadequate solutions", "PROBLEM", 29, 49], ["cloth masks", "TREATMENT", 113, 124], ["viral contamination", "PROBLEM", 221, 240]]], ["First, the urgency of the health situation forced this study to be conducted over a short period of time.", [["this study", "TEST", 50, 60], ["urgency", "OBSERVATION", 11, 18]]], ["Moreover, during the epidemic, there was a lack of material and time needed to control mask conformity with regards to standards.", [["a lack of material", "PROBLEM", 41, 59], ["mask conformity", "TREATMENT", 87, 102]]], ["To our knowledge, mask quality control in an emergency context has not been described before and required the development of new techniques.", [["mask quality control", "TREATMENT", 18, 38], ["new", "OBSERVATION_MODIFIER", 125, 128]]], ["The protocol we described can not guarantee compliance to standards but allows the detection of critical non-compliance.DiscussionThe COVID-19 health crisis led to a shortage of respiratory protection masks but also of all personal protective equipment.", [["respiratory", "ANATOMY", 178, 189], ["The protocol", "TREATMENT", 0, 12], ["critical non-compliance", "PROBLEM", 96, 119], ["respiratory protection masks", "TREATMENT", 178, 206]]], ["The development of emergency quality control protocols for equipment such as gloves or overcoats would allow the rapid release of expired batches.", [["emergency quality control protocols", "TREATMENT", 19, 54], ["equipment", "TREATMENT", 59, 68], ["gloves", "TREATMENT", 77, 83], ["overcoats", "TREATMENT", 87, 96], ["the rapid release of expired batches", "TREATMENT", 109, 145]]], ["Beyond this epidemic, quality control protocols could also allow the rapid identification of counterfeit protective equipment.DiscussionOf the 175 batches of FFP2/N95 masks and 31 batches of surgical masks tested by our laboratory in 36 days, 81% of FFP2 mask batches and 97% of surgical mask batches were released for use.", [["quality control protocols", "TREATMENT", 22, 47], ["counterfeit protective equipment", "TREATMENT", 93, 125], ["FFP2/N95 masks", "TREATMENT", 158, 172], ["surgical masks", "TREATMENT", 191, 205], ["FFP2 mask batches", "TREATMENT", 250, 267], ["surgical mask batches", "TREATMENT", 279, 300]]], ["The testing prevented 19% of defective batches of FFP2/N95 masks and 3% of defective batches of surgical masks being delivered to healthcare personnel.", [["The testing", "TEST", 0, 11], ["defective batches", "TREATMENT", 29, 46], ["FFP2", "TREATMENT", 50, 54], ["N95 masks", "TREATMENT", 55, 64], ["defective batches", "TREATMENT", 75, 92], ["surgical masks", "TREATMENT", 96, 110], ["surgical masks", "OBSERVATION", 96, 110]]], ["Even in a health crisis context, it is vital to take the time to perform the quality checks that guarantee the safety of personnel.DiscussionUnder the conditions of extreme tension and lack of time experienced by hospital staff in contact with COVID-19 patients, the quality control of stockpiled N95 respirators and surgical masks should not be verified by the users themselves.", [["patients", "ORGANISM", 253, 261], ["patients", "SPECIES", 253, 261], ["the quality checks", "TEST", 73, 91], ["extreme tension", "PROBLEM", 165, 180], ["stockpiled N95 respirators", "TREATMENT", 286, 312], ["surgical masks", "TREATMENT", 317, 331]]], ["Pharmaceutical expertise, for example from quality control laboratories, can be help relieve healthcare workers of these verifications and can detect defective masks.Funding sourcesNone.Declaration of Competing InterestNone.", [["these verifications", "TEST", 115, 134], ["defective masks", "PROBLEM", 150, 165]]]], "PMC7543257": [["IntroductionThe coronavirus disease-2019 (COVID-19) pandemic has spread to over 200 countries and territories, and it has made a terrible impact on lives and economies worldwide [1\u20133].", [["coronavirus disease", "DISEASE", 16, 35], ["COVID-19", "CHEMICAL", 42, 50], ["coronavirus", "ORGANISM", 16, 27], ["COVID-19", "ORGANISM", 42, 50], ["coronavirus disease-2019 (COVID-19", "SPECIES", 16, 50], ["The coronavirus disease", "PROBLEM", 12, 35], ["COVID", "TEST", 42, 47], ["pandemic", "PROBLEM", 52, 60], ["coronavirus disease", "OBSERVATION", 16, 35]]], ["Based on the current pandemic situation and many research reports [4], COVID-19 may continue to spread for a long period of time and may eventually become a flu-like seasonal outbreak [5].", [["COVID-19", "CHEMICAL", 71, 79], ["flu-like", "DISEASE", 157, 165], ["COVID-19", "CELL", 71, 79], ["COVID", "TEST", 71, 76], ["a flu-like seasonal outbreak", "PROBLEM", 155, 183]]], ["Under these circumstances, it is important to develop new technologies for rapid detection of COVID-19.IntroductionNucleic acid sequencing is a key technology for identifying and studying severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19.", [["acute respiratory syndrome coronavirus", "DISEASE", 195, 233], ["COVID-19", "CHEMICAL", 94, 102], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 188, 235], ["SARS-CoV-2", "ORGANISM", 237, 247], ["severe acute respiratory syndrome coronavirus", "SPECIES", 188, 233], ["SARS-CoV-2", "SPECIES", 237, 247], ["rapid detection", "TEST", 75, 90], ["COVID", "TEST", 94, 99], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 188, 233], ["SARS", "TEST", 237, 241], ["CoV", "TEST", 242, 245], ["COVID", "TEST", 273, 278], ["severe", "OBSERVATION_MODIFIER", 188, 194], ["acute", "OBSERVATION_MODIFIER", 195, 200], ["respiratory syndrome", "OBSERVATION", 201, 221]]], ["Metagenomic and metatranscriptomic next-generation sequencing (mNGS) are powerful tools to study the genetic composition and function of microbial populations, as well as to analyze the relationship between microorganisms and their host or environment [6, 7].", [["Metagenomic and metatranscriptomic next-generation sequencing", "TREATMENT", 0, 61]]], ["Since the first clinical application of metagenomic sequencing (mNGS) for the diagnosis of leptospirosis in 2014 [8], mNGS has been used widely for the identification and diagnosis of new and rare pathogens.IntroductionNext generation sequencing (NGS) technology has also played an important role in COVID-19 diagnosis and research.", [["leptospirosis", "DISEASE", 91, 104], ["metagenomic sequencing", "TEST", 40, 62], ["leptospirosis", "PROBLEM", 91, 104], ["mNGS", "TREATMENT", 118, 122], ["the identification", "TEST", 148, 166], ["new and rare pathogens", "PROBLEM", 184, 206], ["rare", "OBSERVATION_MODIFIER", 192, 196], ["pathogens", "OBSERVATION", 197, 206]]], ["The earliest COVID-19 case, which was initially diagnosed as pneumonia caused by an unknown pathogen, was identified due to the presence of SARS-like sequences found using mNGS [9].", [["pneumonia", "DISEASE", 61, 70], ["SARS", "DISEASE", 140, 144], ["SARS-like sequences", "DNA", 140, 159], ["pneumonia", "PROBLEM", 61, 70], ["an unknown pathogen", "PROBLEM", 81, 100], ["SARS-like sequences", "PROBLEM", 140, 159], ["pneumonia", "OBSERVATION", 61, 70], ["pathogen", "OBSERVATION", 92, 100]]], ["The first complete genome of SARS-CoV-2 (GenBank: MN908947) reported on January 11, 2020 was assembled using NGS data [10].", [["SARS-CoV-2", "ORGANISM", 29, 39], ["SARS-CoV", "SPECIES", 29, 37], ["NGS data", "TEST", 109, 117]]], ["Soon after, the whole-genome sequence of SARS-CoV-2 was also obtained by mNGS using the Oxford Nanopore platform supplemented with Sanger sequencing [11].", [["SARS-CoV-2", "ORGANISM", 41, 51], ["whole-genome sequence", "DNA", 16, 37], ["SARS-CoV-2", "DNA", 41, 51], ["mNGS", "DNA", 73, 77], ["Oxford Nanopore platform", "DNA", 88, 112], ["SARS-CoV", "SPECIES", 41, 49], ["SARS", "PROBLEM", 41, 45], ["the Oxford Nanopore platform", "TREATMENT", 84, 112]]], ["The rapid acquisition and publication of the SARS-CoV-2 genome was essential to design fluorescent polymerase chain reaction (PCR) probes for COVID-19 nucleic acid detection kits.IntroductionWith the viral genome in hand, we can now explore the possibility of using mNGS directly as a detection method to determine whether SARS-CoV-2 RNA is present or absent in a sample.", [["SARS", "DISEASE", 45, 49], ["COVID-19 nucleic acid", "CHEMICAL", 142, 163], ["hand", "ORGANISM_SUBDIVISION", 216, 220], ["mNGS", "GENE_OR_GENE_PRODUCT", 266, 270], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 323, 333], ["SARS-CoV-2 genome", "DNA", 45, 62], ["viral genome", "DNA", 200, 212], ["mNGS", "PROTEIN", 266, 270], ["SARS-CoV-2 RNA", "RNA", 323, 337], ["SARS-CoV", "SPECIES", 45, 53], ["SARS-CoV", "SPECIES", 323, 331], ["The rapid acquisition", "TEST", 0, 21], ["the SARS", "TEST", 41, 49], ["CoV-2 genome", "TREATMENT", 50, 62], ["design fluorescent polymerase chain reaction", "PROBLEM", 80, 124], ["PCR", "TEST", 126, 129], ["COVID", "TEST", 142, 147], ["nucleic acid detection kits", "TEST", 151, 178], ["a detection method", "TEST", 283, 301], ["SARS", "PROBLEM", 323, 327], ["CoV-2 RNA", "PROBLEM", 328, 337], ["viral genome", "OBSERVATION", 200, 212]]], ["In theory, a simple and straightforward approach would be to first map sequencing reads obtained from the sample to the viral genome using common aligners such as Burrows\u2013Wheeler aligner (BWA) [12] or Bowtie2 [13], and then to analyze the alignment results to determine the coverage of the viral genome and the number of properly mapped reads.", [["viral genome", "DNA", 120, 132], ["viral genome", "DNA", 290, 302], ["the viral genome", "PROBLEM", 286, 302], ["viral genome", "OBSERVATION", 120, 132], ["viral genome", "OBSERVATION", 290, 302]]], ["However, in practice, such an alignment-based method is prone to problems stemming from both false positives and false negatives.", [["false positives", "OBSERVATION", 93, 108], ["false negatives", "OBSERVATION", 113, 128]]], ["On one hand, some viruses have genomes very similar to SARS-CoV-2, which can lead to false positive results.", [["SARS", "DISEASE", 55, 59], ["SARS-CoV-2", "ORGANISM", 55, 65], ["SARS-CoV", "SPECIES", 55, 63], ["some viruses", "PROBLEM", 13, 25], ["SARS", "PROBLEM", 55, 59], ["CoV", "TEST", 60, 63], ["false positive results", "PROBLEM", 85, 107], ["viruses", "OBSERVATION", 18, 25]]], ["For example, the genome of bat coronavirus RaTG13 is sufficiently similar to SARS-CoV-2 (96% identity) to cause non-specific alignment [14].", [["bat coronavirus", "ORGANISM", 27, 42], ["RaTG13", "ORGANISM", 43, 49], ["bat coronavirus", "SPECIES", 27, 42], ["bat coronavirus", "SPECIES", 27, 42], ["SARS-CoV-2", "SPECIES", 77, 87], ["bat coronavirus RaTG13", "TEST", 27, 49], ["SARS", "TEST", 77, 81], ["CoV", "TEST", 82, 85], ["non-specific alignment", "OBSERVATION", 112, 134]]], ["On the other hand, in some cases the virus-specific reads obtained may not be abundant enough for unambiguous detection, which can lead to false negative results.", [["unambiguous detection", "TEST", 98, 119]]], ["Examples of such cases may be when the viral RNA is highly degraded, or when the sequencing library has been incompletely target enriched by multiple PCR [15] or hybrid capture [16].", [["viral RNA", "RNA", 39, 48], ["the viral RNA", "PROBLEM", 35, 48], ["the sequencing library", "TEST", 77, 99], ["multiple PCR", "TEST", 141, 153]]], ["In these scenarios, alignment-based methods may be not specific or sensitive enough.", [["alignment-based methods", "TEST", 20, 43], ["alignment", "OBSERVATION_MODIFIER", 20, 29]]], ["Such alignment-based methods are also computationally intensive and therefore not particularly fast or efficient.IntroductionIn order to detect SARS-CoV-2 more quickly and accurately, we have developed an alignment-free method based on k-mer mapping and extension.", [["SARS-CoV", "SPECIES", 144, 152], ["SARS", "PROBLEM", 144, 148], ["CoV", "TEST", 149, 152], ["free method", "TREATMENT", 215, 226], ["k-mer mapping", "TEST", 236, 249]]], ["The use of k-mer-based methods to analyze microbial sequencing data is not a new method.", [["k-mer-based methods", "TREATMENT", 11, 30], ["microbial sequencing data", "TEST", 42, 67]]], ["For example, researchers have developed k-mer based algorithms to analyze plasmid-derived sequence fragments in metagenomics data [17, 18].", [["fragments", "ANATOMY", 99, 108], ["plasmid", "DNA", 74, 81], ["k-mer based algorithms", "TEST", 40, 62], ["derived sequence fragments", "PROBLEM", 82, 108], ["metagenomics data", "TEST", 112, 129]]], ["Several k-mer based tools for species classification and sequencing read annotation have also been reported.", [["species classification", "TEST", 30, 52], ["sequencing read annotation", "TEST", 57, 83]]], ["For example, SPINGO [19] provides rapid species classification for microbial amplicon sequences based on k-mer mapping technology.", [["microbial amplicon sequences", "DNA", 67, 95], ["rapid species classification", "TEST", 34, 62], ["microbial amplicon sequences", "TREATMENT", 67, 95], ["k-mer mapping technology", "TEST", 105, 129]]], ["KrakenUniq [21], which is built on Kraken [22], can partially address problems due to false positives by using unique k-mer analysis.", [["false positives", "PROBLEM", 86, 101], ["unique k-mer analysis", "TEST", 111, 132]]], ["However, we are currently unaware of a fast, reliable and user-friendly k-mer-based tool for identifying nucleic acids from SARS-CoV-2 and other viruses or microorganisms using sequencing data.", [["nucleic acids", "CHEMICAL", 105, 118], ["SARS-CoV-2", "ORGANISM", 124, 134], ["SARS-CoV", "SPECIES", 124, 132], ["nucleic acids", "TEST", 105, 118], ["SARS", "PROBLEM", 124, 128], ["CoV", "TEST", 129, 132], ["other viruses", "PROBLEM", 139, 152], ["microorganisms", "PROBLEM", 156, 170], ["sequencing data", "TEST", 177, 192]]], ["The fastv tool has three major functions: (i) to analyze which viral and/or microbial sequences are present in the sequencing data, (ii) to determine whether sequences from a specific virus or microorganism (e.g. SARS-CoV-2) can be found in the sequencing data and (iii) to analyze coverage of a specific viral or microbial genome by a set of sequencing data.", [["viral or microbial genome", "DNA", 305, 330], ["viral and/or microbial sequences", "TEST", 63, 95], ["the sequencing data", "TEST", 111, 130], ["a specific virus", "PROBLEM", 173, 189], ["microorganism", "PROBLEM", 193, 206], ["CoV", "TEST", 218, 221], ["the sequencing data", "TEST", 241, 260], ["sequencing data", "TEST", 343, 358]]], ["All three of these methods rely on a unique k-mer set for each microorganism, making it essential to produce high-quality unique k-mer sets.", [["each microorganism", "PROBLEM", 58, 76]]], ["We developed another tool, UniqueKMER, to generate a complete set of unique k-mers for each of a large set of microbial genomes.", [["microbial genomes", "DNA", 110, 127], ["unique k-mers", "TREATMENT", 69, 82], ["large", "OBSERVATION_MODIFIER", 97, 102], ["microbial genomes", "OBSERVATION", 110, 127]]], ["The unique k-mers can be filtered to remove the k-mers that can be mapped to a reference genome (e.g. the human genome).", [["human", "ORGANISM", 106, 111], ["reference genome", "DNA", 79, 95], ["human genome", "DNA", 106, 118], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111]]], ["Generating unique k-mers for tens of thousands of viral and microbial species would typically require tremendous memory and computing resources.", [["unique k-mers", "TREATMENT", 11, 24], ["viral and microbial species", "PROBLEM", 50, 77], ["viral", "OBSERVATION", 50, 55], ["microbial species", "OBSERVATION", 60, 77]]], ["UniqueKMER requires only 1 h to generate reference-filtered unique k-mers for about 12 000 viral genomes on an ordinary PC.IntroductionAs a lightweight tool, fastv accepts FASTQ data as input and directly outputs the results in HTML and JSON formats.", [["PC", "CANCER", 120, 122], ["viral genomes", "DNA", 91, 104], ["an ordinary PC", "TREATMENT", 108, 122]]], ["The HTML result is highly informative and provides interactive reports for manually reading, while the JSON result is structured such that it can easily be used by downstream analysis tools.", [["JSON", "DNA", 103, 107]]], ["Prior to the k-mer analysis, fastv automatically performs adapter trimming, quality pruning, base correction and other preprocessing to ensure the accuracy of k-mer analysis.", [["fastv", "DNA", 29, 34], ["the k-mer analysis", "TEST", 9, 27], ["adapter trimming", "TREATMENT", 58, 74], ["base correction", "TREATMENT", 93, 108], ["other preprocessing", "TREATMENT", 113, 132], ["k-mer analysis", "TEST", 159, 173]]], ["These preprocessing features are derived from fastp [23], a popular quality control and filtering tool for NGS data previously developed by our group.", [["filtering tool", "TEST", 88, 102], ["NGS data", "TEST", 107, 115]]], ["The fastv tool is ultra-fast - it can process 10 M+ bases per second - and can complete the processing of a typical mNGS dataset in a few minutes.IntroductionWe conducted identification experiments on 27 samples positive for SARS-CoV-2 and 25 samples negative for SARS-CoV-2.", [["samples", "ANATOMY", 204, 211], ["samples", "ANATOMY", 243, 250], ["SARS-CoV-2", "ORGANISM", 264, 274], ["SARS-CoV", "SPECIES", 225, 233], ["SARS-CoV", "SPECIES", 264, 272], ["a typical mNGS dataset", "TREATMENT", 106, 128], ["27 samples", "TEST", 201, 211], ["SARS", "PROBLEM", 225, 229], ["CoV", "TEST", 230, 233], ["25 samples", "TEST", 240, 250], ["SARS", "PROBLEM", 264, 268], ["CoV", "TEST", 269, 272]]], ["The results showed that fastv achieved 100% sensitivity and 100% specificity; and that it can distinguish SARS-CoV-2 from SARS [24], middle East respiratory syndrome (MERS) [25] and other coronaviruses [26].", [["SARS", "DISEASE", 106, 110], ["SARS", "DISEASE", 122, 126], ["middle East respiratory syndrome", "DISEASE", 133, 165], ["SARS-CoV", "SPECIES", 106, 114], ["SARS", "TEST", 106, 110], ["CoV", "TEST", 111, 114], ["SARS", "PROBLEM", 122, 126], ["middle East respiratory syndrome", "PROBLEM", 133, 165], ["other coronaviruses", "PROBLEM", 182, 201], ["middle", "ANATOMY_MODIFIER", 133, 139], ["respiratory syndrome", "OBSERVATION", 145, 165]]], ["Although our original intention in developing these tools was to quickly identify SARS-CoV-2 from sequencing data, our tool can detect any target virus or microorganism for which a unique k-mer file is provided.", [["SARS-CoV-2", "DNA", 82, 92], ["SARS-CoV", "SPECIES", 82, 90], ["SARS", "PROBLEM", 82, 86], ["sequencing data", "TEST", 98, 113], ["our tool", "TEST", 115, 123], ["any target virus", "PROBLEM", 135, 151], ["microorganism", "PROBLEM", 155, 168]]], ["We also conducted experiments using several other viral genomes such as Epstein\u2013Barr virus (EBV), human papillomavirus (HPV) and hepatitis B virus (HBV).", [["Epstein\u2013Barr virus (EBV), human papillomavirus (HPV) and hepatitis B", "DISEASE", 72, 140], ["Epstein\u2013Barr virus", "ORGANISM", 72, 90], ["EBV", "ORGANISM", 92, 95], ["human papillomavirus", "ORGANISM", 98, 118], ["HPV", "ORGANISM", 120, 123], ["hepatitis B virus", "ORGANISM", 129, 146], ["HBV", "ORGANISM", 148, 151], ["Barr virus", "SPECIES", 80, 90], ["human", "SPECIES", 98, 103], ["papillomavirus", "SPECIES", 104, 118], ["hepatitis B virus", "SPECIES", 129, 146], ["Epstein\u2013Barr virus", "SPECIES", 72, 90], ["EBV", "SPECIES", 92, 95], ["human papillomavirus", "SPECIES", 98, 118], ["HPV", "SPECIES", 120, 123], ["hepatitis B virus", "SPECIES", 129, 146], ["HBV", "SPECIES", 148, 151], ["several other viral genomes", "PROBLEM", 36, 63], ["Epstein\u2013Barr virus", "TREATMENT", 72, 90], ["human papillomavirus (HPV", "PROBLEM", 98, 123], ["hepatitis B virus", "PROBLEM", 129, 146]]], ["The results demonstrated that our tools perform well on a variety of viral genomic datasets.Read preprocessing ::: Fastv: rapid identification of microorganisms from sequencing data ::: Material and methodsTo avoid generating erroneous k-mer keys, sequencing adapters and low-quality bases must be removed.", [["viral genomic datasets", "PROBLEM", 69, 91], ["erroneous k-mer keys", "PROBLEM", 226, 246], ["sequencing adapters", "TREATMENT", 248, 267], ["low-quality bases", "TREATMENT", 272, 289], ["viral genomic datasets", "OBSERVATION", 69, 91]]], ["Fastv utilizes the adapter cutting and quality pruning features from fastp, which we developed previously.", [["Fastv", "TREATMENT", 0, 5], ["the adapter cutting", "TREATMENT", 15, 34], ["fastp", "PROBLEM", 69, 74]]], ["For paired-end sequencing data, overlapping regions are detected and incorrect bases in the overlapping regions are corrected.", [["paired-end sequencing data", "TEST", 4, 30], ["overlapping regions", "PROBLEM", 32, 51], ["bases", "ANATOMY_MODIFIER", 79, 84], ["overlapping", "OBSERVATION_MODIFIER", 92, 103], ["regions", "ANATOMY_MODIFIER", 104, 111]]], ["The algorithms for, and implementations of, these features can be found in the fastp publication [23].", [["The algorithms", "TEST", 0, 14]]], ["For data generated by long-read platforms (e.g. PacBio or Oxford Nanopore Technologies (ONT)), long reads are segmented, generating multiple short reads.K-mer generation and representation ::: Fastv: rapid identification of microorganisms from sequencing data ::: Material and methodsTo accelerate k-mer generation and lookup, we use a unique 64-bit integer to represent each k-mer.", [["K", "CHEMICAL", 153, 154], ["K", "TEST", 153, 154], ["k-mer generation", "OBSERVATION", 298, 314]]], ["A base (A/T/C/G) is represented by two bits, so a 64-bit integer can represent up to a 32-mer, which is sufficiently long for identifying a virus or microorganism.", [["A base (A/T/C/G", "TEST", 0, 15], ["a virus", "PROBLEM", 138, 145], ["microorganism", "PROBLEM", 149, 162], ["base", "ANATOMY_MODIFIER", 2, 6], ["virus", "OBSERVATION", 140, 145]]], ["Any k-mer key that contains a degenerate base (i.e. N base) is ignored.", [["N", "CHEMICAL", 52, 53], ["a degenerate base", "PROBLEM", 28, 45], ["degenerate", "OBSERVATION_MODIFIER", 30, 40], ["base", "OBSERVATION_MODIFIER", 41, 45]]], ["A progressive method for k-mer calculation is applied to accelerate k-mer generation.", [["A progressive method", "TREATMENT", 0, 20], ["k-mer calculation", "TREATMENT", 25, 42], ["progressive", "OBSERVATION_MODIFIER", 2, 13], ["k-mer generation", "OBSERVATION", 68, 84]]], ["The formula to compute the nth k-mer key can be denoted as: kmer(n) = ((kmer(n-1) < < 2) + base2bit(n)) & bit_mask, where base2bit(n) is the 2-bit representation of a base (A/T/C/G), and bit_mask is a 64-bit value determined by the length k of k-mer.K-mer collection scanning ::: Fastv: rapid identification of microorganisms from sequencing data ::: Material and methodsThe k-mer collection file can contain unique k-mers for tens of thousands of viral or microbial genomes, with each containing hundreds to thousands of k-mer keys.", [["K", "CHEMICAL", 250, 251], ["a base", "TEST", 165, 171], ["A/T/C/G", "TREATMENT", 173, 180], ["K", "TEST", 250, 251], ["mer collection scanning", "TEST", 252, 275], ["The k-mer collection file", "PROBLEM", 371, 396], ["unique k-mers", "TREATMENT", 409, 422], ["viral or microbial genomes", "PROBLEM", 448, 474], ["base", "ANATOMY_MODIFIER", 167, 171], ["viral", "OBSERVATION", 448, 453], ["microbial genomes", "OBSERVATION", 457, 474], ["k-mer keys", "OBSERVATION", 522, 532]]], ["Therefore, there may be tens of millions of k-mer keys in total.", [["may be", "UNCERTAINTY", 17, 23], ["tens", "OBSERVATION_MODIFIER", 24, 28], ["k-mer keys", "OBSERVATION", 44, 54]]], ["It would be trivial to use a map to index this data, but such an implementation would result in very slow access.", [["a map", "TEST", 27, 32], ["trivial", "OBSERVATION", 12, 19]]], ["Our approach was to build a hash function to hash the 64-bit key to a larger number (i.e. 230), which stores the index to the k-mer element.", [["k-mer element", "DNA", 126, 139], ["larger", "OBSERVATION_MODIFIER", 70, 76], ["k-mer element", "OBSERVATION", 126, 139]]], ["However, as long as the hash function is sufficiently random, the probability of collision will follow a probability distribution that will result in only a small fraction of keys to have hash collisions.", [["small", "OBSERVATION_MODIFIER", 157, 162]]], ["This kind of space-for-time approach results in a significant increase in efficiency and makes it feasible to detect tens of thousands of microorganisms at once.", [["a significant increase in efficiency", "PROBLEM", 48, 84], ["microorganisms", "PROBLEM", 138, 152], ["significant", "OBSERVATION_MODIFIER", 50, 61], ["increase", "OBSERVATION_MODIFIER", 62, 70]]], ["The algorithm to build such a k-mer collection index is briefly illustrated as Algorithm 1.", [["The algorithm", "TREATMENT", 0, 13], ["a k-mer collection index", "TEST", 28, 52]]], ["It should be noted that, to obtain a higher running speed, we did not use mutex locks to synchronize the k-mer hit counting operation between multiple threads.", [["mutex locks", "TREATMENT", 74, 85]]], ["Our results demonstrate that, while this might lead to slight instability in the results (less than 1 in 104), it does not have an impact on the overall quality of the results.K-mer collection scanning ::: Fastv: rapid identification of microorganisms from sequencing data ::: Material and methods", [["K", "CHEMICAL", 176, 177], ["slight instability", "PROBLEM", 55, 73], ["K", "TEST", 176, 177], ["mer collection scanning", "TEST", 178, 201], ["slight", "OBSERVATION_MODIFIER", 55, 61], ["instability", "OBSERVATION", 62, 73]]]], "9a918b6082992793ef6751bddf2f3db7f7051c0d": [["INTRODUCTIONRespiratory syncytial virus (RSV) is the leading cause of serious lower respiratory tract disease requiring hospitalization of infants and children in the United States 1-6 where it accounts for up to 120,000 hospitalizations annually in infants <12 months of age.", [["lower respiratory tract", "ANATOMY", 78, 101], ["lower respiratory tract disease", "DISEASE", 78, 109], ["INTRODUCTIONRespiratory syncytial virus", "ORGANISM", 0, 39], ["RSV", "ORGANISM", 41, 44], ["lower", "ORGANISM_SUBDIVISION", 78, 83], ["respiratory tract", "ORGANISM_SUBDIVISION", 84, 101], ["infants", "ORGANISM", 139, 146], ["children", "ORGANISM", 151, 159], ["infants", "ORGANISM", 250, 257], ["infants", "SPECIES", 139, 146], ["children", "SPECIES", 151, 159], ["infants", "SPECIES", 250, 257], ["INTRODUCTIONRespiratory syncytial virus", "SPECIES", 0, 39], ["RSV", "SPECIES", 41, 44], ["INTRODUCTIONRespiratory syncytial virus", "PROBLEM", 0, 39], ["serious lower respiratory tract disease", "PROBLEM", 70, 109], ["syncytial virus", "OBSERVATION", 24, 39], ["leading cause of", "UNCERTAINTY", 53, 69], ["serious", "OBSERVATION_MODIFIER", 70, 77], ["lower", "OBSERVATION_MODIFIER", 78, 83], ["respiratory tract disease", "OBSERVATION", 84, 109]]], ["4, 7, 8 On a broader scale, RSV is the most common cause of childhood acute lower respiratory tract infection.", [["lower respiratory tract", "ANATOMY", 76, 99], ["RSV", "DISEASE", 28, 31], ["lower respiratory tract infection", "DISEASE", 76, 109], ["RSV", "ORGANISM", 28, 31], ["lower", "ORGANISM_SUBDIVISION", 76, 81], ["respiratory tract", "ORGANISM_SUBDIVISION", 82, 99], ["RSV", "SPECIES", 28, 31], ["RSV", "PROBLEM", 28, 31], ["childhood acute lower respiratory tract infection", "PROBLEM", 60, 109], ["RSV", "OBSERVATION", 28, 31], ["most common", "OBSERVATION_MODIFIER", 39, 50], ["childhood", "OBSERVATION_MODIFIER", 60, 69], ["acute", "OBSERVATION_MODIFIER", 70, 75], ["lower", "ANATOMY_MODIFIER", 76, 81], ["respiratory tract", "ANATOMY", 82, 99], ["infection", "OBSERVATION", 100, 109]]], ["9 Costs associated with RSV-related hospitalization and outpatient visits for bronchiolitis are on the rise.", [["bronchiolitis", "DISEASE", 78, 91], ["RSV", "ORGANISM", 24, 27], ["RSV", "SPECIES", 24, 27], ["RSV", "PROBLEM", 24, 27], ["bronchiolitis", "PROBLEM", 78, 91], ["RSV", "OBSERVATION", 24, 27], ["bronchiolitis", "OBSERVATION", 78, 91]]], ["10, 11 The unique ability of RSV to evade maternal antibodies and infect infants very early in life increases the clinical impact of disease, due in part to narrow airways in infants that are susceptible to obstruction and an immature immune system in these children.", [["airways", "ANATOMY", 164, 171], ["immune system", "ANATOMY", 235, 248], ["obstruction", "DISEASE", 207, 218], ["RSV", "ORGANISM", 29, 32], ["infants", "ORGANISM", 73, 80], ["airways", "MULTI-TISSUE_STRUCTURE", 164, 171], ["infants", "ORGANISM", 175, 182], ["immune system", "ANATOMICAL_SYSTEM", 235, 248], ["children", "ORGANISM", 258, 266], ["maternal antibodies", "PROTEIN", 42, 61], ["infants", "SPECIES", 73, 80], ["infants", "SPECIES", 175, 182], ["children", "SPECIES", 258, 266], ["RSV", "SPECIES", 29, 32], ["RSV", "PROBLEM", 29, 32], ["maternal antibodies", "PROBLEM", 42, 61], ["disease", "PROBLEM", 133, 140], ["narrow airways in infants", "PROBLEM", 157, 182], ["obstruction", "PROBLEM", 207, 218], ["an immature immune system", "PROBLEM", 223, 248], ["disease", "OBSERVATION", 133, 140], ["airways", "ANATOMY", 164, 171], ["obstruction", "OBSERVATION", 207, 218], ["immature immune system", "OBSERVATION", 226, 248]]], ["In some cases, the clinical consequences of RSV-related illness do not end in childhood.", [["RSV-related illness", "DISEASE", 44, 63], ["RSV", "ORGANISM", 44, 47], ["RSV", "SPECIES", 44, 47], ["RSV", "PROBLEM", 44, 47], ["related illness", "PROBLEM", 48, 63], ["RSV", "OBSERVATION", 44, 47]]], ["Long-term studies of children hospitalized with RSV-related lower respiratory tract illness before age 24 months who were prospectively followed up for periods ranging from 18 to 25 years indicate that severe illness in early life is an independent risk factor for wheezing throughout childhood.", [["lower respiratory tract", "ANATOMY", 60, 83], ["RSV", "DISEASE", 48, 51], ["lower respiratory tract illness", "DISEASE", 60, 91], ["illness", "DISEASE", 209, 216], ["wheezing", "DISEASE", 265, 273], ["children", "ORGANISM", 21, 29], ["RSV", "ORGANISM", 48, 51], ["lower respiratory tract", "ORGANISM_SUBDIVISION", 60, 83], ["children", "SPECIES", 21, 29], ["RSV", "SPECIES", 48, 51], ["RSV", "SPECIES", 48, 51], ["RSV", "PROBLEM", 48, 51], ["lower respiratory tract illness", "PROBLEM", 60, 91], ["severe illness", "PROBLEM", 202, 216], ["wheezing", "PROBLEM", 265, 273], ["lower", "ANATOMY_MODIFIER", 60, 65], ["respiratory tract", "ANATOMY", 66, 83], ["severe", "OBSERVATION_MODIFIER", 202, 208], ["illness", "OBSERVATION", 209, 216]]], ["[12] [13] [14] Despite the seriousness of RSV illness and its complications, there were few accounts of its existence as a major viral pathogen before the 1950s.DISCOVERY OF RSV AS A RESPIRATORY PATHOGENThe initial description of infants with cough, wheezing, and respiratory difficulty resembling asthma 160 years ago is believed to be the first report of disease resembling RSV in young children (Table 1) .", [["respiratory", "ANATOMY", 264, 275], ["RSV illness", "DISEASE", 42, 53], ["cough", "DISEASE", 243, 248], ["wheezing", "DISEASE", 250, 258], ["respiratory difficulty", "DISEASE", 264, 286], ["asthma", "DISEASE", 298, 304], ["RSV", "DISEASE", 376, 379], ["[12] [13] [14]", "SIMPLE_CHEMICAL", 0, 14], ["RSV", "ORGANISM", 42, 45], ["infants", "ORGANISM", 230, 237], ["RSV", "ORGANISM", 376, 379], ["children", "ORGANISM", 389, 397], ["infants", "SPECIES", 230, 237], ["children", "SPECIES", 389, 397], ["RSV", "SPECIES", 42, 45], ["RSV", "SPECIES", 174, 177], ["RSV", "SPECIES", 376, 379], ["RSV illness", "PROBLEM", 42, 53], ["its complications", "PROBLEM", 58, 75], ["a major viral pathogen", "PROBLEM", 121, 143], ["A RESPIRATORY PATHOGEN", "PROBLEM", 181, 203], ["cough", "PROBLEM", 243, 248], ["wheezing", "PROBLEM", 250, 258], ["respiratory difficulty", "PROBLEM", 264, 286], ["asthma", "PROBLEM", 298, 304], ["disease", "PROBLEM", 357, 364], ["RSV", "OBSERVATION", 42, 45], ["RSV", "OBSERVATION", 174, 177], ["RESPIRATORY PATHOGEN", "OBSERVATION", 183, 203], ["respiratory", "ANATOMY", 264, 275], ["RSV", "OBSERVATION", 376, 379]]], ["Almost 100 years later, a series of winter epidemics was described in which a severe viral infection associated with cough, dyspnea, fever, bronchiolitis, and pneumonia occurred in newborn infants.", [["viral infection", "DISEASE", 85, 100], ["cough", "DISEASE", 117, 122], ["dyspnea", "DISEASE", 124, 131], ["fever", "DISEASE", 133, 138], ["bronchiolitis", "DISEASE", 140, 153], ["pneumonia", "DISEASE", 159, 168], ["infants", "ORGANISM", 189, 196], ["infants", "SPECIES", 189, 196], ["a severe viral infection", "PROBLEM", 76, 100], ["cough", "PROBLEM", 117, 122], ["dyspnea", "PROBLEM", 124, 131], ["fever", "PROBLEM", 133, 138], ["bronchiolitis", "PROBLEM", 140, 153], ["pneumonia", "PROBLEM", 159, 168], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["viral", "OBSERVATION_MODIFIER", 85, 90], ["infection", "OBSERVATION", 91, 100], ["cough", "OBSERVATION", 117, 122], ["fever", "OBSERVATION", 133, 138], ["bronchiolitis", "OBSERVATION", 140, 153], ["pneumonia", "OBSERVATION", 159, 168]]], ["16 (2) epidemics appear annually each winter for a period of 3-5 months but those months vary from year to year; (3) most children become infected by age 4 years; and, (4) reinfection canVaccine technology CharacteristicsAlphavirus vector Alphavirus vaccines have shown excellent protection in numerous models for infectious disease and cancer, including influenza, CMV, breast cancer, melanoma, SARS, HPV, HSV, RSV, PIV, Marburg and Ebola viruses, viral encephalitis viruses, and botulinum toxin.", [["cancer", "ANATOMY", 337, 343], ["breast cancer", "ANATOMY", 371, 384], ["melanoma", "ANATOMY", 386, 394], ["infectious disease", "DISEASE", 314, 332], ["cancer", "DISEASE", 337, 343], ["influenza, CMV, breast cancer", "DISEASE", 355, 384], ["melanoma", "DISEASE", 386, 394], ["SARS, HPV, HSV, RSV, PIV, Marburg and Ebola viruses", "DISEASE", 396, 447], ["viral encephalitis viruses", "DISEASE", 449, 475], ["botulinum toxin", "CHEMICAL", 481, 496], ["children", "ORGANISM", 122, 130], ["cancer", "CANCER", 337, 343], ["CMV", "ORGANISM", 366, 369], ["breast cancer", "CANCER", 371, 384], ["melanoma", "CANCER", 386, 394], ["HPV", "ORGANISM", 402, 405], ["HSV", "ORGANISM", 407, 410], ["RSV", "ORGANISM", 412, 415], ["Marburg", "ORGANISM", 422, 429], ["Ebola viruses", "ORGANISM", 434, 447], ["viral encephalitis viruses", "ORGANISM", 449, 475], ["botulinum toxin", "SIMPLE_CHEMICAL", 481, 496], ["children", "SPECIES", 122, 130], ["RSV", "SPECIES", 412, 415], ["Ebola viruses", "SPECIES", 434, 447], ["CMV", "SPECIES", 366, 369], ["HPV", "SPECIES", 402, 405], ["HSV", "SPECIES", 407, 410], ["RSV", "SPECIES", 412, 415], ["PIV", "SPECIES", 417, 420], ["Ebola viruses", "SPECIES", 434, 447], ["reinfection canVaccine technology", "TREATMENT", 172, 205], ["Alphavirus vector Alphavirus vaccines", "TREATMENT", 221, 258], ["infectious disease", "PROBLEM", 314, 332], ["cancer", "PROBLEM", 337, 343], ["influenza", "PROBLEM", 355, 364], ["CMV", "PROBLEM", 366, 369], ["breast cancer", "PROBLEM", 371, 384], ["melanoma", "PROBLEM", 386, 394], ["SARS", "PROBLEM", 396, 400], ["HPV", "PROBLEM", 402, 405], ["HSV", "PROBLEM", 407, 410], ["RSV", "PROBLEM", 412, 415], ["PIV", "TREATMENT", 417, 420], ["Marburg and Ebola viruses", "PROBLEM", 422, 447], ["viral encephalitis viruses", "PROBLEM", 449, 475], ["botulinum toxin", "PROBLEM", 481, 496], ["infectious", "OBSERVATION", 314, 324], ["cancer", "OBSERVATION", 337, 343], ["breast", "ANATOMY", 371, 377], ["cancer", "OBSERVATION", 378, 384], ["melanoma", "OBSERVATION", 386, 394], ["RSV", "ANATOMY", 412, 415], ["PIV", "ANATOMY", 417, 420], ["Ebola viruses", "OBSERVATION", 434, 447], ["viral encephalitis", "OBSERVATION", 449, 467]]], ["Safe and highly immunogenic in humans.", [["humans", "ORGANISM", 31, 37], ["humans", "SPECIES", 31, 37], ["humans", "SPECIES", 31, 37], ["highly", "OBSERVATION_MODIFIER", 9, 15], ["immunogenic", "OBSERVATION", 16, 27]]], ["Induces broad and robust humoral and cellular immune responses.", [["cellular", "ANATOMY", 37, 45], ["cellular", "CELL", 37, 45], ["broad", "OBSERVATION_MODIFIER", 8, 13], ["robust", "OBSERVATION_MODIFIER", 18, 24], ["humoral", "OBSERVATION", 25, 32], ["cellular immune responses", "OBSERVATION", 37, 62]]], ["Capable of expressing a wide array of bacterial, viral, parasitic, and tumor antigens.", [["tumor", "ANATOMY", 71, 76], ["tumor", "DISEASE", 71, 76], ["tumor", "CANCER", 71, 76], ["bacterial, viral, parasitic, and tumor antigens", "PROTEIN", 38, 85], ["bacterial, viral, parasitic, and tumor antigens", "PROBLEM", 38, 85], ["viral", "OBSERVATION", 49, 54], ["parasitic", "OBSERVATION_MODIFIER", 56, 65], ["tumor", "OBSERVATION", 71, 76]]], ["Naturally targets dendritic cells, the most efficient antigen-presenting cell in the body.", [["dendritic cells", "ANATOMY", 18, 33], ["cell", "ANATOMY", 73, 77], ["body", "ANATOMY", 85, 89], ["dendritic cells", "CELL", 18, 33], ["cell", "CELL", 73, 77], ["body", "ORGANISM_SUBDIVISION", 85, 89], ["dendritic cells", "CELL_TYPE", 18, 33], ["antigen-presenting cell", "CELL_TYPE", 54, 77], ["Naturally targets dendritic cells", "PROBLEM", 0, 33], ["dendritic cells", "OBSERVATION", 18, 33], ["cell", "OBSERVATION", 73, 77], ["body", "ANATOMY", 85, 89]]], ["Allows combination products to be produced through multigene or particle mixtures.Vaccine technology CharacteristicsDNA vaccine Antigen can be expressed without alterations to its original structure, and the vaccine can be made optimally attenuated and highly immunogenic.", [["combination products", "TREATMENT", 7, 27], ["Vaccine technology CharacteristicsDNA vaccine Antigen", "TREATMENT", 82, 135], ["the vaccine", "TREATMENT", 204, 215]]], ["May be well suited for maternal immunization; protective immunity has been demonstrated in mice when maternal antibodies were present.", [["mice", "ORGANISM", 91, 95], ["maternal antibodies", "PROTEIN", 101, 120], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["maternal immunization", "TREATMENT", 23, 44], ["protective immunity", "TREATMENT", 46, 65], ["maternal antibodies", "PROBLEM", 101, 120]]], ["Initial studies have suggested that DNA vaccines are immunogenic but offer only mildly protective effects in RSV challenge studies.", [["DNA", "CELLULAR_COMPONENT", 36, 39], ["RSV", "ORGANISM", 109, 112], ["RSV", "SPECIES", 109, 112], ["Initial studies", "TEST", 0, 15], ["DNA vaccines", "TREATMENT", 36, 48], ["immunogenic", "PROBLEM", 53, 64], ["mildly protective effects", "PROBLEM", 80, 105], ["RSV challenge studies", "TEST", 109, 130]]], ["Large amounts of DNA are required, although methods to overcome this include novel formulations such as nanoencapsulation and microparticles.Vaccine technology CharacteristicsOther proposed concerns include the risk of inducing autoimmune responses and tolerance to the administered antigen.Vaccine technology CharacteristicsLive attenuated virus Can be administered intranasally and induce a balanced local and systemic immune response.", [["DNA", "CELLULAR_COMPONENT", 17, 20], ["Large amounts of DNA", "PROBLEM", 0, 20], ["novel formulations", "TREATMENT", 77, 95], ["nanoencapsulation and microparticles", "TREATMENT", 104, 140], ["Vaccine technology", "TREATMENT", 141, 159], ["inducing autoimmune responses", "PROBLEM", 219, 248], ["the administered antigen", "TREATMENT", 266, 290], ["Vaccine technology CharacteristicsLive attenuated virus", "TREATMENT", 291, 346], ["amounts", "OBSERVATION_MODIFIER", 6, 13], ["DNA", "OBSERVATION", 17, 20]]], ["Potential efficacy in infants with maternal antibodies.", [["infants", "ORGANISM", 22, 29], ["maternal antibodies", "PROTEIN", 35, 54], ["infants", "SPECIES", 22, 29], ["maternal antibodies", "PROBLEM", 35, 54]]], ["Must be frozen.SeV vectorWell tolerated in preclinical and phase 1 studies.", [["SeV", "ORGANISM", 15, 18]]], ["SeV does not infect humans (naturally attenuated).", [["SeV", "ORGANISM", 0, 3], ["humans", "ORGANISM", 20, 26], ["humans", "SPECIES", 20, 26], ["SeV", "SPECIES", 0, 3], ["humans", "SPECIES", 20, 26], ["not", "UNCERTAINTY", 9, 12], ["infect", "OBSERVATION", 13, 19]]], ["SeV confers Jennerian protection against hPIV-1.", [["SeV", "ORGANISM", 0, 3], ["hPIV-1", "GENE_OR_GENE_PRODUCT", 41, 47], ["hPIV", "DNA", 41, 45], ["SeV", "SPECIES", 0, 3], ["hPIV-1", "SPECIES", 41, 47], ["SeV confers Jennerian protection", "TREATMENT", 0, 32]]], ["SeV and rSeV induce rapid (by day 7) and long-lasting antibody responses versus hPIV-1 and passenger gene targets. rSeV-RSV-F produces RSV-specific antibody and T-cell responses and protects against RSV A and B subtypes.", [["T-cell", "ANATOMY", 161, 167], ["SeV", "ORGANISM", 0, 3], ["rSeV", "GENE_OR_GENE_PRODUCT", 8, 12], ["hPIV-1", "GENE_OR_GENE_PRODUCT", 80, 86], ["rSeV", "GENE_OR_GENE_PRODUCT", 115, 119], ["RSV-F", "ORGANISM", 120, 125], ["RSV", "ORGANISM", 135, 138], ["T-cell", "CELL", 161, 167], ["RSV", "ORGANISM", 199, 202], ["B subtypes", "CELL", 209, 219], ["rSeV", "PROTEIN", 8, 12], ["hPIV-1 and passenger gene targets", "DNA", 80, 113], ["rSeV", "PROTEIN", 115, 119], ["SeV", "SPECIES", 0, 3], ["hPIV-1", "SPECIES", 80, 86], ["RSV", "SPECIES", 120, 123], ["RSV", "SPECIES", 135, 138], ["RSV", "SPECIES", 199, 202], ["long-lasting antibody responses", "PROBLEM", 41, 72], ["hPIV", "TEST", 80, 84], ["rSeV", "TEST", 115, 119], ["RSV", "PROBLEM", 120, 123], ["RSV", "PROBLEM", 135, 138], ["specific antibody", "TEST", 139, 156], ["RSV", "PROBLEM", 199, 202], ["rapid", "OBSERVATION_MODIFIER", 20, 25]]], ["Can be formulated for intranasal administration.", [["intranasal administration", "TREATMENT", 22, 47]]], ["The virus is easy to grow and can be manufactured in large lots.SeV vectorVSV vector VSV has been shown to be an effective vaccine vector for use as immunoprophylaxis against numerous viral infections and to induce an immune response against cancer.", [["cancer", "ANATOMY", 242, 248], ["VSV", "CHEMICAL", 85, 88], ["viral infections", "DISEASE", 184, 200], ["cancer", "DISEASE", 242, 248], ["SeV", "ORGANISM", 64, 67], ["VSV", "ORGANISM", 85, 88], ["cancer", "CANCER", 242, 248], ["SeV vectorVSV", "SPECIES", 64, 77], ["VSV", "SPECIES", 85, 88], ["The virus", "PROBLEM", 0, 9], ["SeV vectorVSV vector VSV", "TREATMENT", 64, 88], ["an effective vaccine vector", "TREATMENT", 110, 137], ["immunoprophylaxis", "TREATMENT", 149, 166], ["numerous viral infections", "PROBLEM", 175, 200], ["cancer", "PROBLEM", 242, 248], ["virus", "OBSERVATION", 4, 9], ["large", "OBSERVATION_MODIFIER", 53, 58], ["lots", "OBSERVATION_MODIFIER", 59, 63]]], ["The following diseases have been studied: hepatitis C, HIV, influenza, HPV, Ebola, RSV.", [["hepatitis C, HIV, influenza, HPV, Ebola, RSV", "DISEASE", 42, 86], ["hepatitis C", "ORGANISM", 42, 53], ["HIV", "ORGANISM", 55, 58], ["HPV", "ORGANISM", 71, 74], ["Ebola", "ORGANISM", 76, 81], ["RSV", "ORGANISM", 83, 86], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 55, 58], ["HPV", "SPECIES", 71, 74], ["RSV", "SPECIES", 83, 86], ["hepatitis C", "PROBLEM", 42, 53], ["HIV", "PROBLEM", 55, 58], ["influenza", "PROBLEM", 60, 69], ["HPV", "PROBLEM", 71, 74], ["Ebola", "PROBLEM", 76, 81], ["RSV", "PROBLEM", 83, 86], ["hepatitis", "OBSERVATION", 42, 51]]], ["VSV is not a human pathogen, and there is little pre-existing immunity that might impede its use in humans.", [["VSV", "ORGANISM", 0, 3], ["human", "ORGANISM", 13, 18], ["humans", "ORGANISM", 100, 106], ["human", "SPECIES", 13, 18], ["humans", "SPECIES", 100, 106], ["VSV", "SPECIES", 0, 3], ["human", "SPECIES", 13, 18], ["humans", "SPECIES", 100, 106], ["VSV", "PROBLEM", 0, 3], ["a human pathogen", "PROBLEM", 11, 27]]], ["It propagates efficiently in cell lines suitable for manufacturing immunogenic compositions.", [["cell lines", "ANATOMY", 29, 39], ["cell lines", "CELL", 29, 39], ["cell lines", "CELL_LINE", 29, 39], ["cell lines", "TREATMENT", 29, 39], ["manufacturing immunogenic compositions", "TREATMENT", 53, 91], ["cell lines", "OBSERVATION", 29, 39]]], ["VSV infection is an efficient inducer of both cellular and humoral immunity.", [["cellular", "ANATOMY", 46, 54], ["infection", "DISEASE", 4, 13], ["VSV", "ORGANISM", 0, 3], ["cellular", "CELL", 46, 54], ["VSV", "SPECIES", 0, 3], ["VSV infection", "PROBLEM", 0, 13], ["infection", "OBSERVATION", 4, 13], ["humoral immunity", "OBSERVATION", 59, 75]]], ["It can be administered intranasally or parenterally.", [["intranasally", "ANATOMY", 23, 35]]], ["There are many challenges to overcome before a successful RSV vaccine can be licensed for administration in very young infants.", [["RSV", "ORGANISM", 58, 61], ["infants", "ORGANISM", 119, 126], ["infants", "SPECIES", 119, 126], ["RSV", "SPECIES", 58, 61], ["a successful RSV vaccine", "TREATMENT", 45, 69]]], ["109, 111, 114 The most daunting hurdle is that to prevent clinically significant illness and reinfection, the", [["illness", "DISEASE", 81, 88], ["clinically significant illness", "PROBLEM", 58, 88], ["reinfection", "PROBLEM", 93, 104], ["reinfection", "OBSERVATION", 93, 104]]]], "296b8e4c4cbb8262fa7189045c40b50a7f8f8164": [], "c797b361d67ccfe4f82266b08a0a268363694a75": [["The potential threat represented by the global effects of a targeted smallpox release event has yet to be analyzed with the use of explicit models.", [["a targeted smallpox release", "TREATMENT", 58, 85], ["global", "OBSERVATION_MODIFIER", 40, 46]]], ["Here, building on previous work, we have developed a largescale structured metapopulation model that accurately describes the worldwide spread of smallpox during the initial period of time between the occurrence of the intentional virus release and its detection by health officials.", [["smallpox", "DISEASE", 146, 154], ["a largescale structured metapopulation model", "PROBLEM", 51, 95], ["smallpox", "TREATMENT", 146, 154], ["the intentional virus release", "TREATMENT", 215, 244], ["metapopulation model", "OBSERVATION", 75, 95]]], ["Thus we focus here on the level of worldwide diffusion of smallpox cases before any containment/mitigation policy can be implemented.", [["smallpox", "DISEASE", 58, 66], ["smallpox cases", "TREATMENT", 58, 72], ["any containment/mitigation policy", "TREATMENT", 80, 113]]]]}